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ABSTRACT

Nie, Haichen. Ph.D., Purdue University, December 2016. Acid-Base Reactions in
Different Solid-State Forms. Major Professor: Stephen Byrn.
Most drug substances are reported to be either weak acids or weak bases. Hence, acidbase reactions are commonly observed in pharmaceutical systems with samples including
salts, amorphous solid dispersions, and in formulated products. Salt formation of active
pharmaceutical ingredients (APIs) is widely recognized as one of the most commonly
used approaches to modify the solubility and dissolution rate. Formulating poorly watersoluble weak acids or weak bases into salts can not only increase bioavailability, but also
improve the stability and manufacturability of APIs by changing their solid-state
properties. However, from a formulation perspective, acid-base reactions might occur
between APIs and ionizable excipients, which would induce deleterious form conversions
or chemical degradation of the APIs during storage or manufacturing. Therefore,
understanding the fundamentals of acid-base reactions is critical to design a robust
formulation and to avoid drug-excipients incompatibility issues in multicomponent
pharmaceutical products.
This research is divided into two parts to comprehensively understand the acid-base
reaction in different solid-state formulations. The first part focuses on utilizing acid-base
interactions between drug and polymer to stabilize a drug in the amorphous solid

xxi
dispersion system. The key moiety of each component, the binding motif, and the
underlying mechanism of solid state acid-base interactions are illustrated in this part. In
the second part, the focus is on the salt disproportionation, an adverse effect of an acid
base reaction between drug and excipients in different formulations. The impact of
properties of different excipients, hygroscopicity of formulation, and reaction products on
the kinetics and extent of disproportionation are investigated herein. Furthermore,
feasible formulation approaches are developed to effectively slowdown salt
disproportionation process during storage and manufacturing.
The overall goal of this research is to reveal the mechanisms of acid-base interactions in
different pharmaceutical systems and to better understand the dominant factors
influencing these reactions. An additional objective is to better understand proton transfer
and interaction patterns between drug and excipient, and to develop effective formulation
strategies to minimize the risk of salt disproportionation. Moreover, this thesis also
reports efforts of developing new validated analytical methods to monitor and detect the
salt disproportionation in multicomponent drug products.
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CHAPTER 1. THEORY AND BACKGROUND

1.1

Theories of acids and bases

A large fraction of active pharmaceutical ingredients (APIs) can be categorized weak
electrolytes. In order to further investigate the acid base reactions of these weak acids or
bases in pharmaceutical systems, an understanding of the fundamental theories of the
acid-base chemistry is required. 1
1.1.1

Lewis theory of acid and base

One of the classic theories of acid and base is called Lewis theory, which forms the basis
of electron transfer. Before discussing this theory, we need to understand an electron
deficient compound, which contains atoms with less than an octet of electrons. Hence, the
completion of the octet provides the primary driving force to form the acid or base. Thus,
Lewis acids are defined as substances that are capable of accepting electron pairs to form
a new bond in a chemical reaction. On the other hand, a Lewis base is defined as a
species donating the election pairs to the acid to form the new bonds.2 From a quantum
mechanical perspective, a Lewis acid is referred as Lowest Unoccupied Molecular
Orbital (LOMO) which provides the empty orbital to interact with Highest Occupied
Molecular Orbital (HOMO), Lewis base, to form a chemical bond.
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1.1.2

Brønsted-Lowry theory of acid and base

Another classic theory of acids and bases is named the Brønsted-Lowry theory, which is
commonly used in pharmaceutical sciences. In contrast to the Lewis theory, the BrønstedLowry theory of acid and base focuses on the movement of protons rather than the
electron transfer. The substance that donates the proton in the chemical reactions is
defined as the Brønsted acid. After donating a proton, the Brønsted acid forms its
conjugate base. In contrast, Brønsted bases are defined as species that accept protons.
After gaining the proton from the Brønsted acid, the Brønsted base forms its conjugated
acid.3 The strength of the Brønsted acid can be described by an equilibrium constant,
which is discussed in the following section.
1.1.3

Activity and equilibrium constant of water dissociation

To derive the thermodynamic equilibrium constant, some thermodynamic parameters
need to be clarified first. For instance, the chemical potential (µ) can be described by the
following equation, where the standard state chemical potential is symbolized as µ 0.

   0  RT ln a[ A]

Equation 1.1

The a[A] represents the thermodynamic activity, which is related to the temperature and
concentration of the substances. The relationship of the activity of A (a[A]) and its
concentration ([A]) can be expressed as Equation 1.2, where the activity coefficient is
symbolized as γA .

a[ A]   A  [ A]

Equation 1.2

On the basis of the chemical potential and the activity, the equilibrium constant for a
general chemical reaction (Equation 1.3) can be expressed as Equation 1.4. In the ideal
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situation, the activity of all species can be treated as 1. Therefore, the equil ibrium
constant can be expressed by concentration (Equation 1.5).
aA  bB

K0 

K0

cC  dD

a[C ]c a[ D]d [C ]c [ D]d  C c D d


a[ A]a a[ B]b [ A]a [ B]b  Aa B b

Kideal  K 0 

[C ]c [ D]d
[ A]a [ B]b

Equation 1.3

Equation 1.4

Equation 1.5

For an aqueous solution, the water dissociation process, which is also termed
autoionization, can be described in a similar way. 4 The equilibrium of water dissociation
and its corresponding equilibrium constant, as described by concentration, can be
expressed by Equation 1.6 and Equation 1.7. In aqueous solution, it is well established
that the activity of water is constant due to its high concentration (55.55M). Therefore,
equation 1.7 can be simplified to equation 1.8, where the K w is defined as the
autoionization/dissociation constant of water or ion product of water. 5 It has been
demonstrated that Kw is very small (1.007×10-14). Hence, the Sørensen scale is general
used to express the Kw as pK w, which has an approximate value of 14 at 25°C (Equation
1.9). Similarly, [H3O+] and [OH-] can be expressed by the Sørensen scale as in Equation
1.10 and 1.11. Therefore, the relationship between the pH, pOH and pK w can be derived
accordingly (Equation 1.12).
H 2O  H 2O

K

K

H 3O   OH 

[ H 3O  ][OH  ]
[ H 2O ]2

Equation 1.6

Equation 1.7

4
K  Kw  [ H 3O  ][OH  ]

1.1.4

Equation 1.8

pKw   log( Kw )

Equation 1.9

pH   log[ H 3O  ]

Equation 1.10

pH   log[OH ]

Equation 1.10

pKw  pH  pOH  14

Equation 1.12

Equilibrium constant of acid and base in aqueous solution

The details of the ionization and equilibrium of acid-base systems will be discussed in
section 2. In this part, the dissociation of an acid and base in aqueous systems will be
described and the corresponding equations derived. According to the Brønsted-Lowry
model, the equilibrium of an acid (HA) donating its proton to water can be expressed by
equation 1.13. The equilibrium constant (Keq) and dissociation constant for the acid (Ka)
can be expressed by equation 1.14 and 1.15 respectively. The dissociation constant (K a)
is a critical parameter that describes the strength of a Brønsted acid, and can help us to
understand how well it will transfer a proton a Brønsted base. Typically, each acid has its
dissociation constant which is expressed in the Sørensen scale as the pK a (equation 1.16).
It should be noted that, although there is a term called pK b, the strength of basic
compound is typically evaluated from the pKa of its conjugate acid.

HA  H 2O

Keq

[ H 3O  ][ A ]
K eq 
[ H 2O ][ HA]

H 3O   A

Equation 1.13

Equation 1.14
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[ H 3O  ][ A ]
Ka  Keq  H 2O 
[ HA]

Equation 1.15

pKa   log( Ka )

Equation 1.16

Furthermore, based on the Equation 1.15, the [H 3O+] can be expressed by equation 1.17.
Applying the Sørensen scale, Equation 1.18 is derived as the result, which is also called
Henderson-Hasselbalch equation, and is very useful in describing buffers. For a base, the
Henderson-Hasselbalch equation is given as Equation 1.19.

[ H 3O  ] 

Ka [ HA]
[ A ]

pH  pKa  log

pH  pKa  log

1.1.5

Equation 1.17

[ A ]
[ HA]

Equation 1.18

[ B]
[ BH  ]

Equation 1.19

Relationship between chemical structure and acidity

From a chemical perspective, there are two aspects of chemical structure that influences
acidity of the compound. The first factor is the element effects. According to the periodic
table, different elements with different electron density will affect bond strength, and the
ability to donate or accept electrons. Therefore, substitution of a certain part of the
organic compound could significantly affect the acidity. Secondly, the polar effect is very
critical in influencing the acidity of the organic species. For instance, halogens, or other
electronegative groups, have electron withdrawing effects which can increase the acidity
of the compound. On the other hand, electron donating groups would decrease acidity.
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These factors and the chemical structure of the drug should be carefully assessed before
selecting the counter-ions for the drug substance.
For organic compounds, the carboxylic acid is the most common acid functional group.
Structural features that impact acidity will be discussed below. The ionization
equilibrium for a carboxylic acid is shown in Equation 1.20.
RCOOH  H 2O

RCOO   H 3O 

Equation 1.20

The acidity of the carboxylic acid can be affected by both polar and resonance effects.
The polar effects of the carbonyl group, which is sp2 hybridized and hence very
electronegative, can significantly increase the acidity. Additionally, resonance effects can
stabilize the conjugated carboxylate ions and increase the acidity of the carboxylic acid.
1.2

Fundamentals of ionic equilibria

Organic compounds can be categorized as electrolytes or non-electrolytes based on their
capacity for ionization. It has been reported that two thirds of drug molecules belongs are
weak electrolytes (weak acid or weak base), which means they have the potential to
ionize and form salts with other electrolytes.6 Therefore, understanding the ionization
equilibria of electrolytes provides a foundation for discussion of acid-base reactions in
pharmaceutical systems including salt formation and salt disproportionation.
1.2.1

Ionic equilibria of monoprotic electrolytes

On the basis of the previous discussion of the Brønsted-Lowry theory of acids and bases,
we understand that the acids are proton donors and bases are proton acceptors. Ionization
in an aqueous system occurs when protons are transferred as H 3O+ from the donors to
acceptors. A monoprotic acid (HA) and base (B) will be introduced as an example to
further illustrate related concepts.
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For the mono-acid, the dissociation equilibrium is shown in Equation 1.21. [A -] and [HA]
represent the ionized species and unionized species respectively. [AT] symbolize the
summation of all the species containing A. The derived equations for calculating the
fractions of ionized (fA -) and unionized (f HA ) species are shown as follows.

[ H  ][ A ] [ H  ][ A ]

[ HA]
[ AT ]  [ A ]

Ka 

[ A ] 

f A 

[ H  ]  [ A ]

Ka

[ HA]

Ka [ AT ]
Ka  [ H  ]

[ A ]
Ka
1



[ AT ] [ H ]  K a 1  10 pka  pH

f HA  1  f A 

Equation 1.21

Equation 1.22

Equation 1.23

Equation 1.24

[ HA]
[H  ]
1



[ AT ] [ H ]  Ka 1  10 pH  pka

Equation
1.25

Similarly, for a mono basic compound, the equilibrium and the equations of fractions are
demonstrated as follows.
[ BH  ]

Ka 

[ B]  [ H  ]

[ H  ][ B ]
[ BH  ]

f BH  
fB 

Ka

1
1  10 pH  pka

1
1  10 pka  pH

Equation 1.26

Equation 1.27

Equation 1.28

Equation 1.29
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According to the above equations for monoprotic electrolytes, it is clear that pK a is an
essential parameter to determine the ionization of the drug substance and to provide
critical information about the strength of the acid and base. Specifically, strong acids
have low pKa values, and can donate protons even in solutions with high proton
concentrations. On the other hand, strong bases typically have high pK a values indicating
that they are capable of accepting protons even in solutions with low proton
concentration. Knowing the pKa value of a drug substance is a prerequisite to calculate
the fractions of the ionized and unionized species as a function of pH. A commonly used
organic mono-acid, acetic acid (H3CCOOH, pKa=4.76) is used as an example to generate
a species distribution diagram (Figure 1.1). This speciation diagram provides information
to identify the regions with different percentages of ionization. To be specific, in the
regions with two pH-units higher or lower than the pKa value, more than 99% of one of
the species would exist in that region. For instance, when pH<2.76, the unionized form of
acetic acid would be the dominant species in this pH range. In contrast, when pH>6.76,
more than 99% acetic acid would exist in the ionized form. For the intermediate region
(2.76 <pH <6.76), the unionized form decreases dramatically with increasing pH, while
the ionized form is increasing rapidly. Thus, a small shift of pH will lead to a drastic
change in the faction of ionized or unionized species. The pKa value occurs at the
intersection of the distribution line for the two species, where the fraction of each species
is equal to one other.
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Figure 1.1 Speciation diagram of ionized and unionized acetic acid in aqueous solution
1.2.2

Ionic equilibria of polyportic electrolytes

Multi-step pH-dependent equilibria should be employed to describe the ionization of
polyprotic electrolytes. For instance, maleic acid, a commonly used pharmaceutical
excipient, is a diprotic acid with pKa,1=1.9 and pKa,2=6.07. 7, 8 The two-step dissociation
equilibrium and the calculated fractions of ionized and unionized species are
demonstrated as follows. [H2A], [HA-] and [A 2-] represents the unionized acid, the monoanion and the di-anion respectively.

[ H 2 A]

Ka ,1

f H2 A 

[ HA ]  [ H  ]

Ka ,2

[H  ]
K K
[ H  ]  K a ,1  a ,1  a ,2
[H ]

[ A2 ]  [ H  ]

Equation 1.30

Equation
1.31
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f HA 

K a ,1
[ H  ]  K a ,1 

K a ,1  K a ,2
[H  ]

Equation
1.32

f A2 

K a ,1  K a ,2
K K 

[ H  ]   [ H  ]  K a ,1  a ,1  a ,2 
[H ] 


Equation 1.33

Based on equations 1.30 to 1.33, the speciation diagram of the maleic acid (Figure 1.2)
can be generated, whereby pKa,1 is determined as the intersection of distribution lines for
mono-anion and the unionized acid, and pKa,2 is marked as the intersection of distribution
lines for the mono-anion acid and the di-anion.

Figure 1.2 Speciation diagram of maleic acid in aqueous solution
1.2.3

Ionic equilibria of amphoteric electrolytes

Amphoteric electrolytes are defined as substances containing both acidic and basic
moieties, and hence are capable of both donating and accepting protons. Generally, they
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can be categorized as ordinary ampholytes and zwitterionic ampholytes based on the
relative acidity of the different functional groups. For instance, 4-aminophenol is an
ordinary ampholytes with a simple chemical structure. It has been reported that the pK a,1
(amino group) and pKa,2 (phenol group) are 5.48 and 10.46 respectively. 9,

10

The

equilibrium of 4-aminophenol and its speciation diagram are demonstrated as below
(Figure 1.3). In the region, pH<3.48, the cation exists as the protonated amine and the
neutral phenol is the dominant species. In contrast, at the region pH>12.46, the anion,
neutral amine with phenolate group, is the dominant species. In the scenario of having a
pKa difference of greater than 2 and pKaacid ic larger than pKabasic, it is noteworthy that the
acidic group and basic group cannot be simultaneously ionized.

Figure 1.3 Speciation diagram of 4-aminophenol in aqueous solution
On the other hand, zwitterions are characterized by having no net charge when both
acidic and basic functional group are ionized, and are treated as a special case of
amphoteric electrolytes. Zwitterions are common for amino acids. When an acidic
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solution is titrated by a basic solution, the carboxylic acid group is initially deprotonated,
followed by the deprotonation of NH3+. The zwitterion is the dominant species in the
range of pKa,1+2 to pKa,2-2 in the speciation diagram. For salt formation, we want to
achieve complete ionization state of the drug in order to form a stable salt form.
Therefore, understanding the pH-dependent equilibria for different types of drug
substance is a prerequisite to investigate salt formation and disproportionation..
1.3
1.3.1

Solubility behaviors of acids, bases and salts

Fundamentals of pH-solubility profiles, Ksp and pHmax

Understanding the solubility behavior of salts and their corresponding acids or bases is
critical for salt selection procedures. Generally, the total concentration of an ionizable
compound in aqueous solution can be described as the sum of the concentrations of the
ionized form and the unionized form. The solubility of the unionized species is termed
the intrinsic solubility. As discussed before, the degree of ionization for an organic weak
electrolyte is pH-dependent. Hence, the solubility of the ionizable form changes
accordingly to the pH and the physicochemical properties of the salt can be affected. The
pH solubility profile is defined as the change of solubility of an ionizable compound as a
function of pH, and can be readily measured by phase solubility methods. 11 To be
specific, an excess amount of the salt and its corresponding acid or base are added to
deionized water to obtain a suspension using the shake flask method. The pH of the
suspension is adjusted and measured to establish equilibrium, applying stepwise titration
with strong acid or base as needed. The supernatant solution phase is obtained by
centrifugation of the suspension and subjected to concentration measurement, allowing
generation of the pH solubility profile. The solid phase of the suspension in equilibrium
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should also be investigated at different pHs to identify the conversion from salt form to
free acid or base, using powder x-ray diffraction (PXRD) or differential scanning
calorimetry (DSC).12
1.3.1.1 The pH-solubility profile of free acid and its salt
The pH-solublity profile for flurbiprofen, a weak mono-acid, is discussed as an example
(Figure 1.4) to further illustrate pH-dependent solubility behavior for an acidic weak
electrolyte.13 In Region I of Figure 1.4 (pH<7.3), the free acid form of flurbiprofen is the
dominant solid state form (saturated species). In Region II (red, pH>7.3), the sodium salt
form of Flurbiprofen is the saturated species, i.e. the equilibrium species.

Figure 1.4 pH-solubility profile generated for a weak acid (Flurbiprofen) by titrating
with NaOH13
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For Region I, deriving from the equation 1.21 and 1.22, the equation of total solubility is
demonstrated below.

ST , pH  pH max  [ HA]s  [ A- ]  [ HA]s (1 

Ka
K
)  S0 (1  a )

[H ]
[H ]

Equation 1.34

In equation 1.34, the ST represents the total solubility at any pH value in region I. [HA]
and [A-] symbolize the concentration of the unionized and ionized species respectively.
The subscript s indicates the saturated species in that region. K a represents the
dissociation constant (Equation 1.22). Since the intrinsic solubility (S 0) is defined as the
solubility of the free form, [HA] is substituted by S 0. Similarly, the pH-solubility curve
for Region II is shown by Equation 1.35.
ST , pH  pH max  [ HA]  [ A- ]s  [ A- ]s (1 

[H  ]
[H  ]
)  (1 
) K sp
Ka
Ka

Equation 1.35

K sp  [ A ][ Na  ]

Equation 1.36

The intersection of the two independent curves is termed pH max, which defined as the pH
of maximum solubility. For an acidic compound, when the pH value is higher than pH max,
the total solubility is calculated by the equation 1.35. On the other hand, when the pH
value is lower than pH max, equation 1.34 would be used to calculate the total solubility.
When the pH is 2 units less than pKa, the solubility is independent of pH and maintained
as the intrinsic solubility.
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For the solid phase equilibrated with the solution, the free

acid would be present at pH<pH max, while the salt form would be the dominant species in
the solid phase when pH>pH max. The free acid and its salt can only coexist at the point of
pHmax.15 Inter-conversion between the free acid and its salt can take place when altering
the pH from one side of pH max to the other. For an acidic compound, adding acid to lower
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the pH value will lead to the conversion of the salt to its free acid. Hence, a lower pHmax
would be favorable for salt formation of acidic substances.
For equation 1.35, it is important to point out and discuss the term Ksp, which is defined
as the solubility product of the salt. For a salt formed by sodium and mono-acid, Ksp is
expressed as Equation 1.36. Since the [Na+] and [A-] are considered equal in the ideal
situation, [A -]s can be substituted by the square root of Ksp. On the basis of the above
discussions, the pHmax of weakly acidic compound is described by Equation 1.37.16

pH max acid  pKa  log

K sp
S0

Equation 1.37

1.3.1.2 The pH-solubility profile of free base and its salt
The pH-solubility profile of a free base and its salt can be discussed in a similar way
(Figure 1.5). The total solubility ST at Region I and Region II is addressed by Equation
1.39 and Equation 1.40. In these two equations, [BH+] and [B] symbolize the
concentration of the salt and the free base respectively. Similarly, the point where the two
curves intersect is the pH max, below which the saturated species would be salt, and above
which the equilibrium species would be free form. Hence, a pH higher than the pH max is a
prerequisite for the conversion of the salt form to the free base form. Otherwise, no free
base would be precipitated. The equilibrium around pHmax is described as follows. When
altering the concentration of [H+], the equilibrium would move toward right or left
accordingly. For instance, when base is added into the system, [H +] would be decreased.
Therefore, the salt would convert to the free base. This process is called salt
disproportionation, and will be discussed in more detail.
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Equation 1.38
For a basic compound, a higher pH max value would be desirable to prevent conversion
from the salt to its free from. The equation for pH max for a basic compound is given by
Equation 1.41.17

ST , pH  pH max  [ BH  ]s  [ B]  [ BH  ]s (1 

ST , pH  pH max  [ BH  ]  [ B]s  [ B]s (1 

pH max Base  pKa  log

Ka
K
)  (1  a ) K sp

[H ]
[H ]

[H  ]
[H  ]
)  S0 (1 
)
Ka
Ka

S0
K sp

Figure 1.5 pH-solubility profile for a free base and its salt

Equation 1.39

Equation 1.40

Equation 1.41
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1.3.2

Effects of intrinsic solubility, pKa and Ksp on pHmax

According to the above discussion, pH max plays a critical role in salt formation and salt
conversion. Hence, it is necessary to clarify the parameters which would affect the value
of pH max. Based on Equation 1.37 and Equation 1.41, we note that 3 factors contribute to
the value of pH max including pKa, intrinsic solubility (S0) and the solubility product of the
salt (Ksp). The calculation of pH max for a base would follow Equation 1.41. Thus for a
basic electrolyte, factors influencing pHmax can be summarized as follows:
(1) An increment of pKa by one unit would contribute to an increase of pH max by one unit
(Figure 1.6A)
(2) An increase in the intrinsic solubility by one order of magnitude would result in an
increase of pHmax by one unit (Figure 1.7A)
(3) Two orders of magnitude increase in the solubility product of the salt (K sp) or one
order of magnitude increase in the solubility of salt (square root of K sp) would lead to an
reduction of pHmax by one unit (Figure 1.8A). 14
For an acidic electrolyte, one unit increment of pKa would lead to one unit increase in
pHmax (Figure 1.6B). Increasing intrinsic solubility by one order of magnitude would
contribute to a decrease of the pH max by one unit (Figure 1.7B). In addition, two orders of
magnitude increase in the solubility product of the salt (Ksp) could result in an increasing
of the pHmax by one unit (Figure 1.8B).
In summary, for a basic compound, the higher pKa, higher intrinsic solubility of the free
base, and lower solubility of its salt would be favorable for forming a stable salt and
make it more difficult to convert from the salt back to the free base. In contrast, for an
acidic compound, having the properties of lower pKa and salt solubility and higher
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intrinsic solubility of the free acid would favor the formation of a stable salt with a lower
tendency to disproportionate. As we know, altering the solid state form of the free form
and salt form will change the solubility of the resultant substance. Therefore, the kinetics
and tendency of salt formation and disproportionation will be drastically different for
different solid state forms. This is a major topic that we want to investigate in the future
studies. (Vide Infra)

Figure 1.6 Effect of pKa on pHmax for base(A), acid (B)

Figure 1.7 Effect of instrinsic solubility (S0) on pHmax for base(A), acid (B)
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Figure 1.8 Effect of solubility product of the salt (Ksp) on pHmax for base(A), acid (B)
Although Equation 1.37 and Equation 1.41 can be used to theoretically calculate pH max, it
should be noted that the pH max has been reported as a range of pH values rather than as a
single value. For instance, Serajuddin et.al reported a clear deviation of the pH-solubility
profile and super-saturation behavior of drug substance around pH max.18 The discrepancy
was attributed to inconsistent nucleation of the free base or its salt. To be specific, the
differences of nucleation kinetics of different phases, attributed to kinetics barriers, can
hinder the phase transformation. Hence, the differences of nucleation kinetics between
the free base and the salt could be a dominant factor for salt formation or conversion from
salt to free base. Interestingly, these differences account for some of the variability in salt
disproportionation from compound to compound.
1.3.3

Effects of counterion and common-ion effects

1.3.3.1 Effects of counterion
As we know, a salt is formed by combining the acidic or basic compound with certain
counterions (base or acid) to alter the solubility and physicochemical properties of drug
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substances. The details of salt formation and the underlying mechanisms will be
discussed in the later sections of this document. The counterions used in salt formation
are termed salt-forming agents. It has been reported that selecting different counterions
will form salts with different physicochemical properties. For instance, Li et al.
performed a series of studies for generating the pH-solubility profile of haloperidol by
titrating with the different acid (Figure 1.9).19 According to Figure 1.9, the maximum
solubility of the salt and the pH max is determined by the acid used for the pH adjustment.
In other words, the properties of the salt significantly related to the properties of the
counterions selected for the salt formation including melting point, solubility,
crystallinity, and hydrophobicity.

20, 21

Figure 1.9 pH-solublity profiles of haloperidol with various salt forming agents 19
1.3.3.2 Common ion effects
The common-ion effect is another factor which can impact the solubility of the salt.
Direct evidence can be found from Figure 1.9, which shows that when the pH values
were lower than 2, the solubility of salts formed with methanesulfonate, hydrochloride,
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and phosphate start to decrease gradually primarily due to the presence of excess
counterions generated by the acid at lower pH. A pH-solubility profile measured after
varying the NaCl concentration is demonstrated in Figure 1.10, which further illustrates
the common-ion effect. 22 In the absence of NaCl, the maximum solubility of the salt is
higher than its solubility in the presence of NaCl. Moreover, as the concentration of NaCl
increase, the maximum solubility decreases accordingly. Theoretically, this common ion
effects can be explained by the following equilibria.
( BH Cl  ) solid

[ BH  ]s  [Cl  ]

K sp  [ BH  ]s  [Cl  ]

Equation 1.42
Equation 1.43

The (BH +Cl-)solid symbolizes the non-dissolved solid phase which is in equilibrium with
the solution. [BH +]s is denoted as the solubility of the salt. [Cl -], as the counterion,
represents the concentration of chloride. When an excess amount of counterions is added,
the equilibrium will move towards to the left side, and the solubility of the salt form will
be decreased as a result. Without the addition of an excess amount of the counterion,
[BH+]s =[Cl-]=√Ks . However, in the present of an excesses amount of counterions, the
solubility of the salts drastically decreases. The solubility of the salt can be derived using
Equation 1.44. Furthermore, a more general equation showing counterion effects o n salt
solubility can be derived as shown in Equation 1.45. According to previous studies, it
has been demonstrated that the common ion effects mainly depends on the magnitude of
the Ksp value.23 For a salt with a higher value of Ksp, the common ion effect of salt
solubility is less significant than that for a salt with a lower value of K sp. When weaker
acids are used as the salt forming agents, less common ion effects will be observed at
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lower pH, since the percentage of ionization for the weak acid would be decreased at
lower pH. Therefore, fewer counterions would exist in solution. It is also critical to point
out that hydrochloride salts will have more impacts from common ion effects especially
in the GI tract, where [Cl -] will be present in large amounts.
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[ BH  ]s  Ksp / [Cl  ]

Equation 1.44

[ BH  ]s  Ksp / [ X  ]

Equation 1.45

Figure 1.10 Different pH-solublity profiles of a basic compound in presence of different
concentration of NaCl 22
1.4

Hygroscopicity of pharmaceutical solids

The presence of water can significantly influence the physicochemical properties of
pharmaceutical solids either during storage or sample preparation. For instance,
norfloxacin can undergo proton transfer induced by the water molecule. Therefore, tablet
dissolution can be adversely affected by low relative humidity RH25 The extent of
moisture is termed the hygroscopicity with samples that take up a lot of water being
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described hygroscopic.26 Generally, hygroscopicity is defined as the kinetic and
thermodynamic processes by which solids adsorb and absorb atmospheric moisture. The
kinetic component determines the rate of moisture uptake, while thermodynamic
component determines the energy of this process. 27 The hygroscopicity of the
pharmaceutical ingredients can be described by the classification scheme proposed by
Callahan (Table 1.1).28
Table 1.1 Hygroscopicity classification scheme
Class I

Non-hygroscopic

Class II

Slightly
hygroscopic

Class III

Moderately
hygroscopic

Class IV

Very hygroscopic

No obvious moisture increase below 90% RH; less
than 20% increase in moisture content above 90% RH
in one week
No moisture increase below 80% RH; less than 40%
increase in moisture content above 80% RH in one
week
Moisture content does not increase >5% below 60%
RH; less than 50% increase in moisture content above
80% RH in one week
Moisture content will increase as low as 40–50% RH;
greater than 20% increase in moisture content above
90% RH in one week

As discussed above, salt disproportionation is a solution mediated reaction which
strongly associated with moisture and water activity. Therefore, A detailed discussion of
the water activity and relative humidity (RH) are addressed herein to determine the
storage conditions of salt candidates and to better understand hygroscopic behavior of
pharmaceutical solids. The relative humidity is defined as the ratio of vapor pressure of
water to the saturated vapor pressure of pure water at the given temperature, water
activity a[H 2O] can be calculated by knowing the saturated vapor pressure (P 0) of pure
water and the vapor pressure (P) at a certain temperature (Equation 1.46). It is important
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to point out the water activity could be easily correlate to the relative humidity by
multiply water activity with 100% (Equation 1.47 and 1.48).
a[ H 2O ]eq 

R.H . 

P
 100%
P0

a[ H 2O ]eq 

1.4.1

P
P0

R.H .
100%

Equation 1.46

Equation 1.47

Equation 1.48

Water-solid interactions

Apart from hydrate formation (beyond the scope of this reseach), water solid interactions
also include moisture sorption behavior (surface adsorption, bulk material absorption),
capillary condensation and deliquescence, which will be discussed in detail
subsequently. 29 It is important to note that adsorption is specifically relate to the surface
area of the solid powder, while absorption refers to moisture that penetrates into bulk
solids leading to potential hydrate formation
1.4.1.1 Water vapor sorption
Exposing the solids to water vapor leads to interaction between the water molecules and
the surface of solid via different types of forces (van der Waals, ionic-dipole or hydrogen
bonds). This moisture adsorption process can be thermodynamically described by
Equation 1.49. 30 The process of water molecule adsorption from the vapor phase is
associated with a negative entropy change due to the increasing of the order of the system.
Hence, the ΔHads of the absorption should be a negative value, which indicate the
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adsorption process should be exothermic. The strength of interaction will therefore
determine the reactivity of adsorption process.

Gads  H ads  T S ads

Equation 1.49

Based on these different interaction types, the moisture adsorption can be categorized as
physisorption and chemisorption. Specifically, weaker interaction forces (like van der
waals) will lead to the physisorption and contribute a heat of sorption in a range of -10 to
-40 kJ/mol.

31

On the other hand, chemisorption involves stronger interactions (ionic or

covalent bonds) between the adsorbates (H2O) and adsorbent (the solids), and typically
has a heat of sorption in the range of -40 to -1000 kJ/mol. The details of these two types
of adsorption behavior will not be discussed in this research.
The water adsorption behavior and hygroscopicity of pharmaceutical solids are typically
characterized by using dynamic vapor sorption (DVS) to generate moisture sorption
isotherms, which are plots of the weight changes of the sample as function of RH. 32, 33
The experimental time is highly dependent on the type of sorption. Typically, the surface
adsorption is faster than the bulk absorption.
The moisture sorption behavior could be categorized into five different types (Figure
1.11).34 To be specific, isotherm type I is limited to a monolayer of absorbate. A type I
isotherm, typically due to chemisorption, is also named a Lagmuir isotherm, which shows
a plateau due to the full occupation of the binding sites. A classic example of
physisorption show type II isotherm. It mostly occurs for non-porous materials and the
inflections indicate the formation of the first mono layer. For type III, the additional
adsorption behavior is attributed to the formation of multilayers since the heat of
adsorption is typically lower than heat of liquefaction (exothermic process). The only
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difference between type II and type IV is the later one is mainly for the porous surfaces.
Type V, having small adsorbate-adsorbent interaction, is generally associated with
capillary condensation, which would be introduced together with deliquescence in the
following session.
It is import to note that, for some drug substances or excipients, the sorption or
desorption isotherms may show hysteresis (Fig 1.12). Hygroscopicity studies on salt
candidates can also show hysteresis. For instance, Figure 1.13 demonstrates the water
sorption/desorption curves of three salts. Apparently, the hydrochloride salt shows
marked hysteresis due to the formation of a strong hydrate. In contrast, the hydrogen
malonate salt shows reversible sorption/desorption. 35 This example illustrates the
importance of determining the sorption isotherms for salt with different counterions
during the preformulation process. Hysteresis indicates a non-equilibrium system, which
can make determination of thermodynamic transition points difficult. In such cases,
slurry equilibration should be employed to accelerate the transformation and measure the
according critical relative humidity.
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Figure 1.11 Five types of moisture sorption isotherms

34

Figure 1.12 Water sorption/desorption isotherms A) sorption/desorption is reversible B)
desorption demonstrated hysteresis
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Figure 1.13 Water sorption/desorption isotherms for three salts (solid symbols:
adsorption, empty symbols: desorption) 35

1.4.1.2 Capillary condensation and deliquescence
For capillary condensation, few reports have discussed its impact on pharmaceuticals
solids. However, a brief understanding the fundamental concepts of capillary
condensation would help us better interpret the sorption isotherms, especially for porous
materials. The hysteresis discussed previously can also be attributed to capillary
condensation. Typically, capillary condensation can be described by Kelvin’s equation,
which is used to determine the vapor pressure above a curved surface.
Deliquescence is more commonly observed for pharmaceutical solids, especially for salts
and certain excipients.36,

37

When the RH of the environment higher than the critical

relative humidity (RH0), water soluble crystalline solids undergo dissolution in the
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aqueous layer on the solid surface formed by condensed water. This process is called
deliquescence (Figure 1.14).38 Consequently, a saturated solution with a lower vapor
pressure (Ps ) than that of pure water (P0) would be formed as a film on the surface of the
solid, which lead to further dissolution of the solids until the material is completed
dissolved.

Figure 1.14 Deliquescence process 38
For multi-component systems, the presence of a second deliquescence solid would
decrease the critical relative humidity. The multi-component system is thus showing
more hygroscopicity, and deliquescence occurs at a lower RH 0 than for each individual
component.39, 40 This phenomenon has also been observed for the disproportionation of
pioglitazone in presence of the magnesium stearate. The disproportionation product,
MgCl2, is a deliquescence solid, which can reduce the critical relative humidity leading to
the disproportionation reaction. The details will be discussed in a later chapter. 41
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1.4.2

Effects of moisture on physicochemical stability and physical mechanical
properties

It has been reported that water adsorption can significantly enhance the molecular
mobility of solids and therefore lead to higher solid state reactivity. For instance, some
moisture-sensitive drug substances are reported to have greater reactivity to hydrolysis.
Specifically, the water molecules can facilitate drug- excipients interaction for the
following two reasons: First, water could mediate drug-excipient reactions by forming a
water-layer termed a microenvironment in which conditions for reaction are favorable.
For example, acid-base interaction and salt disproportionation are all water mediated
reactions. Second, water can plasticize both the dr ug substance and the excipients to
enhance the reactivity for the components involved in the reaction. For instance, water
could mediate the acid-base reaction between the delavirdine methanesulfonate and
cromscarmellose sodium. The salt would disproportionate in the water layer formed on
the surface of a crystal as detected by solid state NMR. Afterwards, the dissiocated
methanesulfonate acid would interact with croscarmellose, as confirmed by IR
spectroscopy.42 Moreover, another example was demonstrated by Jain et al. whereby the
anhydrous lactose converted to the monohydrate form and therefore contributed to a more
intimate drug-excipient interaction.43
Moisture can also contribute to change in the physical-mechanical properties of
pharmaceutical solids associated with different manufacturing process. For instance,
incorporation of water molecule into the crystalline lattice of hydroxbenonic acid leads to
plastic deformation. Moisture can also result in to the formation of agglomerates in bulk
powders due to the increasing cohesiveness. Hence, the flowability and bulk density of
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power would be changed accordingly. For amorphous materials, moisture sorption would
affect tablet hardness due to the plastization effects of water. 44
1.5

Acid-Base Reactions

Based on the previous discussion of the acid and bases, we know that most
pharmaceutical compounds are weak electrolytes. Hence, acid-base reactions can be
widely encountered in pharmaceutical systems including salts, amorphous solid
dispersions, and formulated products such as tablets, coated granules, capsule, suspension
etc. It has been reported that most of the drug and excipient incompatibility issue is
attributed to the acid-base reactions in drug product. Therefore, understanding the
fundamental theory of acid-base reactions is critical to further investigate these
pharmaceutical systems.
1.5.1

Theory of acid-base reactions

An equilibrium for a Brønsted acid and a Brønsted base reaction is demonstrated in
Equation 1.50. By comparing the pKa value of the acids involved in this reaction, we can
estimate the direction of the reaction in this equilibrium. The equilibrium in the reaction
of an acid and a base always favors the side of the equilibrium with weaker acid and
weaker base. For instance, if acid and the base of the right hand side of equation 1.50 are
weaker than the left side, the reaction lies to the right. The equilibrium constant (K eq)
could be calculated accordingly by subtracting the pKa of the left side from the pKa of the
right side. In this case, pKa of the HA is expressed as pKAH while pKa of the BH+ is
symbolized as pK BH. Hence, the relationship between Keq and pKAH , pK BH is
demonstrated in equations 1.51 and 1.52.
HA  B

Keq

A  BH 

Equation 1.50
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pKeq  pK BH   pK HA
( pK

Keq  10
1.5.2

BH 

Equation 1.51

 pK HA )

Equation 1.52

Salt formation and disproportionation

1.5.2.1 Salt formation
Salt formation is defined as one type of acid-base reaction involving either proton
transfer or neutralization. Theoretically, each acidic or basic compound can be involved
in the salt formation process. One important factor determining salt formation and
stability is the strength of the acid or the base (acidity or basicity constant of the
compound). 45 Hence, the salt formation rule of thumb states that a ΔpKa value between
acid and base (pKa base- pKa acid) larger than 2 to 3 will result in proton transfer and lead
to the formation of salt.46-48 However, merely dependending on this rule is not enough to
screen and optimize the salt formulation. Trial and error approaches for salt screening
should also be employed to further evaluate the physicochemical properties of ioni zable
compound. The fundamental principles behind the trial and error approaches are utilizing
the acid base reaction in solution and precipitating the targeted compounds with the
appropriate counterions in their salt form. The solid extracted from the precipitation is
subjected to solid state characterization for selecting solids with the desired
physicochemical properties. 49, 50
It has been reported that using salt screening methods typically involves using organic
solvents due to the low aqueous solubility of drug substances. However, such methods
can bring significant issues due to the fact that the pKa value may change in organic
solvents. For instance, methanol drastically impacts the pK a value of ephedrine and acetic
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acid: the acetic acid shifts its pKa value by 5 units in the methanol solvent relative to in
the aqueous system. Hence, the solvent effect for the salt formation should be carefully
considered before screening. Furthermore, the salt forming agent selection needs to
consider pH. One important condition for forming a salt is to adjust the pH to value lower
than the pH max of the basic compound and altering the pH to a value higher than the
pHmax of the acidic compound. Commonly used salt forming can be found in detail from
the references.

51

In an aqueous system, acid-base reactions can be expressed and calculated using
Equations 1.50 to 1.52. By calculating the value of the pKeq of this equilibrium, we can
estimate the direction and the percentage of salt formation. Moreover, the functional
group and the ionizable moiety of the acidic compound or the excipients need to be
further investigated before the salt formation process. In my research plan, there are some
validated methodologies that have been developed to understand the interaction pattern
and the moiety involvement of the acid-base reaction.
1.5.2.2 Salt disproportionation
A primary potential risk of utilizing salt formation is that the salt form of API has the
propensity to revert back to the unionized form/free base which is defined as salt
disproportionation.52,

53

It has been reported that salt disproportionation has severe

detrimental effects on pharmaceutical products including loss of potency, increased tablet
hardness, and the reduction of dissolution rate and bioavailability. 12,

42,

54-56

Disproportionation is also one type of acid base reaction and involves proton exchange.
Although salt disproportionation can be commonly observed in solid state, the presence
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of water is known to be necessary for the disproportionation process, with higher water
contents driving the process, indicating that it is a solution mediated reaction. 12, 52, 57 The
pH of maximum solubility (pH max) and the microenvironmental pH are two pivotal
parameters required to understand the likelihood of disproportionation.15, 56 The concepts
of the pH max have been illustrated in the previous section by evaluating the pH solubility
profile. The microenvironmental pH can be greatly impacted by acidity/basicity of
excipients used in formulations. For instance, excipients with high basicity can elevate
the microenvironmental pH value and are generally reported as problematic components
in formulations containing salts of weak bases.58-60 For a basic compound, when the pH
value is higher than the pH max the solid state phase in equilibrium will change from salt to
free base, and disproportionation will occur. From a formulation perspective, contact
surface, drug loading, excipients properties, and storage conditions could also have
significant impacts on the disproportionation reaction.61
1.5.3

Solid state acid-base reactions

Solid state acid base reactions are commonly observed in pharmaceutical systems
primarily due to the following two reasons. First, as we discussed before, most of drugs
are either acidic or basic compounds. Second, formulating the drug as solid state
pharmaceutical products, tablet or capsule, is a widely used strategy in the
pharmaceutical industry. Moreover, most of the popular excipients involved in
pharmaceutical products also have acidic or basic properties, which could induce the
proton transfer and contribute to acid-base reactions with drug substances in the solid
state. For instance, magnesium stearate, crosscarmellose sodium and A-Tab have been
reported as proton acceptors (Brønsted-base) to impact stability of drug salts.62 On the
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other hand, stearic acid and maleic acid are proton donors (Brønsted-acid), which can
lead to stability issues with acidic pharmaceutical compounds. Such reactions would
dramatically influence the physicochemical properties of the pharmaceutical compound,
or even drastically change its bioavailability. For instance, magnesium oxide, one
important impurity of magnesium stearate, was reported to interact with ibuprofe n during
formulation development, changing the texture of the tablet. The magnesium salt of
ibuprofen was generated as a reaction product.63 Stephenson et al. further demonstrated
that this reaction is not a water mediated reaction and the reaction rate is strongly
correlated to the crystal packing and meting point of the solid form. Furthermore, in
multicomponent solid-state pharmaceutical products containing two drugs, the drugs may
interact via an acid-base reaction. For instance, formulating phenylephrine hydrochloride
together with aspirin may lead phenylephrine degradation due to the acid nature of
aspirin. As a result, the solubility and bioavailability of phenylephrine will change
accordingly. Hence, a compatibility test, a practice of screening the adverse componentcomponent interaction, should be employed in the preformulation stage to further explore
the incompatibility issues between the drug and excipients or even between two drugs.
Although pH in solid state is not well understood, it is important to maintain the desired
microenvironmental pH in the solid state to stabilize the formulation. Therefore,
numerous studies have been published on formulating pH-adjustment agents in the solid
dosage forms to maintain the physical chemical properties and prevent proton transfer
between drug and excipients.
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1.6

Research Overview

The present research addressed two aspects of the acid-base reactions: salt formation and
salt disproportionation. Chapters 2 and 3 focused on salt formation in solid dispersions,
whereby acid-base interactions between drug and polymer to stabilize the amorphous
form of the drug and increased the polymer drug-loading capacity. It was hypothesize
herein that an acid-base interaction can be formed between certain drugs and polymers on
the basis of salt formation rule which enunciates that a ΔpKa value between an acidic
polymer and a basic drug substance (pKa base- pKa acid) larger than 2 to 3 will result in
the proton transfer and salt formation. The overall objective of the first two chapters was
to probe the interaction patterns between a model compound and polymeric carriers in
amorphous solid dispersions and to further elucidate the underlying reaction mechanism
by applying comprehensive spectroscopic investigations.
Chapter 4 to 6 focused on the other direction of acid base reaction, which is
pharmaceutical salt disproportionation. The main objective of chapter 4 was to
investigate the impact of excipient counterion on the disproportionation reaction (both
extent and kinetics), focusing specifically on the excipient properties as well as the
characteristics of the reaction products. The second objective was to further understand
the underlying mechanisms of proton transfer between drug salt and problematic
excipients (i.e. metallic stearates). The hypothesis of chapter 3 was that both reactants
and formed products can significantly affect the salt stability in formulation. Chapter 5
aimed to develop effective formulation approaches to slowdown salt disproportionation
process in solid formulation during storage and manufacturing. Moreover, the research of
chapter also investigated the impacts of different polymer and pH modifier on acid-base
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reactions in solid formulations. The study presented in chapter 6 focused on develop
innovative analytical approaches to detect the salt disproportionation in multi-component
pharmaceutical products with low drug loadings. The logic flow of this research is
summarized in Figure 1.15

Figure 1.15 Logic flow chart of this research
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CHAPTER 2. INVESTIGATING THE INTERACTION PATTERN AND
STRUCTURAL ELEMENTS OF A DRUG-POLYMER COMPLEX AT THE
MOLECULAR LEVEL1

2.1

Abstract:

Strong associations between drug and polymeric carrier are expected to contribute to
higher drug loading capacities and better physical stability of amorphous solid
dispersions. However, molecular details of the interaction patterns and underlying
mechanisms are still unclear. In the present study, a series of amorphous solid dispersions
of clofazimine (CLF), an anti-leprosy drug, was prepared with different polymers by
applying the solvent evaporation method. When using hypromellose phthalate (HPMCP)
as the carrier, the amorphous solid dispersion system exhibits not only superior drug
loading capacity (63% w/w), but also color change due to strong drug-polymer
association. In order to further explain these experimental observations, the interaction
between CLF and HPMCP was investigated in a non-polar volatile solvent system
(chloroform) prior to forming the solid dispersion. We observed significant UV/Vis and
1

H NMR spectral changes suggesting the protonation of CLF and formation of ion-pairs

between CLF and HPMCP in chloroform. Furthermore, Nuclear Overhauser Effect
Spectroscopy (NOESY) and Diffusion Order Spectroscopy (DOSY) were employed to

1

The content of this chapter is adapted with permission from Haichen Nie, Huaping Mo, Mingtao Zhang et
al. Investigating the Interaction Pattern and Structural Elements of a Drug–Polymer Complex at the
Molecular Level. Molecular pharmaceutics 2015, 12, (7), 2459-2468. Copyright (2015) American
Chemical Society.
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evaluate the strength of associations between drug and polymers, as well as the molecular
mobility of CLF. Finally, by correlating the experimental values with quantum chemistry
calculations, we demonstrate that the protonated CLF is binding to the carboxylate group
of HPMCP as an ion-pair and propose a possible structural model of the drug-polymer
complex. Understanding the drug and carrier interaction patterns from a molecular
perspective is critical for the rational design of new amorphous solid dispersions.
2.2

Keywords

Clofazimine; Amorphous Solid Dispersion; Drug Polymer Interactions; Ionic Interaction;
Drug Loading Capacity; Solution NMR;
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2.3

Introduction

Formation of an amorphous solid dispersion (ASD), where drug molecules are dispersed
into a polymer matrix, is a widely used formulation strategy to enhance the aqueous
solubility and dissolution rate for drug candidates with inadequate bioavailability. 64, 65
These ASD systems replace strong intermolecular forces in the crystalline state with
drug-polymer interactions. Understanding the interaction pattern between the drug and
polymer is critical to formulating robust ASDs to overcome the limited drug loading
capacity or recrystallization during storage. 66, 67 However, it has been very challenging to
determine the detailed molecular characteristics of ASDs, because amorphous mater ials
lack long range order.68 Therefore, knowledge about the patterns of molecular
interactions (strength, interaction type, and functional group involvement) between drug
and polymers is still limited.69
One structural element of particular interest is the strength of the drug polymer
interaction in ASDs. Typically, dispersions with stronger intermolecular interactions are
expected to be more physically stable by disrupting the crystallization tendency and
reducing the molecular mobility. 70,

71

Perhaps the most important intermolecular

interactions between drugs and polymers are ionic interaction and hydrogen bonding. For
instance, ionic interactions, a strong electrostatic interaction formed by protonated
molecules, are reported as making significant contributions to increase both the drug
loading and the physical stability of ASDs. 72-74 On the other hand, the existence of an
intra-molecular hydrogen bond in a drug molecule might have significant negative
influence on physical stability. 75, 76 These findings suggest that identifying the molecular
details of drug-polymer interactions and revealing their underlying mechanisms would be
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extremely useful for selecting appropriate polymers without the reliance on empirical
tests and screening.
A variety of techniques have been applied to investigate drug-polymer interactions
including spectroscopic characterizations and molecular modeling. 77-80 High resolution
solution state NMR, for instance, can provide structural insights into drug-polymer
interactions at the molecular or atomic level in a non-polar volatile solvent system prior
to forming the spray dried amorphous solid dispersions. By detecting the chemical shifts
and line-shape changes, solution 1H NMR spectra provide important information about
the changes of the electron densities around hydrogen atoms, which could be
significantly affected by certain interactions. 81, 82 Moreover, Nuclear Overhauser Effect
Spectroscopy (NOESY) is an effective measurement for motional behavior of drug
molecules associated with binding or aggregation. Therefore, it could be employed to
evaluate the strength of drug-polymer associations and to investigate the ability of
polymers to inhibit recrystallization in super-saturated solutions.83, 84 DOSY (Diffusion
Order Spectroscopy) readily measures solution state self-diffusion coefficients of
different size molecules without physical separations. 85 Hence, it has the potential to
evaluate molecular mobility of active pharmaceutical ingredients (APIs) in the presence
of polymers.
The primary objective of this investigation is to reveal the critical drug-polymer
interaction pattern and to elucidate the underlying mechanisms involved in the formation
of drug-polymer complexes from a molecular perspective. In addition, the second major
objective of this study is developing new formulations for rare diseases. For leprosy,
clofazimine (CLF, Figure2.1A), one of the three recommended drugs by World Health
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Organization, is poorly bioavailable and must be given in a high dose. 86, 87 Thus, CLF is
used as a model compound for our studies of interaction pattern between drug and
polymers. CLF contains both a hydrogen bond donor and hydrogen bond acceptor, and
also has a relatively high pKa value (8.51) 88. These characteristics should enable CLF to
form different types of interactions with various functional groups present on polymeric
carriers both in solution state and in solid state. In this study, we chose HPMCP, HPMC,
and PVP/VA as model polymers because the different chemical features of these
polymers would enable the formation of various intermolecular interactions with CLF.
One previous study has attempted to disperse CLF into polyvinylpyrrolidone matrix to
form an amorphous system, but achieved a limited 10% drug loading. 89 In our study, we
formulated an ASD of CLF and HPMCP with more than 60% (w/w) drug loading, and
achieved a dispersion system with superior physical stability. By combining
spectroscopic characterization and quantum chemistry calculations, we investigated the
molecular interaction pattern of drug-polymer complex and the underlying binding
mechanism in a non-polar solvent system to further explain the improved performance
and experimental observations.
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2.4
2.4.1

Experimental
Chemicals

Clofazimine (CLF) in crystalline form and phthalic acid (ACS reagent) were purchased
from Sigma-Aldrich (St. Louis, MO). HPMCP (HP-55, Figure2.1B) was provided by
Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan). HPMC (METHOCELTM E15,
Hypromellose, United States Pharmacopeia class 2910, Figure 2.1C) and PVP/VA
(vinylpyrrolidone-vinyl acetate copolymer, Figure2.1D) were generously provided by
Colorcon Inc. (West Point, PA) and BASF SE (Florham Park, NJ) respectively.
Chloroform (CHCl 3) and glacial acetic acid were purchased from Mallinckrodt Baker, Inc.
(Paris Kentucky), and deuterated chloroform was obtained from Cambridge Isotopes
Laboratories Inc. (Andover, MA).
2.4.2

Preparation of solid dispersion

A series of homogeneous solutions with the desired weight ratio between drug and
polymers were prepared in chloroform. Sonication was applied as needed for solutions
with HPMC. Solid dispersions were prepared either by rotary evaporation or spin coating.
For rotary evaporation, chloroform was removed by a rotary-evaporator (Buchi, New
Castle, DE) with a reduced pressure and immersed into water bath with a constant
temperature (~50°C) for 2-3 minutes. Afterwards, in order to remove the residual solvent,
samples were placed under vacuum at room temperature for a minimum of 12 hours. For
spin coating, solvent was rapidly removed by adding several drops of the solution to a
quartz microscope slide (VWR, Radnor, PA) which was rapidly rotated on a KW-4A spin
coater (Chemat Technology Inc., Northridge, CA) with a rate of 200rpm for 20s at room
temperature.90
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2.4.3

Powder X-Ray diffraction (PXRD)

The X-ray diffraction patterns of solid dispersions prepared by rotary evaporation were
obtained using a Siemens D5000 X-Ray diffractometer equipped with a Cu Kα source.
All the measurements were conducted at room temperature in Bragg–Brentano geometry
with 2θ ranging from 4° to 40° using a 0.02° step size. The voltage and the current of the
generator were set to 40 kV and 40 mA respectively.
2.4.4

Ultraviolet-Visible spectroscopy

For solution, UV spectra were recorded on a S.I. Photonics 400 Series UV/Vis
Spectrophotometer (Tuscon, Arizona) equipped with a fiber optic dip probe (20 mm pathlength). Samples evaluated comprised mixtures of CLF (0.06 mg/mL) with various
polymers (HPMCP, HPMC, PVP/VA) in chloroform at room temperature with a constant
stirring rate. A Cary 300 Bio UV spectrometer coupled with WinUV software (Varian
Inc., Palo Alto, CA) was used to analyze thin films of CLF dispersed with the polymers
onto quartz slides. The wavelength range was set from 200nm to 800nm for both liquid
and solid state samples.
2.4.5

Solution NMR

1D 1H NMR spectra were acquired on a Bruker 800 MHz Avance-III spectrometer
equipped with a HCN single axis gradient probe at 25°C using standard sequences. CLF
concentration (final) was maintained at 2 mg/mL in fresh deuterated chloroform (CDCl 3),
and other polymers (HPMCP, HPMCP or PVP/VA) were mixed with CLF at the desired
(w/w) ratio for all applicable samples. Solutions were then transferred to 5 mm NMR
tube for NMR data acquisitions. For NOESY, the mixing time was set to 300 ms. For
DOSY, stimulated spin echo with bipolar gradient pulses was employed for self-diffusion
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coefficient measurement. For CLF with HPMCP, relaxation delay was 10 s, the total
diffusion time (Δ) was fixed as 50 ms, gradient duration (δ) was 4 ms and strength varied
from 1.07 G/cm to 50.8 G/cm; for CLF with HPMC or PVPVA, the corresponding time
was 15 s, 50 ms, and 1.6 ms. Chemical shifts were referenced to residual solvent, CHCl 3,
at 7.26 ppm. CLF proton chemical shift assignments in CDCl 3 solution were derived
from COSY and NOESY, and confirmed by assignments made in d6-DMSO under the
similar conditions.
2.4.6

Computational methods

Calculations of each system were carried out by using the Gaussian 09 software
package91 at the density functional theory (DFT) level of the hybrid B3PW91 function
and 6-311++g(2d,2p) basis set.77, 92, 93 The initial structure of CLF was obtained from the
literature.94 All optimizations were completed without any geometrical constraints. The
solvent effect of chloroform (=4.7113) was taken into account by applying a SCRF
(self-consistent reaction field) through the polarizable continuum model (PCM) 95.
Frequency analysis of each compound was performed at the same level to achieve the
optimized minima/zero imaginary frequency, so that Zero Point Energies (ZPE) and
Gibbs free energies (at 298.15 K and 1 atm.) were obtained. The Gauge-Independent
Atomic Orbital (GIAO) method was used to calculate NMR chemical shifts. 96 UV/Vis
spectra were simulated by utilizing the time-dependent density functional theory (TDDFT)
with 30 computed excited states 97
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2.5
2.5.1

Results

Powder X-Ray diffraction

Drug loading (DL) and physical stability of powdered ASD systems with acidic polymer
(HPMCP) and neutral polymers (HPMC, PVP/VA) were characterized by powder X-ray
diffraction (PXRD). When HPMCP was used as the carrier, an amorphous dispersion
with 63% drug loading could be achieved (Figure 2.2A). However, for the dispersions
formed by CLF and the neutral polymers, the drug loading capacities were significantly
lower than that of the system with HPMCP. For example, the drug loading of CLF was
limited to 10% when employing PVP/VA as the carrier (Figure 2.2C). Although the drug
loading could be increased to 25% with HPMC, crystalline drug was clearly observed in
dispersion system at a 50% drug loading (Figure 2.2B).
ASD samples with HPMCP (63% DL), HPMC (25% DL), and PVP/VA (10% DL) were
exposed to 40°C and 75% relative humidity (R.H.) for short term physical stability
studies. The PXRD results show that ASDs formed with HPMC or PVP/VA
recrystallized within a week. In comparison, the HPMCP dispersion system remained
amorphous over two weeks (Figure A.1). The above results indicate that HPMCP would
be a more efficient carrier to form an ASD with CLF for its superior drug loading
capacity and better physical stability.
2.5.2

Ultraviolet Visible Spectroscopy

When CLF was mixed with HPMCP in chloroform at a weight ratio of 1 to 5, visual
observation indicated a color change from orange to dark purple. Accordingly, the
ultraviolet-visible spectrum revealed that the wavelength of the broad peak centered at
450nm was bathochromically shifted to 487nm. Additionally, a similar pattern of shifts
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could be observed in the drug-polymer films prepared by spin coating (Figure 2.3A). A
similar color-changing phenomenon was detected when glacial acetic acid was added to a
CHCl3 solution of CLF. Based on the spectra shown in Figure2.3D, the wavelength of the
broad peak in visible wavelength range has shifted 37 nm both in the solution and the
solid state samples, which is very similar behavior to that observed when mixing CLF
with HPMCP. In contrast, virtually no color change was detected whe n CLF was codissolved with the neutral polymers (HPMC or PVP/VA) in the same solvent and the
same weight ratio. Predictably, the corresponding UV/Vis spectra did not change either
for the solution or for the solid thin films produced by spin coating (Figure 2.3B and
2.3C). These results are consistent with the formation of a protonated salt of CLF.
2.5.3

Solution NMR

2.5.3.1 1D 1H NMR spectra
The peak assignments for each proton of CLF were made (Figure A.2) by evaluating 1D
1

H NMR, COSY, NOESY and 1H,

13

C-HSQC (Figure A.3 to A.6. 1H NMR spectra of

CLF with the ionic polymer (HPMCP) or neutral polymers (HPMC and PVPVA), and
CLF alone are shown in Figure2.4. For the spectrum of CLF with HPMCP, not only are
the 1H chemical shifts moved downfield, but line broadening also occurs for all the
signals throughout the molecule. A similar change in the chemical shifts was observed
when glacial acetic acid was added (Figure A.7). However, the spectra of CLF with
HPMC and PVP/VA exhibited minimum changes of this type.
To quantitatively investigate the influence of HPMCP on both chemical shifts and lineshape changes, CLF solution was titrated by adding varying amounts of HPMCP with a
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HPMCP: CLF (w/w) ratio increasing from 0:1 to 5:1, and the corresponding 1D 1H NMR
spectra were acquired (Figure 2.5). Both the chemical shifts and the line-shapes of the
protons on the riminophenazine core exhibited the most significant changes. For instance,
the peak of H4 at 5.27 ppm demonstrated a line-width of less than 1.5 Hz in the absence
of HPMCP. When the ratio of HPMCP to CLF increased to 1:1, the line-width
dramatically increased to more than 36 Hz, and the chemical shift changed to 5.41 ppm.
As the amount of HPMCP further increased, however, the line-width decreased to 17 Hz
for a 5:1 ratio of HPMCP to CLF. Similar behavior was observed for the peak of H 6
located at 6.44 ppm. The line-width of each doublet-doublet component (coupling
constants 8.2 Hz and 1.1 Hz) was about 1 Hz or less without HPMCP. As the HPMCP:
CLF ratio increased to 1:1, the doublet-doublet peak coalesced into a single broad peak
with a 40 Hz line-width, and shifted downfield to 6.58 ppm. Again, when the ratio of
HPMCP to CLF increased to 5:1, a broad doublet re-appeared at 6.89 ppm with a 19 Hz
combined line-width. We also noticed that a clear new sharp doublet-doublet appeared at
8.35 ppm, which coincides with the spectrum of the phthalic acid and CLF mixture
(Figure A.8). This observation suggests that the binding is between the phthalic acid
group of HPMCP and CLF.
2.5.3.2 2D NMR spectra: NOESY and DOSY
The NOESY of CLF is shown in Figure2.6A. A positive sign (red color) of a NOE cross
peak (circled red for clarity) was observed between H 4 (5.27ppm) and the proton of the
isopropyl group located at 3.47 ppm, indicating fast tumbling of this part of the molecule.
However, when CLF was mixed with HPMCP at a ratio of 0.5: 1 by weight, not only did
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the same cross-peak switch sign to negative (same sign as diagonal; Figure2.6B), but also
more negative cross-peaks in other regions were observed. The change of the cross-peak
sign suggests CLF molecules tumble more slowly overall and the NOE build up was
becoming more efficient as a result. For comparison, only positive NOEs among these
protons were observed even in the presences of higher amount (drug: polymer = 1:1) of
either HPMC or PVPVA (Figure 2.6C and Figure2.6D).
To explore the changes associated with molecular mobility, DOSY was recorded for CLF
with different polymers (Figure A.9). The apparent self-diffusion coefficient appears at
7.94×10-10 m2/s for the sample with the 0.5: 1 ratio of HPMCP: CLF. However, the selfdiffusion coefficients for the two samples of CLF with HPMC or PVP/VA at a 1:1 weight
ratio were recorded as 3.16×10 -9 m2/s and 5.01×10-9 m2/s respectively. The sample of
CLF with HPMC or PVP/VA thus exhibit much higher self-diffusion coefficients than
that of CLF with HPMCP, presumably due to the different strength of association
between CLF and these polymers.
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2.6

Discussion

A prerequisite of investigating drug-polymer interactions is to understand the functional
group involvement of CLF and polymers. Neutral Population Analysis (NPA) was
conducted to show partial atomic charges of CLF (Figure 2.7A) as a means of further
delineating the structure and properties of the free molecule (details of charges are listed
in Table A.1). Nβ from the imine group is the most negatively charged atom (-0.542e) and
the proton (Hα) from secondary amine group has the highest positive value (+0.425e)
throughout the molecule. Hence, Nβ could serve as a strong hydrogen bond acceptor,
while Hα could potentially be an active hydrogen bond donor. Moreover, the short
distance between the Nβ and Hα (1.987Å) indicates the potential of forming a partial
intra-molecular hydrogen bond, which could weaken the intermolecular interaction
between Hα and other hydrogen bond acceptors due to the physical and geometrical
characteristics of hydrogen bonding. 98
On the other hand, the functional group characteristics of polymers and the potential for
intermolecular interactions could be evaluated by analyzing the chemical structure of
HPMC, HPMCP, and PVP/VA (Figure 2.1). Based on the pK BHX scale of functional
groups, the carboxylic acid of HPMCP and hydroxyl group of HPMC could be
categorized as strong hydrogen bond donors, while the carbonyl group of PVP/VA was
treated as a strong hydrogen bond acceptor. 99, 100 In addition, experimental data, such as
the similarity in the CLF NMR chemical shift changes induced by both HPMCP and
acetic acid (Figure A.7) indicate that the carboxylic acid group of HPMCP is a key
functional group in forming ionic interactions with CLF. This is further supported by the
salt formation rule which states that a ΔpKa value (pKa base- pKa acid) larger than 2 to 3
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will result in proton transfer. 46-48 For this study, it appears likely that proton transfer and
subsequent ion-pair formation can occur between HPMCP (pKa~3) and CLF (pKa=8.5)
even in a non-polar solvent (chloroform). 101, 102 To be specific, the phthalic acid group
provides a proton to protonate CLF, gaining negative charge for ionic bonding with the
now positive CLF, in addition to the potential for hydrogen bonding interactions.
According to the discussion of the molecular characteristics of each binding moiety,
variations we can rationalized in drug loading capacities and physical stability upon
storage for the different dispersions based on the different drug-polymer interaction
strengths. CLF is expected to form the weakest interactions with PVP/VA since this
polymer only contains an acceptor group, and hydrogen bonding between CLF and this
polymer is expected to be hindered by the presence of a partial intra-molecular hydrogen
bond involving the CLF donor group. The ASDs of CLF and HPMCP demonstrated
superior drug loading capacities, and this is attributed mainly to the ionic interactions
formed in the CLF-HPMCP dispersions which are strongly supported by the UV/Vis and
NMR spectra.
The color changes and red-shifted UV/Vis absorption spectrum of CLF in the amorphous
dispersion with HPMCP strongly supports the protonation and charge transfer between
the CLF and HPMCP leading to strong interactions. 103-105 When CLF interacts with the
carboxylic acid group of HPMCP, protonation of the π-conjugated riminophenazine
(chromophore) will impact its electronic properties, resulting in the observed color
change.106,

107

This supposition is strongly supported by the consistent nature of the

results observed in solution and in the solid state. Hence, the interaction pattern observed
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between CLF and HPMCP in the non-polar solvent is thought to correlate well with the
interaction between the drug and polymer in the ASD.
Moreover, the observed changes in the 1H NMR chemical shifts and line-shapes strongly
suggest that CLF exists in more than one state in the presence of HPMCP. Under the
assumption of fast exchange, a simple two-site equilibrium model is proposed in
Equation 2.1, in which CLF can exist either in the free-state or as ion-pair formed with
the carboxylate group of HPMCP (Figure 2.7B). A similar system has been analyzed in
the literature by applying the theory of dynamic NMR. 108
CLF + HPMCP ⇌ [CLF+ HPMCP - ]

Equation 2.1

Formation of an ion-pair would lead to a change of electron density, and therefore exhibit
different chemical shifts of 1H NMR for the two states.81 Basically, the observed proton
chemical shift is the population average of each individual state and the line-shape is
expected to be broadened by the exchange between the two states. Furthermore, the
existence of free and bound-states of CLF can be quantitatively estimated by titration.
Based on the previous studies of NMR line-shape changes for equilibrium systems, the
line-width would be expected to be broadest when 1/3 of the CLF exists in the boundstate with carboxylic acid of HPMCP. 109,

110

In the titration study (Figure 2.5A), this

occurs when the weight ratio of CLF: HPMCP is about 1:1. Due to the limited solubility
of HPMCP in chloroform, even with the highest concentration of HPMCP (10 mg/mL),
only about two-thirds of CLF exists in the bound-state. In the current case, the H 4
resonance, a singlet, was selected for the dynamic NMR calculation due to its proximity
to the center of interaction (Nβ) and lack of spectral interference from other protons
throughout the titration. With some simple assumptions for the dissociation constant,
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dissociation rate constant, and chemical shift of bound state, the peak position and linewidth of the H 4 resonance are calculated to show good agreement with the experiments,
which validates the two-site equilibrium model (Figure 2.8). Although the line-shape and
chemical shifts for H4 are satisfactorily explained, it should be pointed out that this model
is a rather simplified and approximate one as it does not account for the heterogeneity
and complexity of the polymer.
In the free-state, a small molecule, such as CLF (MW 474), is expected to tumble
relatively rapidly in solution leading to positive proton-proton NOEs. In contrast, when
associated to a much larger molecule, such as a polymer, the same small molecule would
tumble more slowly leading to negative NOEs due to a larger correlation time. 111 We
observed that NOEs of CLF (2mg/mL) changed signs from positive to negative when 1
mg/mL HPMCP was added. Based on the above two-state equilibrium model, NOEs of
the bound-state CLF with a negative sign become dominant and are clearly visible in
NOESY (Figure 2.6B) suggesting that a significant portion of CLF is associated with
HPMCP. In contrast, HPMC or PVPVA does not appear to strongly associate with CLF,
because no NOE sign changes were observed for CLF (Figure 2.6C and 2.6D).
Similarly, we can interpret the DOSY results by applying the two-site equilibrium model.
In the presence of HPMCP, CLF will spend a significant amount of time in the boundstate, and therefore its translational movement will be slower than the free-state of the
drug. In our study, we treat the observed CLF diffusion coefficient as an averaged
population of self-diffusion constants for the free-state and bound-state CLF. According
to the DOSY results, the self-diffusion coefficient of CLF and HPMCP complexes is
much lower than that of CLF with other control polymers indicating a larger population
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of the bound-state complex and a slower average movement of the CLF molecule.
Therefore, we can claim that the molecular mobility of CLF is significantly reduced due
to the strong association between CLF and HPMCP. This conclusion is also consistent
with the fact that ASD of CLF and HPMCP has greater stability and lower crystallization
tendency during storage.
After evaluating the interaction type and strength between CLF and HPMCP, we were
curious about the molecular details of the CLF and HPMCP complex. As discussed
previously, the carboxylic acid group of HPMCP serves as the key moiety in interacting
with CLF. For computational modeling, HPMCP was simplified to acetic acid, and
simulations were performed to probe the possible molecular structure of the CLF and
carboxylic acid complex. According to a previous report, two potential complexes
(complex I and complex II) with two different types of interactions are proposed. 112 The
structures and geometrical positions of the two complexes were optimized by the
methods described in the experimental section (listed in Table A.2 and A.3). To be
specific, for complex I, protonated Nβ H+ of CLF interacts with the COO- group by
electrostatic force. In addition, the complex is stabilized by a bifurcated hydrogen
bonding system formed between Hα and Hβ and the carboxylate group (Figure 2.7C). In
complex II, hydrogen bond dimer formation is involved between CLF and the carboxylic
acid without ionization (Figure 2.7D). At a first glance, it seems that formation of a dimer
system without protonation would be highly possible in a non-polar solvent (chloroform).
However, we deem that interactions between CLF and HPMCP should be very similar to
interactions within complex I for the following three reasons.
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First, our calculated Gibbs free energy of complex I is 1.24 kcal/mol lower than that of
complex II (Table A.4, A.6) suggesting the complex I is more thermodynamically
favorable and stable. Second, with regard to changes in chemical shifts, the simulated
NMR spectrum of complex I generally agrees well with the experimental NMR spectrum
(Figure A.10). Specifically, in this study, there is a particular interest in the chemical
shifts of H 4 and H 6, because they are located on the π conjugated riminophenazine core
and have little spectral interference from other signals. For complex I, H4 shifts
downfield from 5.49 ppm to 6.04 ppm, and H 6 changes from 7.43ppm to 7.85ppm in the
simulated spectrum. In contrast, for complex II, the calculated NMR spectrum
demonstrates an obvious discrepancy with experiments: H 4 shifts downfield 0.18 ppm,
and H 6 is shifted upfield by 0.2 ppm (Table A.8). Apparently, experimental observations
are more consistent with the simulated spectral changes of complex I. Third, for complex
I, the strong absorption peak appeared at 583 nm in the simulated visible spectrum, and
this correlates well with the experimentally observed red-shifted spectrum and
solution/film color-changes. In contrast, for complex II, the simulated UV/Vis spectrum
has no significant differences compared to that of pure CLF (Figure A.11). Thus, the
simulations further support the existence of ionic interactions between CLF and HPMCP
in chloroform and suggest a possible binding motif for the CLF and HPMCP complex.
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2.7

Conclusion

An amorphous solid dispersion system of clofazimine and HPMCP was found to have
superior drug loading capacity and better physical stability due to strong drug-polymer
interactions. By studying the drug-polymer interactions in a non-polar solvent system
prior to forming ASDs, we are able to explain and predict the improved solid state
performance of dispersions, and this approach is expected to reduce the need for the timeconsuming, traditional polymer screening process. Furthermore, by correlating the
spectroscopic measurements with quantum chemistry calculations, the functional groups
involved in the binding moiety are identified, and ionic interactions are confirmed as the
dominant force in the CLF and HPMCP complex. Protonation of CLF leads to the
electron density changes of the riminophenazine core, which result in a corresponding
downfield shifted 1H NMR spectra and a red-shifted visible spectrum. The line-width
changes of the NMR spectra reveal an exchange two-site equilibrium model as the
underlying mechanism of CLF-HPMCP association in a non-polar solvent. Based on this
equilibrium model, we are able to quantify the free and the bound states of CLF in
chloroform. Furthermore, the molecular mobility of API molecules and drug-polymer
association were investigated by NOESY and DOSY. The strong drug-polymer
association in the CLF-HPMCP complex correlates well with its lower self-assembly
tendency in the amorphous solid dispersions and its lower tendency to crystallize upon
storage
In summary, the ASD system of CLF and HPMCP serves as an example of illustrating
the utility of ionic interactions in formulations as a means to improve the drug loading
capacity and physical stability. Our study also provides fundamental information about
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the underlying interaction strength, interaction types, and functional group involvement
between drug and polymer at a molecular level. To the best of our knowledge, this is the
first time whereby solution state NOESY and DOSY results have been correlated to the
molecular mobility of API molecules in ASDs. These interesting discoveries should
profoundly impact the selection of appropriate polymers when designing new amorphous
solid dispersion products.
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Figure 2.1 Chemical structures of CLF (A), HPMCP (B), PVP/VA(C), and HPMC (D)
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Figure 2.2 PXRD for dispersion system of CLF with different polymers (A: HPMCP; B:
HPMC and C: PVPVA). Percentage in the legend indicates CLF loading
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Figure 2.3 UV/ Visible spectra of CLF with different polymers and acetic acid for both
solution state (dashed line) and solid state (solid line). A) HPMCP; B) HPMC; C)
PVPVA; D) acetic acid
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Figure 2.4 1D 1H spectra for CLF with different polymers in CDCl 3, 298K
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Figure 2.5 1H spectra of CLF in CDCl 3 when titrated by HPMCP at 298K
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Figure 2.6 2D NOESY of CLF alone (A) and with HPMCP (B), HPMC (C) or PVP/VA
(D)

Figure 2.7 NPA of charges for CLF (A), Mechanism of CLF interact with carboxylic
acid (B), Complex I (C), Complex II (D)
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Figure 2.8 Calculated (dash line) and measured (solid) dynamic NMR spectra for H 4 (A)
and summary of line-width (red) and chemical shift (blue) for dynamic NMR of H 4 (B)

65

CHAPTER 3. SOLID-STATE SPECTROSCOPIC INVESTIGATION OF
MOLECULAR INTERACTIONS BETWEEN CLOFAZIMINE AND
HYPROMELLOSE PHTHALATE IN AMORPHOUS SOLID DISPERSIONS

3.1

Abstract

It has been technically challenging to specify the detailed molecular interactions and
binding motif between drugs and polymeric inhibitors in the solid state. To further
investigate drug-polymer interactions from a molecular perspective, a solid dispersion of
clofazimine (CLF) and hypromellose phthalate (HPMCP), with reported superior
amorphous drug loading capacity and physical stability, was selected as a model system.
The CLF-HPMCP interactions in solid dispersions were investigated by various solid
state spectroscopic methods including ultraviolet-visible (UV/Vis), infrared (IR), and
solid-state NMR (ssNMR) spectroscopy. Significant spectral changes suggest that
protonated CLF is ionically bonded to the carboxylate from the phthalyl substituents of
HPMCP. In addition, multivariate analysis of spectra was applied to optimize the
concentration of polymeric inhibitor used to formulate the amorphous solid dispersions.
Most interestingly, proton transfer between CLF and carboxylic acid was experimentally
investigated from 2D 1H-1H homonuclear double quantum NMR spectra by utilizing the
ultrafast Magic-Angle Spinning (MAS) technique. The molecular interaction pattern and
the critical bonding structure in CLF-HPMCP dispersions were further delineated by
successfully correlating ssNMR findings with quantum chemistry calculations.
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These high resolution investigations provide critical structural information of APIpolymer interaction, which can be useful for rational selection of appropriate polymeric
carriers which are effective crystallization inhibitors for amorphous drugs.
3.2

Keywords

Amorphous; Solid Dispersion; Drug Polymer Interactions; Acid-Base Interaction; SolidState NMR; Ultrafast MAS; Principal Components Analysis
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3.3

Introduction

Amorphous solid dispersion (ASD) formulations, where the active pharmaceutical
ingredient (API) is molecularly dispersed in a polymeric matrix, are widely applied to
improve bioavailability for poorly water soluble pharmaceutical entities. 64,

65, 67, 113, 114

However, maintaining the amorphous state of drug substances in ASDs is a challenge,
whereby intermolecular interactions formed between the API molecule and functional
groups of the polymer are thought to be of critical importance.66, 70, 115-117 For instance, it
has been demonstrated that polyvinylpyrrolidone forms strong intermolecular interactions
with resveratrol in the dispersion, leading to satisfactory physical stability at stressed
condition; 118 while polyvinylpyrrolidone can also show insufficient inhibitory effects on
itraconazole crystallization due to the absence of drug-polymer interactions.119 Typically,
stronger drug-polymer intermolecular interactions can more effectively disrupt molecular
self-assembly of the API in the dispersion, and therefore lead to a relatively stable ASD
system with a high drug loading. For example, formation of strong association between
clofazimine (CLF) and hypromellose phthalate (HPMCP) leads to an ASD system with
superior drug loading capacity and physical stability. 120 Acid-base interaction, an
electrostatic interaction formed by ionized molecules, is perhaps the strongest inter molecular association possible between an API and polymeric carrier. The formations of
such strong intermolecular interactions in dispersions are generally favorable especially
for high-dose formulations.72-74,

121-123

For instance, ASD systems of lapatinib with

ionizable polymers illustrated the utility of acid-base interactions in formulations as a
strategy to enhance the drug loading capacity. 102 Hence, understanding the molecular
interaction patterns between API and polymeric carriers is of significance to efficiently
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design robust formulations of ASDs with satisfactory physical stability at minimal
polymer concentrations avoiding the reliance on the empirical polymer screening process.
However, molecular details of drug-polymer interaction patterns are still unclear due to
the challenges of identifying the interaction type, functional group involvement, and the
binding motif in amorphous materials. 69
Although our previous research provided an improved understanding of intermolecular
interaction patterns between CLF and HPMCP in a nonpolar solvent system prior to
forming the solid dispersion120, knowledge about CLF-HPMCP interactions in the solid
state is still limited, which necessitates the employment of comprehensive solid state
spectroscopic investigations. Infrared (IR) spectroscopic analysis, a pow erful tool to
select the appropriate polymer for ASD formulations, can be used to monitor drugpolymer interactions by evaluating the vibrational changes of involved functional
group.124-126 Ultraviolet-Visible (UV/VIS) spectroscopy is a useful method to estimate the
electronic property changes of molecules containing conjugated structures. 82, 92, 127 In the
past decade, solid-state NMR (ssNMR) has been successfully applied to provide atomiclevel structural insights of intra- and intermolecular interactions in ASDs. 128-133 The
molecular proximity between API and polymer has been experimentally detected in
various dipolar experiments utilizing homo- and heteronuclear correlation. For example,
2D 1H- 1H correlation experiments have observed cross peaks between the –OH and
aliphatic groups of diflunisal and aromatic groups of PVP, suggesting their close contact
(~ 3 Å).132 Moreover, the recent advances of ultrafast magic angle spinning (MAS) NMR
technology enables the 1H detection at a largely improved resolution, allowing a more
extensive application of the

1

H-detected multi-dimensional correlation to further
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determine convoluted structures. 134, 135 The 1H-detection technique under ultrafast MAS
spinning also makes 2D 1H- 1H homonuclear correlation experiments more applicable for
probing detailed structural information of natural-abundant organic solids.132, 136
In the present research, taking advantage of aforementioned spectroscopic analyses, the
goal was to probe the solid-state interaction patterns of CLF and HPMCP dispersions at a
molecular level and to further elucidate the underlying reaction mechanism. On the basis
of our previous research about ion-pair formation of CLF and HPMCP in a non-polar
solvent system, we herein hypothesized the presence of acid-base interactions in CLFHPMCP solid dispersions and focused on obtaining direct spectroscopic evidence of such
an interaction. An objective of particular interest was to combine the molecular-level
results from ssNMR and computational chemistry to determine the structure or, at a
minimum, the critical structure elements of the CLF-HPMCP complex. Moreover,
another goal of this study was to determine an optimized ratio of drug and polymer by
using multivariate analysis of spectra. The findings of this research can serve as a
precedent demonstrating the utility of comprehensive spectroscopic investigations on
drug and polymer interactions, which is critical for the rational design of innovative ASD
formulations.
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3.4

Experimental

3.4.1

Materials

CLF (Figure 3.1A) in crystalline form was purchased from Sigma-Aldrich (St. Louis,
MO). HPMCP (HP-55, Figure 3.1B) was generously provided by Shin-Etsu Chemical
Co., Ltd. (Tokyo, Japan). Dichloromethane (ChromAR grade) was obtained from
Mallinckrodt Baker, Inc. (Paris Kentucky). Ethanol (200 proof) was supplied by
Pharmaco Products, Inc. (Brookfield, CT). Both CLF and HPMCP were individually
stored in desiccators with calcium sulfate (W.A. Hammond Drierite Co. Ltd, Xenia, OH)
for at least 7 days at 25°C. The melt-quenching method was employed to prepare a neat
reference sample of amorphous CLF: the crystalline form of CLF was placed on a
THMS600 temperature controlled hot-stage (LINKAM scientific, Surrey, UK) at 220 °C
for approximately 10 minutes and then quench-cooled by liquid nitrogen.
3.4.2

Preparation of solid dispersion

Both CLF and HPMCP at the desired dry weight ratios were fully dissolved (visually
inspected, sonication was applied as needed) in a 50%: 50% (v/v) solvent mixture of
dichloromethane and ethanol to form homogenous solutions. These uniform single-phase
solutions were then employed to prepare solid dispersions by using rotary evaporation or
spin coating to remove the solvents. For rotary evaporation, dichloromethane and ethanol
were removed by a rotary-evaporator (Buchi, New Castle, DE) under vacuum and
submersed into a water bath maintained at a constant temperature (~50°C) for 2-3
minutes. Dispersions of CLF-HPMCP were afterwards exposed to a vacuum at room
temperature for at least 24 hours to further remove any residual solvents in the powder.
Dispersions prepared by spin coating were used for ultraviolet-visible spectroscopic and
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infrared spectroscopic analysis. Several drops of the solution were placed either on a
quartz microscope slide or on a barium fluoride (BaF 2) infrared substrate (VWR, Radnor,
PA). Spin coating were performed using a KW-4A spin coater (Chemat Technology Inc.,
Northridge, CA) with a rate of 200 rpm for 20s (for quartz slides) and 100 rpm for 10s
(for barium fluoride substrate) at ambient temperature to readily remove solvents. 90
3.4.3

Powder X-Ray diffraction (PXRD)

The X-ray diffraction patterns of CLF-HPMCP solid dispersions prepared by rotary
evaporation were collected on a Panalytical X’Pert pro X-Ray diffractometer
(PANalytical Inc., Westborough, MA) with Cu Kα radiation of 1.5406 Å in transmission
mode. Measurements were conducted at ambient conditions in transmission geometry
with 2θ ranging from 2° to 40° using a 0.0167° step size. The voltage and the current of
the generator were set to 45 kV and 40 mA respectively. PXRD data were processed by
Panalytical X’Pert Data Viewer (version 1.5) software.
3.4.4

Solid-State Ultraviolet-Visible (UV/Vis) spectroscopy

A Cary 300 Bio UV spectrometer coupled with WinUV software (Varian Inc., Palo Alto,
CA) was employed to analyze dispersions of CLF and HPMCP spin-coated onto quartz
slides. Data were collected over the wavelength range from 200nm to 800nm, while the
spectral region of 370nm to 600nm was used for subsequent analyses. Multivariate
analysis software SIMCA v13 (Umetrics AB, Umeå, Sweden) was applied for principal
components analysis (PCA). Standard normal variate transformation (SNV) was
employed to preprocess the spectra.
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3.4.5

Infrared (IR) spectroscopy

IR spectra of CLF and HPMCP dispersions were obtained in transmission mode using a
Bruker Optics IR IFS 66V/S spectrophotometer (Billerica, MA) equipped with globar
infrared source, KBr beam splitter, and DTGS detector. A scan range from 1000 to 4000
cm-1 was set with 128 scans co-added and 4 cm-1 resolution. A vacuum was applied to the
sample and detector compartments to minimize the interference from moisture present in
air. IR spectra of pure CLF or HPMCP were collected by the same method. Spectra were
virtually inspected by OPUS software v7 (Bruker Optics, Ettlingen, Germany). PCA of
infrared spectra were processed using SIMCA v13 (Umetrics AB, Umeå, Sweden).
3.4.6

Solid-state NMR spectroscopy (ssNMR)

All ssNMR spectra were acquired on a Bruker HD Avance III triple-resonance
spectrometer operating at 1H and
respectively. All

13

C resonance frequency of 400 MHz and 100 MHz

13

C experiments were carried out by using a Bruker 4 mm triple

resonance HXY MAS probe tuned to 1H and

13

C double-resonance mode, as previously

described.137 Approximately 90 mg of ASD powder was packed into 4.0 mm MAS
zirconium rotors for each experiment. Sample temperature is maintained at 293 K using a
BCU cooling system. One-dimensional (1D) 13C spectra were acquired using the crosspolarization magic angle spinning (CP-MAS) experiment under a spinning frequency of
12 kHz. 1H to 13C cross polarization applied a 1.5 ms contact time with a linear ramp on
the 1H channel and constant field on the

13

C channel. 83 kHz SPINAL 1H decoupling

was used during acquisition.
1

H-detected experiments were carried out using a H/F/X ultrafast spinning probe on

approximately 4 mg of sample packed into a Bruker 1.3 mm rotor spinning at 60 kHz and

73
at a proton frequency of 400 MHz. The cooling gas streams from BCU-II at a 253 K
were streamed to control the sample temperature. 2D 1H-1H dipolar double quantum (DQ)
correction spectra were recorded using back-to-back (BABA) scheme. 138 This ssNMR
method describes a rotor-synchronized pulse sequence which excites DQ coherence from
1

H homonuclear dipolar coupling in the excitation period and reconverted to single

quantum coherence for detection. For all 2D experiments, the 1H 90o pulses during the
excitation and reconversion blocks were 1.2 μs. Other experiment parameters include 32
scan average with a 2.5 s recycle delay, one rotor cycle BABA recoupling, 12.9 ms
maximum evolution time in indirect dimension and 9.1 ms during direct acquisition
period, a 16-step phase cycle and ultrafast MAS frequency of 60 kHz.
Glycine was used as an external

13

C chemical shift reference by setting the carbonyl

13

C

peak at 176.49 ppm. 1H chemical shifts are referenced by setting the single 1H resonance
of Adamantine at 1.6 ppm on the TMS scale. All spectra are recorded and processed in
TopSpin 3.5.
3.4.7

Computational methods

The density functional theory (DFT) based calculations for both pure CLF and its
complexes were performed by applying Gaussian 09 software package 91 with the DFT
level of the hybrid B3PW91 function and 6-311++g(2d,2p) basis set.77, 92, 93 using the
previously published CLF structure as a starting point 94, optimizations were conducted in
the gas state without any geometrical constraints as a fair comparison to the structure in
the amorphous solid state. Zero imaginary frequency was achieved in the output of
frequency analysis of each system. The Gauge-Independent Atomic Orbital (GIAO)
method was applied herein for NMR chemical shifts calculations.
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3.5
3.5.1

Results and Discussion

Amorphous Drug Loading and Chemical Features

The X-ray diffraction patterns of powdered CLF-HPMCP dispersions with CLF: HPMCP
(w/w) ratios increasing from 1: 0.25 to 1: 2 are shown in Figure 3.2. The amorphous form
of CLF could be effectively maintained for the dispersion with a 0.75: 1 ratio of HPMCP
to CLF. In comparison to the limited amorphous drug loading reported for CLF
dispersions prepared with neutral polymeric carriers, 120 the ASD of CLF-HPMCP was
shown to have a superior drug loading capacity (~60%) indicating that HPMCP is an
effective crystallization inhibitor for amorphous CLF. Hence, formation of strong
intermolecular interactions is expected between CLF and HPMCP.
In order to better investigate the specific drug-polymer interaction, understanding the
chemical features of free drug and polymer molecules is a reasonable starting point.
Natural Population Analysis (NPA) was applied herein to scrutinize the atomic charges of
CLF (Figure 3.1C, details of charges are attached in Table A.10-12) as a means to
identify potential interaction sites of drug molecules.139 In Figure 3.1C, the atomic charge
of Nα (-5.35e), which is part of the imine group, was shown to have the most negative
value throughout the CLF molecule, implying a potential for serving as a strong proton
acceptor. On the other hand, Hβ , located at the secondary amine group, stood out as the
most positively charged atom (+0.425e), indicating that the NH group is capable of being
a proton donor. In addition, based on the geometrical characteristics of hydrogen bonds,
the close atomic range between the Hβ and Nα (1.976 Å) enables the formation of a partial
intramolecular hydrogen bond. 98, 140 The existence of such an intramolecular interaction
can impair the intermolecular interaction between H β and other acceptors. Hence,
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polymeric carriers with chemical structures containing only acceptor groups are expected
to have limited inhibitory effects on the crystallization of CLF. This expectation is in
satisfactory agreement with previous research: lacking of proton donor groups to interact
with Nα, polyvinylpyrrolidone were shown as a poor polymeric inhibitor to disrupting the
self-assembly of CLF.89
According to the chemical structure of HPMCP shown in Figure 3.1B, one substituent of
particular interest is the phthalyl group which is expected to be a key functional group in
bonding with CLF. To be specific, the carboxylic acid of the phthalyl can not only be a
strong hydrogen bond donor, but also can become negatively charged by proton donation,
subsequently forming an ionic interaction. Considering the pKa values of CLF (8.5)141
and HPMCP (~3) 102, further support for the formation of an acid-base interaction can be
established on the basis of the salt formation rule which enunciates that proton transfer
likely occurs between acidic/basic components when the ΔpKa value (pKa basic
component- pKa acidic component) is greater than 2 to 3. 46-48, 101 Therefore, spectroscopic
evidence of ionic bonding between negatively charged phthalate and protonated CLF
were sought as described below.
3.5.2

Solid-State Spectroscopic Investigation of Drug-Polymer Interactions

3.5.2.1 UV/Vis Spectroscopy
Pure CLF presents with a red color in both crystalline and amorphous forms, while an
apparent color change from red to dark purple can be visually inspected when
formulating CLF with HPMCP as a solid dispersion (Figure A.12). This color-change
phenomenon also can be observed for solvent evaporated mixtures of CLF and glacial
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acetic acid/formic acid. Interestingly, no color change can be detected for CLF solid
dispersions prepared with polymers that lack of carboxylic acid group (e.g. PVP/VA or
HPMC). These interesting findings further suggest that the carboxylic acid group from
phthalyl on HPMCP is the key functional group that interacts with CLF in solid
dispersions.
Furthermore, significant differences of the UV/Vis spectra between the pure CLF and
CLF-HPMCP dispersions were observed in the visible wavelength range. To be specific,
CLF alone shows a broad peak centered at 450 nm. This peak gradually bathochromically
shifted to 487nm when preparing CLF-HPMCP dispersions with different weight ratios
(Figure 3.3A). It is important to point out that the HPMCP alone has no visible
absorption peak in this spectral region. The color-change phenomenon and the
corresponding red-shifted visible absorption spectra of CLF-HPMCP dispersions are
directly caused by the impact of electrostatic interactions on chromophore of the drug
molecule.103-105 In this case, Nα of the imine group is located at the π-conjugated
riminophenazine core which is the chromophore of the CLF. The proton of polymer
carboxylic acid group transfers to the Nα, yielding a carboxylate group and a protonated
imine group. Therefore, protonation of the riminophenazine core leads to electron density
changes in the conjugated chromophore resulting in the obvious color-change and redshifted visible spectra.106, 107
To further quantitatively investigate the effect of HPMCP on this bathochromic shift,
spectra of dispersions with CLF: HPMCP (w/w) ratios ranging from 1: 0.1 to 1: 2 were
subjected to principal components analysis (PCA). The first principal component (PC1)
captures over 97% of the spectral variation in the wavelength range 380-600nm. A score
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value of a component is defined as the projection of a spectrum onto a multidimensional
space as a single point. In this case, score values of PC1 were applied to represent the
spectral region with peaks located at different wavelength positions. The score values of
PC1 were then plotted against HPMCP/CLF (w/w) to probe the best HPMCP content in
the CLF solid dispersion formulations (Figure 3.3B). Based on Figure 3.3A and 3.3B, no
significant red-shift was observed for the peak centered at 450nm when the CLF:
HPMCP (w/w) ratio was less than 1: 0.5, indicating that the low content of HPMCP in
these dispersions was insufficient to protonate the CLF chromophore. On the other hand,
the wavelength of the broad peak has the largest bathochromic shift (~37nm) when the
weight ratio of CLF to HPMCP reaches 1: 1.5, suggesting total protonation of the
interaction center. The sharpest changes of the PC1 score value were observed for the
intermediate compositions (CLF: HPMCP= 1: 0.75 or 1) of this titration curve. Similar
quantitative results of correlating the spectral variables and polymer content of
dispersions can be found from the mid-IR and ssNMR studies (vide infra).
3.5.2.2 IR spectroscopy
IR spectra of dispersions were evaluated herein to delineate how the drug-polymer
interaction resulted in changes of vibrational modes for the involved chemical moieties of
CLF or HPMCP. According to Figure 3.4A, a clear new peak (peak A) appears at 3310
cm-1 in the IR spectra of the CLF-HPMCP dispersions. This new peak corresponds to the
Nα-H+ stretching of the protonated imine group. Interestingly, peak A was absent for
dispersions with ratio of CLF to HPMCP less than 1: 0.5 (w/w) suggesting that the
limited concentration of carboxylic acid groups in the phthalyl substituent is insufficient
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to protonate the imine group. As the concentration of the HPMCP in dispersions
increases, the intensity of peak A was enhanced accordingly. This finding is in a good
agreement with the UV/vis spectra discussed above.
HPMCP alone has a fairly broad peak centered at 1724 cm-1 (peak B) assigned to the
stretching of the carboxylic acid C=O group. The carboxylic acid from the phthalyl
substituents can be converted to carboxylate group by forming ionic interaction with CLF.
This interaction is supported by the appearance of peak at 1540 cm-1 (peak D) and 1395
cm-1 (peak F) which can be assigned to the antisymmetric and symmetric stretching of
the carboxylate group. A hypsochromic shift of Peak B from 1724 to 1733 cm-1 in the IR
spectra of dispersions was also noted(Figure 3.4B); and this may be due to some
accompanying changes in the hydrogen bond interactions of C=O groups. More evidence
of the existence of acid base interactions between CLF and HPMCP can be found from
the changes of spectra features in the region of 1650 cm -1 to 1350 cm-1 (Figure 3.5).
Specifically, Peak C located at 1626 cm-1 corresponds to the stretching of C=Nα from the
imine group. In the presence of HPMCP, peak C undergoes a bathochromic shift to 1619
cm-1, indicating that protonation of Nα leads to changes in the vibrational properties of the
imine group. This observation is consistent with a previous report of a similar red-shift of
imine peak in the IR spectra of CLF salts prepared with low-molecular weight counterions such as maleic acid or isonicotinic acid.112 Finally, the appearance of an intense new
peak at 1481 cm-1 (peak E) is assigned to Nα H+ deformation, further supporting the
protonation of Nα.
Spectral regions containing peaks A-F were subjected to PCA to further quantitatively
study the relationship between HPMCP content and acid-base interactions. Plots of PC1
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score value against the HPMCP/CLF weight ratio for each peak are shown in Figure 3.6
A-F. Each plot shows good agreement with the score plots obtained from the UV/Vis
spectra; For the HPMCP/CLF ratio in the range of 0.75 to 1, the steepest changes of the
PC1 score value were noted; indicating CLF consists of a mixture of the ionized and
neutral states at these polymer concentrations. A detailed calculation of the molar ratio of
drug and polymer and how this determines the optimized polymer concentration will be
further discussed in detail.
3.5.2.3 Solid state NMR spectroscopy
Intermolecular geometry between API and polymer carrier have been successfully
detected by dipolar based ssNMR experiments utilizing cross polarization, spin diffusion
effect, and multi-quantum correlations.128-130 To further obtain site specific information at
a molecular level, we have utilized ssNMR to elucidate the structural basis of the
interactions between CLF and HPMCP. Figure 3.7 shows the 13C CP-MAS spectra of the
HPMCP, melt-quenched and as-received CLF. The relatively broad peaks, i.e. 13C peak
width at full width at half maximum (FWHM) of 4.1-7.1 ppm and 2.8-3.8 ppm
respectively for polymer and melt-quenched API, indicate the amorphous nature of the
two samples. In comparison, the crystalline CLF has relatively sharp

13

C peak of ~ 1.0

ppm. It is useful to note the resolved –C=O peak (in red) of HPMCP and isopropyl-C (in
green) in CLF from all other peaks, providing good probes to detect possible perturbation
of local structures.
The spectral comparison of CLF-HPMCP dispersions at various API-to-polymer weigh
ratios is exhibited in Figure 3.8A. Spectral features of CLF peaks in terms of linewidth
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and resonance position largely match with the melt-quenched API, confirming the
amorphous state. The only exception is the

13

C spectrum of the dispersion sample at the

CLF: HPMCP ratio of 1:0.25, which contains a large amount of sharp peaks from
crystalline content. This confirms the PXRD finding in Figure 3.2. Interestingly,
chemical shift changes of –C=O and isopropyl-C peaks, respectively in HPMCP and CLF,
are observed in Figure 3.8A and B, suggesting the molecular interaction between these
two groups. Specifically, as summarized in Table A.9, 13C chemical shift of isopropyl-C
of pure CLF in crystalline and amorphous forms show a peak 49.4 ppm. In dispersion
samples, this peak shifts to upfield positions, e.g. 47.0 ppm at the CLF: HPMCP ratio of
1: 9. The chemical shift difference of isopropyl-C between pure CLF and the ASD is
correlated with the computational results in Table 3.1 for determining a model of the
CLF-HPMCP complex, which will be discussed more in the next section. Moreover, the
13

C resonance of carboxylic acid C=O in pure polymer is at 169.5 ppm and shifts to a

new position at 174.2 ppm in CLF-HPMCP dispersions (Figure 3.8B), assigned to the
carboxylate bound to CLF. This new component accounts for more peak intensity and
area with respect to the original peak of pure HPMCP at a higher CLP: HPMCP ratio. PC
analysis of this drug-loading dependent peak change shows sharpest change of the score
value at the CLF: HPMCP ratio equal to 1 (Figure 3.8C), in good agreement with the
findings of UV/Vis and IR spectroscopy.
1

H double quantum (DQ) correlation experiment utilizing back-to-back (BABA)

excitation and reconversion pulse schedule has shown the capability of detecting close
contacts of up to 5 Å in pharmaceutical solids. 132, 136, 142 2D 1H-1H spectra of pure CLF
and HPMCP are shown in Figure 3.9 A and B respectively, showing correction peaks
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between aliphatic and aromatic protons. Hypothetically, the formation of CLF-HPMCP
ASD involves proton transfer from –COOH of polymer to Nα of CLF. This formation of
a new Nα and Hα contact, if exists, will impact the local electronic configuration of N-H.
Therefore, it would be of particular interest to pay attention to peaks of protons attached
to Nand N  (exists only if the proton transfer happens). The proton chemical shift of NH in pure CLF has been experimentally measured to be 8.6 ppm in chloroform in our
previous study, which is presumably overlapped with the aromatic protons in Figure 3.9A.
Therefore, the possible intramolecular correlations between H and other protons within
the same CLF molecule will be underneath the aliphatic-aromatic cross peaks. HPMCP
has no N-H groups and thus no amine proton peak in Figure 3.9B. Very interestingly, a
pair of new cross peaks at 11.5 ppm and 10.0 ppm respectively appears in the spectrum of
the HPMCP ASD (50% CLF by weight) in Figure 3.9C, which has equal peak intensity
as shown in the 1D slice in red. These relatively large chemical shifts can only be
assigned to protons adjacent to a nitrogen atom in the current molecular systems.
Considering both the fact that no N-H containing compound has been introduced in
forming the ASD and characteristic chemical shifts, these two new resonances can be
assigned to the existing Nβ-Hβ and the newly formed Nα-Hα. As shown in Table 3.2,
computational data in the next session show a peak shift to downfield for H when bound
to polymer, resulting in the resolved peak in the spectrum of ASD. The correlation
between Hα-Hβ in the DQ-SQ BABA spectrum of the CLF-HPMCP complex further
confirmed the two protons are strongly dipolar coupled, suggesting their close distance in
space.
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3.5.3

Understanding the mechanism of CLF-HPMCP interaction from correlating
ssNMR findings and computational analysis

The aforementioned experimental investigations provide valuable spectroscopic evidence
for understanding the molecular interactions with CLF-HPMCP ASDs. Computational
modeling is applied herein to better interpret these experimental findings, for elucidating
the interaction mechanism, and for depicting critical structure elements of CLF-HPMCP
complex. As the carboxylic acid of HPMCP is the key chemical moiety to bond with CLF,
the HPMCP structure was simplified as acetic acid in the computational modeling for
ease of calculation.
Two possible structures of CLF and carboxylic acid complex (complex I and complex II)
with optimized geometrical positions and different binding motif were proposed herein
according to a previously published report.112, 120 Briefly, ionic interaction was formed in
complex I (Figure 3.10A, Table A.11) between the protonated imine group of CLF (NαH+)
and the carboxylate group. In addition, NαH + and the secondary amide group (NβH) form
a bifurcated hydrogen bond with the COO - group to further stabilize complex I. On the
other hand, the bonding motif of complex II (Figure 3.10 B, Table A.12) was proposed as
forming a hydrogen bond dimer between CLF and HPMCP without proton transfer. The
atomic distance between Hα and Hβ is 1.702 Å and 2.176 Å in complex I and II
respectively; hence both are within the detection range of the 1H DQ BABA experiment.
Simulated NMR chemical shifts of each complex were calculated by methods described
in the experimental sections (summarized in Table A.10 to A.12). Interestingly, the
chemical shifts of the simulated NMR spectrum for complex I has a satisfactory
agreement with the experimental NMR spectrum of the CLF-HPMCP dispersion. To be
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specific, there is a particular interest in the changes of chemical shifts of the isopropyl
group in 13C CP-MAS spectra due to its direct connection to the imine group (interaction
center) and lack of spectral interference from the HPMCP. According to the experimental
ssNMR results, the chemical shift of the isopropyl group in 13C ssNMR spectrum of pure
CLF was located at 49.4 ppm, while this peak was shielded to 47.5 ppm for 50% drug
loading CLF-HPMCP ASD. For the simulated NMR spectrum, we observed that this
peak upfield shifted from 53.2 to 51.1ppm (Table 3.1) showing a satisfactory concurrence
with the experimental result. In contrast, peak of isopropyl moiety shows a downfield
shift for complex II (Table 3.1), exhibiting an obvious discrepancy with experimental
chemical shift. Moreover, for the 50% drug loading CLF-HPMCP dispersion, the
chemical shifts of Hα and Hβ are experimentally reported as 11.5 and 10.0 ppm
respectively in 1H NMR spectra giving a difference of 1.5 ppm. On the other hand, the
simulated chemical shifts of Hα and Hβ for complex I are calculated to be 15.2 and 13.8
ppm (Table 3.2), while the calculated chemical shifts of Hα and Hβ become 13.7 and 9.3
ppm applying the complex II as a model structure (Table 3.2). These calculated results
give a chemical shift difference of 1.4 ppm and 4.4 ppm for complex I and II respectively.
The good agreement between the experimental and computational results suggests that
complex I is a better model to illustrate interactions existed in the CLF-HPMCP ASD
system. Thus, these simulations further support the presence of and acid-base interaction
in the CLF-HPMCP ASD system, and indicate that the molecular interaction pattern
between CLF and HPMCP should be very similar to the bonding motif of complex I.
Hence, the following detailed molecular structure and binding mechanism is proposed
(Figure 3.10C): Nα on the imine group of CLF is protonated by the carboxylic acid group
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on the phthalyl from HPMCP. The intra-molecular hydrogen bond formed between Nα
and the secondary amide group is cleaved to make N βH as active hydrogen bond donor.
Therefore, Nα H+ and NβH form a bifurcated hydrogen bond to further enforce the binding
strength between CLF and HPMCP in ASDs.
In order to further optimize the HPMCP concentration in the ASD system, the molar ratio
between the CLF and key substituents of HPMCP (phthalyl group) were calculated on the
basis of the chemical reaction discussed above (Figure 3.10C). According to the
certificate of analysis of the HPMCP HP-55 (provided by Shin-Etsu Chemical Co., Ltd.),
the weight percentage of the phthalyl group is around 33%. Hence, a 1: 1 molar ratio
between CLF and phthalyl group is achieved when the weight ratio of CLF to HPMCP is
in the approximate range of 1: 0.75 to 1: 1 (w/w). This molar ratio of CLF to phthalyl
group be can correlated with the changes observed in the various spectra processing by
multivariate analysis. To be specific, according to the plots of PC1 score value against
HPMCP/CLF (w/w) ratio (Figure 3.3B, Figure 3.6A-F, Figure 3.8C), the sharpest PC1
score value changes were observed for dispersions with molar ratio of CLF: phthalyl is 1:
1, which suggests that this is the composition where CLF is undergoing a substantial
change from the neutral to the protonated state. Hence, in this case, an optimized CLFHPMCP solid dispersion with sufficient drug-polymer interaction and superior
amorphous drug loading can be achieve at a 1 to 1 molar ratio between CLF and phthalyl
group. It is also noteworthy that only half of the CLF present is protonated by the method
applied in this study at this specific CLF to phthalyl molar ratio due to the limited proton
transfer ability of the non-polar solvent used in preparing the ASDs.
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3.6

Conclusion

This study serves to illustrate the utility of various solid state spectroscopic methods,
alone and in combination with multivariate analysis, to evaluate the interaction pattern in
ASDs from a molecular perspective, thereby reducing the reliance on time-consuming
empirical polymer screening. Ionic interactions are shown to be the dominant forces
present in ASD systems of CLF and HPMCP. Protonation of the imine group on the
riminophenazine core result in changes of electronic properties of the chromophore,
which lead to an obvious color changing phenomenon and a corresponding bathochromic
peak shift in UV/Vis spectrum. Spectral evidence of protonated imine and ionization of
the carboxylic acid group from HPMCP can also be found from IR and 13C NMR spectra,
further confirming the formation of ionic interaction between CLF and the phthalyl group
of HPMCP. Moreover, the 2D double quantum NMR spectrum of CLF-HPMCP ASD
provides important structural clues for proton transfer between CLF and HPMCP. To the
best of our knowledge, it is the first documented study to utilize the ultrafast MAS
technique (VMAS = 60 kHz) to explore drug-polymer interactions in ASDs. By combining
computational chemistry with the NMR spectroscopy, molecular details of the CLFHPMCP interaction and a possible bonding motif are delineated. We also demonstrated
that principal components analysis can be utilized to process spectra to further optimize
the drug and polymer ratio based on the spectral changes. The interesting findings of this
research should be helpful for scientists to design innovative formulations of amorphous
solid dispersion with improved solid state performance.
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Table 3.1 Calculated NMR chemical shifts (ppm) and experimental chemical shifts (ppm)
for isopropyl-C (-CH(CH3)2) in pure CLF and CLF-HPMCP complex (1:1, w/w). Refer
to Figure 3.10 for schematic structures of complexes I and II.

isopropyl-C

Experimental Chemical
Shifts
Pure CLF CLF+HPMCP
49.4
47.5

Calculated Chemical Shifts
Pure CLF
53.2

Complex I
51.1

Complex II
55.32

Table 3.2 Calculated NMR chemical shifts (ppm) and experimental chemical shifts (ppm)
for Hα and Hβ in CLF-HPMCP complex (1:1, w/w). Refer to Figure 3.10 for schematic
structures of complexes I and II.

Hα
Hβ

Experimental
CLF *
8.6

Chemical Shifts
CLF+HPMCP ASD
11.5
10.0

Calculated Chemical Shifts
Complex I
Complex II
15.2
13.7
13.8
9.3

* The experimental chemical shift is taken from solution NMR measurement of pure CLF
dissolved in chloroform1203
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Figure 3.1 Chemical structures of CLF (A) HPMCP (B) and NPA of charges for CLF (C)

89

Figure 3.2 PXRD for CLF-HPMCP dispersion systems (weight ratio of CLF to HPMCP
is listed in legend)
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Figure 3.3 Solid state UV/ Visible spectra of CLF and HPMCP dispersions with different
CLF to HPMCP weight ratios (A); the score value of 1 st principal component in principal
components analysis of UV/Vis spectra in the wavelength region of 380 nm to 600 nm
versus the weight fraction of HPMCP/CLF (w/w)
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Figure 3.4 Infrared spectra of CLF-HPMCP with different CLF to HPMC weight ratios
in the spectral region of 4000 to 2200 cm-1 (A) and region of 1850 to 1650 cm-1 (B)
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Figure 3.5 Infrared spectra of CLF-HPMCP with different CLF to HPMC weight ratios
in the spectral region of 1650 to 1350 cm-1
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Figure 3.6 Plots of the score value of the 1st principal component in principal
components analysis of IR spectra in the regions containing peaks A to F versus the
weight fraction of HPMCP/CLF (w/w)
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Figure 3.7 13C CP-MAS NMR spectra of HPMCP (top), as-received crystalline CLF
(middle), and amorphous CLF prepared by melt quenching (bottom).
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Figure 3.8 13C CP-MAS NMR spectra of CLF-HPMCP dispersions with different API to
polymer weight ratios (A) and the enlarged spectral region from 157 ppm to 183 ppm (B);
(C) Plots of the score value of 1st principal component in principal components analysis
for peaks in the carbonyl region.
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Figure 3.9 2D 1H-1H double quantum-single quantum (DQ-SQ) back-to-back (BABA)
ssNMR spectra of amorphous CLF (A), HPMCP (B) and CLF-HPMCP ASD with 50%
drug loading (C). The 1D slice at 21.5 ppm (indirect dimension and DQ frequency) is
shown in red in (C). 1D projections are shown along with all 2Ds. All spectra are
acquired at a MAS frequency of 60 kHz.
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Figure 3.10 Models of CLF and carboxylic acid complex I (A) and II (B) for quantum
chemistry calculation; (C) Molecular mechanism of the solid-state CLF-HPMCP reaction
proposed based on experimental and computational results.
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CHAPTER 4. IMPACT OF METALLIC STEARATES ON DISPROPORTIONATION
OF HYDROCHLORIDE SALTS OF WEAK BASES IN SOLID-STATE
FORMULATIONS2

4.1

Abstract

Excipient-induced salt disproportionation (conversion from salt form to free form) in the
solid state during storage or manufacturing is a severe formulation issue that can
negatively influence product performance. However, the role of excipient properties on
salt disproportionation and mechanisms of proton transfer between salt and excipients are
still unclear. Moreover, knowledge about the formation of disproportionation products
and the consequent impact of these reactions products on the disproportionation process
is still inadequate. In the present study, three commonly used lubricants (sodium stearate,
calcium stearate, and magnesium stearate) were mixed with a hydrochloride salt as binary
mixtures to examine their different capabilities for inducing salt disproportionation at a
stressed storage condition (40°C 65% RH). The overall objective of this research is to
explore factors influencing the kinetics and extent of disproportionation including surface
area, alkalinity, hygroscopicity, formation of new species etc. In addition, we also aim to
clarify the reaction mechanism and proton transfer between the model salt and stearates
to provide insight into the in-situ formed reaction products. We found that the properties

2

The content of this chapter is adapted with permission from Haichen Nie, Wei Xu, Jie Ren et al. Impact of
Metallic Stearates on Disproportionation of Hydrochloride Salts of Weak Bases in Solid-State
Formulations. Molecular pharmaceutics 2016. Copyright (2016) American Chemical Society.
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of stearates significantly affect the disproportionation process in the initial stage of
storage, while properties of the reaction products negatively affect the hygroscopicity of
the powder mixture promoting disproportionation during longer-term storage. In addition,
lubrication difference among three stearates was evaluated by performing compaction
studies. The findings of this study provide an improved understanding of the proton
transfer mechanism between the ionized form of an active pharmaceutical ingredients and
excipients in solid dosage forms. It also provides pragmatic information for formulation
scientists to select appropriate lubricants and other excipients, and to design robust
formulations.
4.2

Keywords

Salt stability, Proton transfer, Surface area, Hygroscopicity, Deliquescence, Solid state
acid-base reaction, Lubricants, Form conversion
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4.3

Introduction

Many active pharmaceutical ingredients (APIs) can be categorized as weak acids or weak
bases.1 A large fraction of these weak electrolytes are poorly soluble in aqueous media in
their neutral form. 143,

144

To increase the water solubility and bioavailability of such

substances, salt formation of ionizable APIs is a preferred formulation strategy. 45, 145, 146
Physicochemical advantages of salt formation include modifying solid-state properties,
such as melting point and hygroscopicity, to improve the stability during storage and
manufacturing.120, 147, 148 However, the propensity of conversion from the ionized form of
drug species to its neutral form is considered as an important potential risk associated
with employing pharmaceutical salts. This undesirable conversion is generally referred to
in pharmaceutical reports as disproportionation. 52, 53, 56 Many detrimental effects of salt
disproportionation on pharmaceutical product performance have been reported. For
instance, conversion of maleate or hydrochloride salts to the respective free base was
shown to lead to the loss of API with a consequent decrease in tablet potency.12, 54, 55
Rohrs et al. ascribed a significant decrease in the extent of dissolution of a tablet
formulation to the disproportionation of delavirdine mesylate to the free base.42 Hence, in
order to ensure that robust formulations are produced, it is imperative to have a
comprehensive understanding of the mechanisms of salt disproportionation and to
scrutinize key factors associated with such reactions.
Although disproportionation is observed in solid state systems, the presence of water is
known to be necessary for the disproportionation process, with higher water contents
driving the process, indicating that it is a solution mediated reaction. 12, 52, 57 The pH of
maximum solubility (pH max) and the microenvironmental pH are two pivotal parameters
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required to understand the likelihood of disproportionation occurring.15, 56 Herein, only
the disproportionation of salts of weak bases will be discussed; examples relating to the
stability of weakly acidic salt can be found in the literature.16, 149, 150 The pH of maximum
solubility (pH max), viewed as the threshold value of disproportionation, is determined by
the dissociation constant (pKa) of the base, the intrinsic solubility of the free base, and
the salt solubility. 17, 151 Solids of both salt and free base are considered to coexist at pH max
with the formation of an equilibrium between unionized and ionized drug substance in
solution. Microenvironment, a theoretical concept, is postulated as an idealistic medi um
for proton transfer in a microscopic water layer on the surface of solid particles. When
the pH value of microenvironment exceeds the value of pH max, the salt form can
potentially reverse back to its free base. 18, 60 The microenvironmental pH can be greatly
impacted by acidity/basicity of excipients in a multicomponent formulation. To be
specific, excipients with high basicity can elevate the microenvironmental pH value and
are generally reported as problematic components in formulations containing salts of
weak bases.58-60 For instance, croscarmellose sodium and di/tribasic sodium phosphate
were implicated in the conversion of the mesylate salt to the free base form as a result of
their highly basic nature.42,
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The pH of a slurry of a given excipient is generally

employed as an empirical approach to estimate the microenvironmental pH, and to
provide an indication of the likely drug-excipient compatibility. 152, 153 For example, using
the excipient slurry pH as a starting point, a quantitative model was developed by Merritt
et al. to predict the salt disproportionation.154
However, merely considering the slurry pH value of a given excipient is insufficient to
describe the role of excipient on disproportionation. 41, 154 For instance, both surface pH
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and slurry pH of excipients were demonstrated as unsatisfactory predictors of salt
stability in a formulation. Instead, excipients containing proton accepting groups, such as
carboxylate

groups, were

found to

significantly increase

the

risk of salt

disproportionation.41 In addition, particle size and surface area of problematic excipients
is also a crucial element impacting the salt stability.61 The formulation hygroscopicity is
another significant factor influencing the disproportionation process. To be specific, the
hygroscopicity of drug salts is typically affected by counterions employed for salt
formation, and is a benchmark used during screening to identify the optimal salt form. 57,
155, 156

On the other hand, excipients and disproportionation reaction products can be

hygroscopic. For instance, in a formulation containing a hydrochloride salt of API,
magnesium stearate was highlighted as the most problematic excipient due to its unique
deleterious ability to form magnesium chloride as a disproportionation product. The
formation of this new highly hygroscopic substance, following acid-base reaction with
the drug salt, in turn accelerated the disproportionation of the hydrochloride drug salt.41
Building upon this observation, the current work will seek to further delineate how the
properties of excipients (such as surface area and hydroscopicity) and the properties of
reaction products formed following proton transfer impact the disproportionation process.
The primary objective of the current study was to investigate the impact of excipient
counterion on the disproportionation reaction, focusing specifically on the excipient
properties as well as the characteristics of the reaction products. The second objective
was to further understand the underlying mechanisms of proton transfer and salt
disproportionation. The hydrochloride salt of pioglitazone, a thiazolidinedione for
treating diabetes mellitus type II, was used herein as model compound for two reasons.
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First, hydrochloride salts are still the most predominant salt forms employed for weakly
basic APIs.15, 157 Second, pioglitazone hydrochloride salt (PIO-HCl) was selected due to
its reported low pHmax and the tendency to readily undergo disproportionation. 158-160
Three metallic stearates with different counterions, typically used as lubricants in tablet
formulations 8,
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, were blended with PIO-HCl salt to induce and accelerate the

disproportionation process. Based on the previously reported analytical approaches of
quantifying disproportionation of PIO-HCl in tablets, 62 we quantified and differentiated
disproportionation kinetics of PIO-HCl in mixtures with different metallic stearates by
combining Raman spectroscopy and chemometrics. In addition, the lubrication properties
of the three metallic stearates were further evaluated to assess the amount of lubricant
needed to provide utility in formulations containing API-HCl salts.
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4.4

Experimental Section
4.4.1

Chemicals

Pioglitazone hydrochloride (PIO-HCl) salt was supplied by Tokyo Chemical Industry
(TCI) Co, ltd. (Portland, OR). Pioglitazone free base/neutral (PIO-FB) form was obtained
from Dr. Reddy's Laboratory (India). The chemical composition and the solid state form
of the PIO-HCl salt and PIO-FB were confirmed prior to the experiments by Fourier
transform infrared (IR) spectroscopy (Smiths Detection Inc., MD) and powder X-ray
diffraction (Panalytical X'pert Pro diffractometer). The IR spectra (Figure A.13) of PIOHCl and PIO FB demonstrate satisfactory agreement with literature reports. In addition,
the X-ray diffractogram (Figure A.14) manifest peak positions for both pioglitazone HCl
salt and its free base that are consistent with references. 162 Magnesium stearate (MgSt)
was obtained from Mallinckrodt (St. Louis, MO). Sodium stearate (NaSt) and calcium
stearate (CaSt) were purchased from Acme-Hardesty Co. (Blue Bell, PA). Chemical
structures of PIO-HCl salt and different metallic stearates are shown in Figure 4.1.
Mannitol, for compaction studies, was ordered from SPI Pharm. (Wilmington, DE).
4.4.2

Sample Preparation of Binary Mixture for Disproportionation Studies

PIO-HCl salt and each stearate were prepared as binary mixtures at a 90% to 10% ratio
which is a reasonable representation of the typical ratio of API and lubricant found in a
pharmaceutical tablet. For instance, a 200 mg tablet with 2-3% lubricant and an API
potency of 50 mg would not be considered an unusual formulation. 41 Prior to blending,
all materials used in this study were individually stored in desiccators with calcium
sulfate (W.A. Hammond Drierite Co. Ltd, Xenia, OH) for 7 days at 25°C. Powders of
PIO-HCl and stearates were gravimetrically dispensed into a 20ml glass scintillation vial
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at the desired weight ratio in a glovebox (sidENTRYTM) purged with dry nitrogen to
maintain a low relative humidity (RH) condition. The binary formulations with a targeted
weight (300 mg) were subjected to additional mixing by a ResodynTM LABRAM acoustic
mixer (Butte, MT) with 30% intensity for 3 minutes. Each binary mixture of PIO-HCl
salt and metallic stearates was prepared in triplicate. Samples, in open dish conditions,
were then placed into a 40°C/65% RH stability chamber and periodically analyzed by
Raman spectroscopy.
4.4.3

Sample Preparation of Placebo Formulation for Compaction Studies

Placebo formulations were prepared for tablet compaction to investigate the different
lubrication effects of various stearates. Each metallic stearate was added with diluents in
a ratio of 0.5: 99.5 or 1: 99 (w/w) respectively as a placebo mixture. Powder samples
were gravimetrically dispensed into glass vials and then subjected to a TURBULA ® T2F
Shaker-Mixer (Glen Mills Inc., Clifton, NJ) for mixing (1 minute). In order to ensure
enough friction between compacts and die-wall to differentiate the lubricating capacity of
the different stearates, mannitol was selected as a diluent in placebo formulation due to
the rugged nature of its surface.163-166
4.4.4

Raman Spectroscopy Bulk Measurement

A Kaiser Raman RXN1 Workstation (Kaiser Optical Systems, Inc., Ann Arbor, MI)
equipped with a PhAT™ large volumetric bulk sampling probe was used to conduct
Raman spectroscopy bulk measurements. HoloGrams™ v4.1 software was employed for
data acquisition. The PhAT probe, coupled to the base unit via a fiber bundle, delivered
the excitation energy from a 785 nm high power NIR diode laser (Invictus TM) located
within the base unit. Laser power was set electronically to 400 mW for bulk
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measurements. A 6 mm laser spot was generated by employing a 250 mm focal length
lens. In order to ensure spectral quality, calibration of the laser excitation wavelength
(cyclohexane; ASTM standard), spectrograph wavelength (neon atomic lines; ASTM
standard), and instrument spectral response (white-light source; NIST standard) were
performed. Taking into account the penetration of the PhAT Raman measurement,
powder samples were carefully placed into a specially designed sample holder with
controlled thickness for reproducibility. The CCD was cooled to -40°C and a dark
subtraction was automatically applied to each spectrum to mitigate the baseline offset.
Data acquisition time for each measurement was set as 10 seconds and 6 accumulations
were averaged for all the samples. All Raman spectral data were processed by Grams AI
(Thermo, Inc. Waltham, MA) for visual inspection. Multivariate analysis software
SIMCA v13 (Umetrics AB, Umeå, Sweden) was used for chemometric analyses.
4.4.5

Slurry pH of Stearates

The slurry pH values of stearates were evaluated by preparing a 10% (w/v) slurry by
weight of each stearate in water. After 90 minutes of forming the slurry, pH was
potentiometrically measured by a calibrated Accumet® Research AR15 pH meter
equipped with Accumet® electrode (Fisher Scientific, Pittsburgh, PA). The slurry pH
values after 90 minutes and the values after 720 minutes were identical.
4.4.6

Specific Surface Area Measurement

The specific surface area of each stearate was measured using a Micromeritics TriStar
3000 automatic physisorption analyzer operated in the 11 point Brunauer–Emmett–Teller
(BET) analysis mode.167 Powder samples were loaded into glass sample tubes and
outgassed in a stream of dry nitrogen for 120 minutes at room temperature prior to
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measurement. Afterward, samples were vacuum outgassed for 60 minutes at room
temperature until a stable baseline pressure was detected. The nitrogen adsorption
isotherm was then generated in a bath of liquid nitrogen (77.4 K) using nitrogen dosing at
the relative pressure range (p/p o) range of 0.05-0.30.
4.4.7

Particle Morphology

Particle morphology of each stearate was evaluated by a Quanta FEG 250F (Field
Electron and Ion Co., Hillsboro, OR) environmental Scanning Electron Microscopy
(SEM). SEM was operated at 2.0 kV beam energy in a high vacuum condition. A small
amount of sample powder was poured from a spatula onto double-sided conductive
carbon tape mounted on aluminum stubs for the SEM analyses.
4.4.8

Dynamic Vapor Sorption Measurements

A Q5000SA Dynamic Vapor Sorption (DVS) (TA Instruments, New Castle, DE) was
employed to measure the isohumidity moisture sorption at 40°C/65%RH. A sample of
approximately 10 mg was pre-weighed and carefully dispensed into a crucible. All
samples were dried at 50°C at the beginning of the experiments for 60 minutes until the
change of %weight was less than 0.01 over a five minute period. Afterward, data
acquisition to determine the percentage weight change was conducted at 40°C/65%RH
condition for 2880 minutes. All the moisture sorption data were processed by the
Universal Analysis 2000 (version 4.5A) software.
4.4.9

Powder X-Ray diffraction (PXRD)

The X-ray diffraction patterns of raw material, initial binary mixtures, and the stressed
binary mixtures were collected on a Panalytical X’Pert pro X-Ray diffractometer
(PANalytical Inc., Westborough, MA) with Cu Kα radiation of 1.5406 Å in the
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reflectance mode. All the measurements were conducted at ambient conditions in Bragg–
Brentano geometry with 2θ ranging from 4° to 80° using a 0.0167° step size. The voltage
and the current of the generator were set to 45 kV and 40 mA respectively. PXRD data
were processed by Panalytical X’Pert Data Viewer (version 1.5) and X’Pert High Score
Plus (version 4.1) software.
4.4.10 Tablet Compaction
Tablet compaction was carried out using a Huxley-Bertram compaction simulator
(Huxley Bertram Engineering, Ltd., Cambridge, UK), with 9.525 mm round flat punches
following a two-stage displacement-controlled compression profile. The fill depth was
adjusted to achieve 300mg tablet weight. The punch motion was set up as follows. The
upper punch applies a pre-compression and a main-compression to the powder bed, while
the lower punch stays stationary during compression. In both pre- and main- compression,
the upper punch moves down following a sine-wave, waits a certain time lapse
(simulating a dwell time), and moves up following a symmetric sine-wave. After main
compression, the lower punch moves up at a constant speed to eject the tablet out-of-die.
Two punch speeds were used to make tablets in order to evaluate strain-rate effect on
compaction performance. In the low-speed case, the upper punch moved at a maximum
speed of 120mm/s with 32ms dwell time in both pre- and main- compression, and the
lower punch ejected tablets at ~25mm/s. In the high-speed case, the entire punch profile
was accelerated 8X with 960mm/s maximum punch speed, 4ms dwell time, and
~200mm/s ejection speed. The low and high speeds were designed to cover the range of
realistic punch speeds on a high rotary tablet press. 13 tablets were made for each placebo
formulation at each speed, with minimum punch separations varying from 3.4mm to
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2.2mm to achieve a range of compression pressures between 80MPa and 400MPa.
During the compression and ejection process, the compaction simulator recorded force
and displacement of both punches at a data acquisition rate of 2,060 Hz for low -speed,
and 16,480 Hz for high-speed punch motion.
The ejected tablets were kept for about 10 minutes in room temperature (23 oC) and low
humidity (22%RH) before being tested for weight (m), thickness (t), diameter (D), and
breaking force (F). An automatic tablet tester (Dr. Schleuniger ® Pharmatron SmartTest,
Switzerland) was used for these measurements. Tablet tensile strength (TS) was then
calculated based on equation 1.168
TS 

2F
 Dt

Equation 4.1
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4.5
4.5.1

Results and Discussion

Properties of drug substances and metallic stearates

Raman spectra of pioglitazone (HCl salt and free base) and three metallic stearates are
shown in Figure 4.2. A specific spectral region (1560-1660 cm-1) was used for evaluation
for the following two reasons: first, stearates are Raman inactive in this spectral range,
while distinct Raman peaks of both PIO-HCl and PIO-FB are clearly visible. These
strong Raman peaks enable us to discriminate the drug s ubstance from the different
lubricants in mixtures. Second, in spite of overlapping peaks in this spectral region, the
peak pattern differences between PIO-HCl and PIO-FB can be readily discerned without
using multivariate analysis. To be specific, PIO-FB demonstrates a single peak located at
1610 cm-1, while a doublet peak was observed for PIO-HCl in the region 1600-1650 cm-1.
A plausible explanation for these spectral differences is that the vibrational modes of the
pyridine ring are changed after protonation. 169-171 To rule out the possibility of laserinduced form conversion, pure PIO-HCl and its mixture with stearates were exposed at
the same set laser power for 10mins. No data drift were observed for the specified
spectral region (Figure A.15).
SEM images of three different metallic stearates are shown in Figure 4.3A-C. Although
the particle size of the three stearates are in the similar range (10-30 µm), a greater
number of fine particles of NaSt (Figure 4.3A) were observed under the microscope. For
particle morphology, MgSt (Figure 4.3B) and CaSt (Figure 4.3C) are characterized as
flake-shaped particles, while NaSt present as nonspherical granule-like particles with an
irregular shape. The different particle shape and particle size of NaSt mostly likely
contributes to its large specific surface area. Based on the data shown in Figure 4 (right Y
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axis), the BET surface area of NaSt (51.3 m2/g) is almost five times greater than that of
MgSt (10.1 m2/g) and CaSt (13.9 m2/g). The measured slurry pH value of each stearate is
also shown in Figure 4.4 (left Y axis), and provides an indication of their potential to
elevate the microenvironmental pH.12 Basic pH values were observed for all three
metallic stearates whereby MgSt (8.23) and CaSt (8.28) have similar slurry pH value, and
NaSt (9.51) has the highest slurry pH value. The alkaline nature of the metallic stearates
can be partially ascribed to the existence of basic impurities in the stearates. For instance,
magnesium oxide is well documented as a basic impurity of MgSt, CaSt has calcium
hydroxide as an impurity while sodium hydroxide has been reported as an impurity in
NaSt. 8, 63, 172, 173 The slurry pH values of all three stearates are much higher than the pH max
(2.8) of PIO-HCl salt indicating the potential for inducing salt disproportionation.
Intuitively, based on the above observations, NaSt is expected to be the most problematic
excipient in the formulation of hydrochloride salts due to its high specific surface area
and strong alkalinity. However, some counterintuitive results were observed from
disproportionation studies indicating that other factors need to be considered (vide infra).
4.5.2

Chemometric models and Raman calibration curves

Based on the aforementioned spectral region, chemometric models for calibration
samples were established to obtain a validated calibration curve to quantify the salt
disproportionation in mixtures. A series of samples with different PIO-HCl salt to PIOFB ratio was prepared to generate a calibration curve ranging from 50% PIO-HCl (50%
PIO-FB) to 100% PIO-HCl (0% PIO-FB). Each calibration standard was freshly prepared
in triplicate and stored in desiccators with calcium sulfate at ambient temperature prior to
bulk Raman measurements. Figure 4.5A shows the Raman spectra of 21 calibration
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samples over the selected spectral region. A decreasing intensity of the higher
wavenumber peak (peak II) with an increasing amount of PIO-FB can be observed from
Figure 4.5A. Based on the spectral difference, a chemometrics model could be built to
directly discern and quantify the existence of PIO-FB.
The spectra of the calibration sample were preprocessed by standard normal variate
transformation (SNV), a mean centering and auto-scaling algorithm, to eliminate the
multiplicative effects generated from light scattering and particle size variations of
powdered sample.174-177 Pretreated spectra were then subjected to principal components
analysis (PCA). The PCA results suggested that the first two components capture over
99.7% of the spectral variation. According to the loading plots of PCA (Figure A.16),
loadings of first principal component (PC1) and second principal component (PC2) both
demonstrate the spectral variation from peak I and peak II. It is noteworthy that PC 1
captures 99.2% spectral variations, and hence makes a much larger contribution to the
model than that of PC2. Moreover, in the PC1-PC2 score plot (Figure 4.5B), no outliers
were detected in the Hotelling’s T 2 ellipse at 95% confidence region. Calibration standard
of each level segregates into discriminating clusters along PC1 (X-axis). Hence, selecting
PC1 as the only principal component for the partial least squares (PLS) models is
reasonable to avoid over-fitting. The selection of principal component is further
confirmed by applying the “leave-one-out” cross validation (a trade-off between the
goodness of fitting and prediction), which is discussed as follows.
Based on the above analysis, PLS calibration (blue dots) was established by employing
PC1 as the major principal component (Figure 4.5C). The small value of root mean
squares error of cross validation (RMSECV) signifies a satisfactory balance between
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fitting of the model and predictive power. 178 In addition, the reasonable values of R2Y
and Q 2 suggest that the PLS model is appropriate to quantify the amount of PIO-FB.179
Furthermore, this PLS calibration curve was applied for validation (red dots in Figure
4.5C) using another group of samples (each level of the standard prepared in triplicate).
The consistency between the calibration points and the validation points further implies
the robustness of applying this PLS model. Moreover, a low value of the root mean
squares error of prediction (RMSEP) further indicates the accuracy and good quantitative
performance of this calibration model.180 On the basis of the Raman spectral differences
and the validated chemometric model, the disproportionation of PIO-HCl could be
quantified.
4.5.3

Quantitation of disproportionation in binary mixtures

Binary mixtures containing PIO-HCl and each stearate were prepared in a 9:1 ratio (w/w)
and stressed at a high humidity condition (40°C and 65% RH) for a period of up to 30
days. The levels of disproportionation (% conversion) were quantified by combining the
Raman spectroscopy and aforementioned PLS model (Figure 4.6). Less than 1% of form
conversion was observed for the neat PIO-HCl salt stressed at 40°C and 65% RH for 30
days. On the other hand, at the same stress condition, a considerable amount of form
conversion was observed for PIO-HCl in the mixtures with metallic stearates indicating
that all three stearates are capable of inducing the disproportionation of PIO-HCl salt.
Differences in both the kinetics and the extent of disproportionation were obvious among
the blends containing different stearates. For the mixtures containing MgSt or NaSt, the
extents of disproportionation (% conversion) reached a plateau within 2 days, while the
percentage conversion to the PIO-FB reached a plateau after 10 days for the mixture of
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PIO-HCl and CaSt, indicating slower disproportionation kinetics. Additional points were
collected over the first 72 hours (Figure 4.6A) in order to further differentiate variations
in disproportionation kinetics between samples containing MgSt (blue dots) and NaSt
(grey dots). In Figure 4.6A, it can be observed that the highest extent of
disproportionation was achieved within 12 hours for the mixture of PIO-HCl and NaSt
indicating the fastest disproportionation rate. For the mixture of PIO-HCl and MgSt, the
plateau disproportionation value was reached after 36 hours. Based on the plateau value
of disproportionation at 30 days for each blend, the blend of PIO-HCl and NaSt had the
lowest level (13%) of disproportionation, whereas higher percentages conversion to PIOFB were observed for blends in presence of MgSt (20%) or CaSt (18%). Clearly,
according to the above disproportionation results for binary mixtures of PIO-HCl and
metallic stearates, considering factors such as excipient surface area and excipient slurry
pH are insufficient to understand differences in the rate and extent of disproportionation,
in particular due to two counterintuitive observations. First, although CaSt and MgSt
have similar particle sizes and morphologies, specific surface area, and slurry pH values,
there is a considerable differences in disproportionation kinetics observed between the
MgSt blends and CaSt blends. Second, NaSt has the highest surface area and alkalinity,
whereas the mixture of PIO-HCl was shown to have the lowest extent of
disproportionation. Hence, it is necessary to take into account of the moisture sorption
profiles for both the initial components and the powder mixtures as another important
parameter to describe the disproportionation of PIO-HCl.
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4.5.4

Moisture sorption

Salt disproportionation, which is conversion from the ionized state of a molecule to its
neutral form via proton transfer, is considered a solution mediated reaction. Hence, the
presence of water in the powder sample, even a small amount of adsorbed water on the
surface of solids, is crucial to form the microenvironment and to promote the interactions
between the API salt and reactive excipients. In this case, factors of particular interest are
the hygroscopicity of the PIO-HCl salt, the moisture uptake of each stearate, and the
water sorption of binary mixtures of PIO-HCl and stearates at the stressed condition.
The hygroscopicity of a salt is considered as an important criterion in salt screening,
since hygroscopic salts often have stability issues. In the present study, based on the
moisture sorption isotherm (40°C), little water uptake was observed (<0.1%) up to 95%
RH for the PIO-HCl salt (Figure A.17). In addition, the water sorption curves of PIO-HCl
and PIO-FB at the stressed storage condition of this study (40°C and 65% RH)
demonstrate minimum percent weight changes over a period of 48 hours (Figure A.18).
It is also necessary to explore the moisture uptake of the additives used to form the binary
mixture and moisture sorption profiles for each stearate are shown in Figure 4.7A. At the
condition of 40°C/65% RH, the plateau values of the percentage weight change for all
stearates were reached within 10 minutes. The plateau values of percentage water gained
for NaSt and MgSt are 1.18% and 0.81% respectively, while the % water in CaSt is only
0.16% at the same storage condition. The hygroscopic characteristic of NaSt can be
partially attributed to its high surface area. It is well documented that powder samples
with high surface areas are typically more hygroscopic due to enhanced surface
adsorption.181 Obviously, in this study, CaSt is characterized as the least hygroscopic
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material when comparing among three stearates. At 40°C/65% RH, the equilibrium water
content in CaSt is only one seventh of the amount of water in NaSt, and five times less
than the adsorbed water presented in MgSt. The hygroscopic variations among the
stearates are thus lead to the different amount of adsorbed water on the surface solid
particles. It has been suggested that the amount of adsorbed water on the surface of
crystalline solids determines the molecular mobility of solvated species, which in turn
can react with other mobilized species in the near vicinity.182-186 Accordingly, it is
expected that this factor influenced the initial rate of disproportionation observed herein.
For instance, the PIO-HCl and CaSt mixture had the slowest disproportionation kinetics
due to the limited hygroscopicity of CaSt. In contrast, PIO-HCl and NaSt was observed to
have the highest disproportionation rate, which can be partially ascribed to the more
hygroscopic nature of NaSt. However, as shown in Figure A.19, none of the stearates are
very hygroscopic at the storage conditions employed. Hence, even the presence of small
amount adsorbed moisture on the surface of the solids is sufficient to trigger the reaction
of proton transfer. This finding is also consistent with other publications which associated
chemical instability issues with the existence of low level of adsorbed water layers on the
solid surfaces.187-189
It is perhaps of most significance to investigate the percentage water gained in binary
mixtures of PIO-HCl (90% w/w) and stearates (10% w/w) at the storage condition
directly relevant to the disproportionation process. The percentage weight change of each
blend at 40 °C/65% RH plotted as a function of time is shown in Figure 4.7B. It can be
observed that the plateau value of % water for the mixture of PIO-HCl and NaSt was
reached in 12 hours whereas the maximum percentage water was achieved within 30
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hours for the mixture of PIO-HCl and MgSt. For the blend of PIO-HCl and CaSt,
equilibrium was not reached within 48 hour, and the moisture sorption is still increasing.
It is noteworthy that the kinetics of the water sorption roughly mirrors the
aforementioned kinetics of disproportionation (Figure 4.6A). To be specific, for PIO-HCl
with MgSt or NaSt, the time of reaching equilibrium with respect to water sorption is
similar to the time taken to achieve the highest extent of form conversion. For PIO-HCl
and CaSt, increasing trends were observed both in water sorption profile and
disproportionation kinetics. This interesting finding not only further confirms the vital
role of moisture in disproportionation, but also suggests that water sorption kinetics at the
storage condition of interest can be used to evaluate the disproportionation kinetics. A
similar observation was reported by Hsieh et al. when assessing the disproportionation
kinetics of benzocaine mesylate. 61 Interestingly, although a significant water gain was
absent in the moisture sorption profiles of pure MgSt (Figure 4.7A) and pure PIO-HCl
(Figure A.18), a considerable water uptake (5.3% w/w) was noted in the water sorption
profile of the mixture (blue line in Figure 4.7B). This observation was originally reported
by John, et. al.41 where it was discovered that the increased hygroscopicity of the
formulation could be attributed to a chemical interaction between MgSt and the weakly
basic HCl salt. The byproduct of this MgSt induced disproportionation of PIO-HCl salt is
the generation of deliquescent MgCl 2. Building upon this observation, we deliberately
selected stearate lubricants with different cation to further assess the impact of excipient
counterion on the disproportionation reaction. For mixtures containing CaSt, it is also
suspected that highly hygroscopic reaction products that can undergo deliquescence at
40 °C/65% RH have been formed. Specifically, neither CaSt nor PIO-HCl is a
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hygroscopic material. At 40 °C and 65% RH, based on the results of water gained for
each neat component, the % water adsorbed by the mixture of PIO-HCl and CaSt in a 9 to
1 ratio is expected to be lower than 0.1% if there is no chemical reaction between two
species. However, 0.63% adsorbed moisture was detected in the powder mixture over 48
hours of stressed storage. In addition, it was noted that the equilibrium of moisture uptake
was not reached in 48 hours for the blend of PIO-HCl and CaSt, as evidenced by the
upward-trend shaped water sorption curve. In contrast, no synergistic moisture sorption
was observed in a powder blend containing PIO-HCl and NaSt.

These interesting

findings suggest that different reaction products, with varying hygroscopicities, can be
formed via proton transfer between the PIO-HCl and the different stearates in the
following manner.
During the process of converting the PIO-HCl to PIO-FB, protons transfer from the
ionized drug (PIO-HCl) to proton acceptors present in the metallic stearates (carboxylate
groups). In other words, in order to ensure the overall charge neutrality of the chemical
reaction190, cations of the metallic stearates have to combine with chlorine anions to form
inorganic metallic chloride salts as reaction products. The reaction scheme between PIOHCl and metallic stearates is summarized in Figure 4.8. Thus, magnesium chloride
(MgCl2), calcium chloride (CaCl 2), and sodium chloride (NaCl) were formed as
disproportionation products when MgSt, CaSt, NaSt respectively were blended with PIOHCl salt and subjected to stress storage conditions. It is well known that both MgCl2 and
CaCl2 undergo deliquescence, whereby the salt dissolves upon exposure to ambient
relative humidity forming a salt solution, at relative humidities that are lower than the
storage conditions employed in this study.

Specifically, the deliquescent relative
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humidity (DRH) of MgCl 2 is reported as 31%.191 For CaCl2, the DRH value was
estimated ~20% by applying both conductivity and hygrometer methods.192,

193

In

contrast, NaCl does not undergo deliquescence until exposure to a much higher RH and
the DRH of NaCl is 75% RH at 40 °C.194
In order to further confirm the formation of metallic chloride as a disproportionation
product, PXRD was employed, scanning a wide angular range (2 theta range from 4° to
80°) to detect the existence of inorganic salts. 195 PIO-HCl and stearates mixtures were
prepared in a 1:1 ratio, exposed at 40°C 65% RH for 24 hours, and subsequently
subjected to PXRD to obtain a diffractogram. Although the diffractograms of pure PIOHCl, PIO-FB, and NaSt demonstrated no strong peaks at the high 2 theta range, several
new peaks in this region were clearly observed in the stressed mixture of PIO-HCl and
NaSt (Figure 4.9A). These intense peaks (located at 31.7°, 45.5°, 56.6°, 66.2°, and 73°)
correspond to peaks reported in the diffractogram of NaCl. 196 In contrast, no peaks
representative of MgCl2 or CaCl2 could be detected (Figure 4.9B) for PIO-HCl blends
with MgSt or CaSt, which can be accounted for on the following basis. First, the low
DRH of MgCl 2 and CaCl 2 is expected to result in a loss of crystallinity during storage and
analysis due to deliquescence and hence an absence of peaks. Second, relatively small
amounts of MgCl2 or CaCl2 are anticipated to form in the powder mixtures, and the
intensities of the peaks at high two theta values are relatively weak based on their
reported diffractograms.197,

198
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4.5.5

Impact of excipients properties on kinetics and extent of PIO-HCl
disproportionation

Based on the above discussion, the main properties of excipients and reaction products
influencing the kinetics and the extent of salt disproportionation are summarized in this
section. During the initial stage of stressed storage at 40°C 65% RH, disproportionation
of PIO-HCl in binary mixtures is determined by the properties of the additives (stearates)
including their alkalinities, hygroscopicities, and specific surface areas. The alkalinity
and the hygroscopicity of each stearate directly influence the microenvironmental pH of
each blend of PIO-HCl and stearate. Although the microenvironmental pH in powder
blends is generally difficult to characterize 59, the alkalinity of pure component (evaluated
by slurry pH value) provides a reasonable indicator of the likelihood of creating a
favorable microenvironmental pH to induce PIO-HCl salt disproportionation. On the
other hand, the hygroscopicitiy of each stearate impacts the mobilization of reactive
species via solvation at the surface, at least at the initial stage of the reaction. Clearly,
more hygroscopic stearates adsorb more water from the environment, and more solvated
species can be potentially formed as a result, depending on the location and physical state
of the sorbed water. Following the sorption of water, in the mixture of PIO-HCl with a
basic stearate, the microenvironmental pH of the blend exceeds the pH max of PIO-HCl
(2.8). Consequently, conversion from PIO-HCl salt to its neutral form occurs during the
initial stage of stressed storage. 14, 199 The specific surface areas of reactants also have
been reported to impact the chemical relativity.200-202 In this case, we observe that
specific surface areas of stearates also extensively affect the salt disproportionation
during the initial period of storage at high humidity condition, because a higher surface
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area will lead to the greater area of contact with the PIO-HCl, as well as leading to a
larger extent of surface water adsorption. These results are consistent with a previous
study in which it was noted that mesylate salts with higher surface area per unit mass
were observed to undergo a larger extent of disproportionation. 61 For the systems studied
herein, NaSt has the highest specific surface area, hygroscopicity, and alkalinity.
Therefore, during the initial stages of storage, the binary mixture of PIO-HCl and NaSt
demonstrate greater rate and extent of disproportionation.
However, as the disproportionation reaction proceeds at 40°C 65% RH for longer periods
of time, different metallic chlorides are accumulated as reaction products in the mixtures,
and these new components start to influence the water sorption behavior of the powder
blends. To be specific, the aforementioned in-situ formation of MgCl 2 and CaCl2 lead to a
significant increase in the amount of water sorbed by the powders due to their
deliquescence with the subsequent formation of a solution phase within the powder
mixture.38, 203 Consequently, the bulk water now present in the powder blends is expected
to further facilitate the disproportionation reaction to a greater extent, as is
experimentally observed. Therefore, during the later stages of storage at stressed
condition, it is clear that the extent of disproportionation is dominated by the
hygroscopicity of the products formed via proton transfer.
4.5.6

Compaction study and composition suggestions in formulation

In addition to the previously discussed physicochemical factors that influence HCl salt
disproportionation, the amount of a given problematic excipients will also have an impact.
Thus, a greater weight fraction of a given problematic excipient in the powder mixture
poses a greater risk for salt stability. However, the appropriate weight percent of the
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various stearates studied herein in terms of achieving a sufficient lubrication effect was
unknown. MgSt is frequently used as a lubricant, but the other metallic stearates have
been less studied in this context. Therefore, 0.5% and 1% of each metallic stearate was
added as a lubricant for a placebo mannitol formulation, evaluating both high speed
(Figure 4.10A) and low speed compaction, (Figure 4.10B) to discriminate the different
lubrication effects. It was observed that CaSt has the worst lubrication effect during the
compaction of placebo formulation tablets. For instance, severe breakage issues, such as
sticking, were observed for tablets employing 0.5% w/w CaSt in the placebo formulation.
In addition, according to Figure 4.10, both high-speed and low-speed compactions for
formulations with 0.5% CaSt exhibit extensive friction during the ejection, indicating
insufficient lubrication effects. In contrast, satisfactory lubrication effect for formulations
containing MgSt or NaSt are observed based on their ejection forces. It is noteworthy that,
based on the high speed compaction study (Figure 4.10A), the ejection force of the
formulation containing 0.5% w/w NaSt is equivalent to the ejection force of formulation
containing 1% w/w MgSt, implying that NaSt has the best lubrication effect, probably
due to its high surface area. This interesting result suggests that a lower weight fraction of
NaSt in the tablet formulation is required to achieve an acceptable lubrication effect.
When formulating susceptible HCl salts, employing a lower weight fraction of a stearate
would be expected to reduce the extent of HCl salt disproportionation. Hence, as
compared to CaSt and MgSt, NaSt can be potentially used as a more favorable lubricant
in formulations containing HCl salt due to the lower required amount. However,
according to previous reports, different lubricants can impact the mechanical strength of
tablets.204,

205

Therefore, the tensile strength of the tablets produced with different
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stearates was investigated. At both low and high compaction speed, no significant
differences of tablet tensile strength (MPa) were observed among the formulations with
different stearate in the 100-400MPa compressive stress range (Figure A.20). These
results suggest that employing CaSt, MgSt, and NaSt as lubricants in a formulation lead
to different lubrication effects, but similar impacts on the mechanical strength of tablets.
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4.6

Conclusion

Three metallic stearates (MgSt, CaSt, and NaSt) can induce a significant extent of PIOHCl salt disproportionation in powder blends stored at 40°C/65% RH condition. The
differing properties of the three metallic stearates result in different kinetics and extent of
PIO-HCl salt disproportionation. During the initial stages of stressed storage, the extent
and kinetics of PIO-HCl salt disproportionation in the mixture of PIO-HCl and stearates
is dominated by the hygroscopicity, alkalinity, and surface area of each stearate. Hence,
during the initial period of storage, blends of NaSt and PIO-HCl have the largest rate due
to large surface area, high hygroscopicity, and strong alkalinity of NaSt. In contrast, the
mixture of CaSt and PIO-HCl demonstrates the slowest rate of disproportionation due to
the non-hygroscopic nature of CaSt.
However, the reaction products were also found to influence the progression of
disproportionation. The metallic chlorides, formed as reaction products, exhibit different
tendencies to undergo deliquescence at the storage conditions employed. Since both
CaCl2 and MgCl 2 can readily deliquesce, blends of PIO-HCl and MgSt/CaSt
demonstrated a greater extent of disproportionation during the later period of storage
when the reaction products had formed. Hence, it can be concluded that with the
accumulation of the reaction products, their hygroscopicity becomes a dominant factor in
facilitating additional disproportionation. These observations, together with initial studies
demonstrating that NaSt shows adequate lubrication properties when present at a low
amount, suggest that alternative lubricants with a lower propensity to induce
disproportionation than the commonly employed MgSt, might need to be considered to
improve product robustness when a HCl salt of a weak base is present in the formulation.
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Figure 4.1 Chemical structure of Pioglitazone HCl salt (A) and metallic stearates:
sodium stearate (B); Magnesium stearate (C); Calcium Stearate (D).
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Figure 4.2 Raman spectra of API and stearates over the spectral range 200cm-1 to
2000cm-1
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Figure 4.3 SEM images of metallic stearates: sodium stearate (A); magnesium stearate
(B); calcium stearate (C)
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Figure 4.4 BET specific surface area (right Y axis) and slurry pH value (left Y axis) of
metallic stearates
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Figure 4.5 Raman spectra of calibration (50% PIO-HCl to 100% PIO-HCl) standards
over the spectral range 1560cm-1 to 1660cm-1 (A); PCA of calibration standards (B); PLS
model of calibration standards (C) showing validations and the important statistical
parameters.
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Figure 4.6 Extent of disproportionation (% Conversion) of PIO-HCl salt in a binary
mixture with different stearates (ratio 9:1 w/w) for 30 days and for 48 hours (A) at
40°C/65% RH
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Figure 4.7 (A) Water sorption curves of pure CaSt (Red), pure MgSt (Blue), and pure
NaSt (grey) at 40°C 65% RH over the period of 50 minutes. (B) Water sorption curves of
binary mixture of PIO-HCl and stearates in a 9:1 ratio: PIO-HCl and CaSt mixture (red);
PIO-HCl and MgSt mixture (Blue); PIO-HCl and NaSt mixture (grey)
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Figure 4.8 Mechanism of proton transfer between PIO-HCl and Metallic Stearates

Figure 4.9 Wide-angular diffractogram of PIO-HCl, PIO-FB, NaSt, MgSt, CaSt, and the
mixtures of PIO-HCl and different stearates
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Figure 4.10 Ejection forces of high speed compaction (A) and low speed compaction (B)
studies for mannitol placebo formulation with 0.5% and 1% stearates addition.
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CHAPTER 5. CRYSTALLINE SOLID DISPERSION-A STRATEGY TO
SLOWDOWN SALT DISPROPORTIONATION IN SOLID STATE
FORMULATIONS DURING STORAGE AND WET GRANULATION

5.1

Abstract

Salt disproportionation (a conversion from the ionized to the neutral state) in solid
formulations is a potential concern during manufacturing or storage of products
containing a salt of the active pharmaceutical ingredient (API) due to the negative
ramifications on product performance. However, it is challenging to find an effective
approach to prevent or mitigate this undesirable reaction in formulations. Hence, the
overall objective of this study is to seek a practical formulation strategy to reduce the risk
of salt disproportionation in pharmaceutical products. Crystals of pioglitazone
hydrochloride salt were dispersed into polymeric matrices as a means of preventing the
pharmaceutical salt from direct contact with problematic excipients. It was found that the
level of salt disproportionation could be successfully reduced during storage or wet
granulation by embedding a crystalline salt into a polymeric carrier. Furthermore, the
impact of different polymers on the disproportionation process of a salt of a weakly basic
API was investigated herein. Salt disproportionation was significantly affected by the
physicochemical properties of different polymers in formulation including hygroscopicity,
acidity of substituents, and inhibitory effects on the crystallization of the neutral form of
API. These finding provide an improved understanding of the role of polymeric carriers
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on the stability of a salt in solid formulations. Moreover, adding pH modifier into
granulation fluid was found to be another useful method to retard the salt
disproportionation. Combining the developed salt protection approach and the
granulation fluid with pH modification, salt disproportionation can be significantly
reduced during the wet granulation process. These interesting discoveries enable salt
disproportionation to be mitigated during storage or processing, which provide critical
information that will allow pharmaceutical scientists to develop appropriate formulations
with improved drug stability.
5.2

Keywords

Salt stability, solid dispersion, acid-base interaction, HPMCAS, PVPVA, inhibitory effect,
pH modifier, hygroscopicity, crystal growth, microenvironmental pH, pioglitazone
hydrochloride salt
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5.3

Introduction

Salt formation is a crucial formulation strategy to increase the bioavailability of ionizable
active pharmaceutical ingredients (APIs) with poor aqueous solubility. 45,

145, 146

In

addition, salt formation can also be applied to avoid polymorphism and to improve the
stability and manufacturability of APIs by changing their solid-state properties.120, 147, 148
However, the ionized form of drug substances can be metastable and have a propensity of
converting to its neutral form, which can be considered a critical potential risk, narrowing
the application of pharmaceutical salts. This unwanted conversion of drug salt to its
neutral form is termed salt disproportionation in pharmaceutical literature. 16,

52, 53, 56

Prasugrel hydrochloride salt, a platelet inhibitor, severs as a recent example of salt
disproportionation showing salt-to-base conversion within a pharmaceutical tablet. 206, 207
Salt disproportionation has been reported to negatively influence the performance of
pharmaceutical products. For instance, Erlotinib HCl salt disproportionate to its free base
resulting in a rapid precipitation followed by a decreasing of dissolution rate in simulated
intestinal fluid.208 Therefore, it is imperative to develop formulation approaches to
prevent or, at minimum, slowdown salt disporportionation to ensure that robust
formulations are produced.
In order to effectively inhibit salt disproportionation, it is a prerequisite to understand the
following three key factors influencing the disproportionation process. The first of these
factors is the presence of water, since salt disproportionation is reported to be a solution
mediated reaction.12, 42, 57 For solid dosage forms, the presence of residual water from
manufacturing or after moisture sorption from the atmosphere is almost inevitable, and
even a slight amount of water is sufficient to form a microscopic aqueous layer on the
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solid surface, which can mediate disproportionation.15 Second, microenvironmental pH,
affected by the acidity/alkalinity of the excipient used in formulation, is another
important factor impacting salt stability. 58-60 For salt of a weak base, salt
disproportionation can potentially occur when the pH of microenvironment surpasses the
pH of maximum solubility (pH max). 14, 18, 60, 151 Hence, modifying the microenvironmental
pH is a feasible approach to reduce the risk of salt disproportionation. For instance,
microenvironmental pH can be decreased by avoiding alkaline excipients such as metallic
stearates or croscarmellose sodium. 153, 154, 209 Moreover, pH modifers, such as maleic acid
or tartaric acid, can be added into solid formulations to further adjust the pH value of
microenvironment.12,

210

Third, the greater area of contact between the drug salt and

problematic excipients was reported to significantly accelerate the disproportionation
reaction (e.g. for miconazole and benzocaine salt).61 Therefore, reducing the exposure of
the salt surface to the surface of the problematic excipient can be potentially used as a
means to decrease the extent of salt conversion.
In the present study, the overall aim was to develop effective formulation approaches to
slow down salt disproportionation in a solid formulation during storage and
manufacturing. Pioglitazone hydrochloride (PIO-HCl), a thiazolidinedione for type II
diabetes treatment 158, 160, was employed herein as model compound for two reasons. First,
the hydrochloride salt is one of the most commonly used salt forms for weakly basic
APIs. 15,

157

Second, PIO-HCl has a low reported pHmax and was shown to readily

disproportionate when interacting with problematic excipients (e.g. croscarmellose
sodium).41, 209 According to the previously developed analytical approaches of detecting
disproportionation of PIO-HCl in pharmaceutical tablets, Raman spectroscopy and
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chemometrics were combined herein to monitor the conversion of PIO-HCl to its free
base.62 In this study, polymers were formulated with crystalline PIO-HCl salt to form
crystalline solid dispersion (CSD) to slow down disproportionation of the drug salt.
Embedding the PIO-HCl crystals into a polymeric matrix serves as an approach to protect
the API by minimizing the contact surface between the drug salt and problematic
excipients. In addition, acidic substituents present in some polymers, such as the phthalyl
group of hypromellose phthalate, can also function as a pH modifier to adjust the
microenvironmental pH. Employing different polymers in solid formulations could have
different effects on salt disproportionation due to the different physicochemical properties
of the polymers including factors such as functional group chemistry and hygroscopicity.
Hence, the first objective of this study was to investigate the impact of different polymer
on salt disproportionation in solid formulations. Hypromellose acetate succinate
(HPMCAS) and vinylpyrrolidone-vinyl acetate (PVPVA) are selected due to their very
different chemistry and hygroscopicity211, 212 and used to produce either physical mixtures
(PMs) or CSDs with PIO-HCl. Salt disproportionation in PMs and CSDs was monitored
following exposure to high relative humidity (RH) storage conditions. The second goal
was to further investigate salt disproportionation in the presence of bulk water. During
aqueous wet granulation, disproportionation of PIO-HCl was compared when using
acidic polymers versus adding pH modifiers to the granulation fluid. The findings of this
research provide feasible approaches for slowing down salt disproportionation during
storage and wet granulation, as well as a mechanistic understanding of the impact of
polymers on acid-base reactions between API and excipients in solid formulations.
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5.4
5.4.1

Experimental
Chemicals

PIO-HCl salt was ordered from Tokyo Chemical Industry (TCI) Co, ltd. (Portland, OR).
PIO free base was supplied by Dr. Reddy's Laboratory (India). Sodium croscarmellose
(CCNa) was obtained from Mallinckrodt (St. Louis, MO). HPMCAS-LF was provided by
Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan). PVPVA was generously provided by
BASF SE (Florham Park, NJ). Succinic acid and maleic acid were purchased from
Sigma-Aldrich (St. Louis, MO) and Acros Organics (Fisher scientific Co. NJ)
respectively. Chemical structures of PIO-HCl and various excipients used in this study
are shown in Figure 5.1A-F. Weight percentage of each substituents present in
HPMCAS-LF is listed in Figure 5.1C according to its certificate of analysis. Mannitol,
used as a diluent for wet granulation studies, was ordered from SPI Pharm. (Wilmington,
DE).
5.4.2

Sample preparations of CSDs and PMs

PIO-HCl salt and polymers were individually stored in desiccators with calcium sulfate
(W.A. Hammond Drierite Co. Ltd, Xenia, OH) for at least 5 days at 25°C prior to use.
HPMCAS or PVPVA was first dissolved into an excess amount of acetone (Avantor
Performance Materials, Center Valley, PA) to form a homogenous polymer solution
(sonication was applied as needed). Afterwards, approximately 2/3 of the acetone in the
polymer solution was removed under a reduced pressure by a rotary-evaporator (Buchi,
New Castle, DE) immersed into a water bath maintained at a constant temperature
(~50°C) for 2-3 minutes until a viscous solution formed. PIO-HCl salt in crystalline form
was then dispersed into this viscous solution under agitation to form a suspension with
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1:1 drug and polymer weight ratio. The remaining acetone was rotary evaporated under
the same conditions for another 2-3 minutes. CSDs were afterwards placed under vacuum
at ambient temperature for a minimum of 48 hours to remove residual solvent. Samples
of salt-polymer physical mixtures were prepared by gravimetrically dispersing powders
of PIO-HCl and each polymer (HPMCAS or PVPVA) into a 20 mL scintillation glass
vial at 1:1 (w/w) weight ratio in a glove box (sidENTRYTM) purged with dry nitrogen to
maintain a low relative humidity (RH) condition. Physical mixtures were then subjected
to additional mixing by a ResodynTM LABRAM acoustic mixer (Butte, MT) with 30%
intensity for 5 minutes.
5.4.3

Preparation of samples for disproportionation studies at 40°C/75%RH storage
condition

The prepared 50% drug loading CSDs and PMs of PIO-HCl were individually placed in
desiccators with calcium sulfate for at least 36 hours at ambient temperature prior to
blending. Samples of CSDs or PMs were then gravimetrically mixed with CCNa as
powder mixtures at an 80% to 20% weight ratio in the glove box with purge dry nitrogen.
A ResodynTM LABRAM acoustic mixer was employed for 3 minutes of additional
mixing at 30% intensity. Samples were then placed into a 40°C/75% relative humidity
(RH) stability chamber in open dish conditions for stress storage. It is noteworthy that the
designed weight ratio of PIO-HCl to CCNa is 2 to 1, which is a realistic representation of
typical API and disintegrant ratio found in formulation of conventional pharmaceutical
tablet. For example, a 200 mg tablet with 10% disintegrant and a 50 mg API potency and
would be considered as a typical formulation.
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5.4.4

Preparation of samples for disproportionation studies at different RH conditions

Stability chambers with different RH at 25°C were prepared by filling DURAN®
dessicators (Fisher Scientific, Pittsburgh, PA) with different saturated salt solutions.
Subsequently, the desiccators were sealed from the outside environment for at least 3
days prior to use. Saturated salt solutions of magnesium nitrite and potassium chloride
were prepared to control relative humidity (RH) at 52% and 86% respectively. Blends of
CSDs and CCNa were prepared in a 1:1 (w/w) ratio and subjected to 3 minutes additional
mixing using a LABRAM acoustic mixer (30% intensity). Afterwards, samples
containing salt CSDs of HPMCAS and PVPVA were stored at 86% RH and 52% RH
respectively.
5.4.5

Powder X-Ray diffraction (PXRD)

The X-ray diffraction patterns of CSDs and PMs were collected on a Panalytical X’Pert
pro X-Ray diffractometer (PANalytical Inc., Westborough, MA) with Cu Kα radiation of
1.5406 Å in transmission mode. Samples were measured at ambient conditions in
transmission geometry with 2θ ranging from 2° to 40° using a 0.0167° step size. The 45
kV voltage and 40 mA current of the generator were set respectively. PXRD data were
processed by Panalytical X’Pert Data Viewer (version 1.5) software.
5.4.6

Raman Spectroscopy Bulk Measurement

Raman spectra were obtained using a Kaiser Raman RXN1 Workstation (Kaiser Optical
Systems, Inc., Ann Arbor, MI) equipped with a PhAT™ bulk volumetric sampling probe.
HoloGrams™ v4.1 software was employed for data acquisition. The excitation energy
was transferred from a 785nm high power NIR diode laser (Invictus TM) located within the
base unit to the PhAT probe via a fiber bundle. Laser power was set electronically to 400
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mW, and a 6mm laser spot was generated by employing a 250 mm focal length lens. In
order to ensure spectral quality, calibration of the laser excitation wavelength
(cyclohexane; ASTM standard), spectrograph wavelength (neon atomic lines; ASTM
standard), and instrument spectral response (white-light source; NIST standard) were
performed. Taking into account the penetration of the PhAT Raman measurement,
powder samples were carefully placed into a specially designed sample holder with
controlled thickness for reproducibility. The CCD was cooled to -40°C and a dark
subtraction was automatically applied to each spectrum to mitigate the baseline offset.
Data acquisition time for each measurement was set as 10 seconds and 6 accumulations
were averaged for all the samples. Collected Raman spectra were then processed by
Grams AI (Thermo, Inc. Waltham, MA) for visual inspection.
5.4.7

Dynamic Vapor Sorption (DVS) Measurements

Moisture sorption isotherms of PIO-HCl CSDs were obtained at 25°C employing a
Q5000SA Dynamic Vapor Sorption (DVS) equipped with an auto-sampler (TA
Instruments, New Castle, DE). About 10 mg of a CSD powder sample was pre-weighted
and gently dispensed into a crucible. All samples were dried at 50°C at the beginning of
the experiments for 60 minutes until the weight changes were less than 0.01% over 5
minutes. Moisture sorption data were then collected at conditions ranging from 5% to 95%
RH with a step size of 5% change in humidity. Less than 0.01% weight change over 5
minutes with a maximum dwell time of 240 minutes were set as equilibrium criteria for
samples at different humidity step. The data of moisture sorption isotherms were
processed by the Universal Analysis 2000 (version 4.5A) software.
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5.4.8

Polarized Light Microscopy (PLM)

A BX51P polarizing microscope (Olympus Corporation of the Americas, MA) equipped
with a 10X objective and a Nikon DS-Ri1 high-resolution digital camera (Nikon
Instruments Inc., Tokyo, Japan) was employed to collect images of both pure PIO-HCl
crystalline and the powder samples of salt-polymer CSDs placed on glass slides (VWR,
Radnor, PA). Polarized light microscopy was also applied to monitor the crystallization
in film samples of PIO-polymer amorphous solid dispersions which were prepared by a
solvent evaporation method. To be specific, PIO-free base and polymer (HPMCAS or
PVPVA) with a 1 to 1 dry weight ratio were fully dissolved213 (visually inspected) in a
50%: 50% (v/v) solvent mixture of dichloromethane and methanol to form a set of
homogenous solutions (sonication was applied as needed). Several drops of the solution
were added to a microscope slide and readily removed by using a KW-4A spin coater
(Chemat Technology Inc., Northridge, CA) with a rate of 500 rpm for 20s at ambient
temperature. The Images acquired by polarized light microscopy were further processed
by NIS-Elements software package (Version 4.4, Nikon Instruments Inc., Tokyo, Japan)
5.4.9

High-Shear Wet Granulation

The lab scale high-shear granulator used in this study was constructed from a 300 mL
food processor equipped with an electric high-shear chopper. A spray nozzle was inserted
into drilled hole on the top the granulator. The nozzle was connected to a 10 mL s yringe
loaded into a pulsating syringe pump (Harvard Apparatus, Holliston, MA). Prior to
granulation, pure PIO-HCl salt and PM or CSD of PIO-HCl and HPMCAS were
respectively blended with mannitol (diluent) and CCNa (disintegrant) in the designed
weight ratio (Table 5.1) by a TURBULA®T2F Shaker-Mixer (Glen Mills Inc., Clifton,
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NJ) for 3 minutes. Three formulations in 20g batch size (Table 5.1) were then loaded into
the granulator for wet granulation. Purified water and 10 mg/mL maleic acid or succinic
acid solutions were employed as granulation fluids. Samples with 15%, 25%, and 35%
(w/w) granulation fluid addition were analyzed by Raman spectroscopy.
Table 5.1 Three Formulations used for wet granulation studies
Formulation 1
Material
Weight
(g)
PIO-HCl
1.0

CCNa
Mannitol

0.5
18.5

Formulation 2
Material
Weight
(g)
PM of salt
2.0
and
HPMCAS
(1:1 w/w)
CCNa
0.5
Mannitol
17.5

Formulation 3
Materials
Weight
(g)
CSD of salt and
2.0
HPMCAS(1:1
w/w)
CCNa
Mannitol

0.5
17.5
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5.5
5.5.1

Results and Discussion

Sample characterization and calibration curve

The chemical composition and the crystalline form of PIO-free base and PIO-HCl salt
were confirmed by Fourier transform infrared spectroscopy (Smiths Detection Inc., MD)
and PXRD respectively. Both the IR spectra (Figure A.13) and X-ray diffractograms
(Figure A.14) of PIO-HCl and PIO free base showed satisfactory agreement with
reference data.162 In order to prepare CSDs of PIO-HCl salt, it is a prerequisite to form a
suspension system where the polymer is fully dissolved, but where PIO-HCl remains as
undissolved crystalline salt. Acetone, which can readily dissolve both HPMCAS and
PVPVA, was selected as the solvent to prepare the suspensions of drug salt in the
polymer, because PIO-HCl is almost insoluble in acetone. 214 After the solvent was
removed, PIO-HCl crystals should be dispersed within a polymer matrix. Based on the
PLM images of pure PIO-HCl (Figure 5.2A)and its CSDs, the crystalline nature of PIOHCl in the CSD can be confirmed; birefringence of PIO-HCl crystals can be clearly
observed under polarized light for CSDs prepared in PVPVA (Figure 5.2B) or HPMCAS
(Figure 5.2C). In addition, the X-ray diffraction pattern of the PIO-HCl CSD with
PVPVA showed good agreement with the diffractogram of the corresponding physical
mixture (Figure 5.3A). Similarly, the X-ray diffractograms of the CSD and physical
mixtures of PIO-HCl and HPMCAS (Figure 5.3B) are consistent. The results of PLM and
PXRD indicate that the crystalline form of PIO-HCl salt was maintained during sample
preparation.
Raman spectra of all the substances used in the solid state formulations are shown in
Figure 5.4, including CCNa, HPMCAS, PVPVA, mannitol, and pioglitazone (both HCl
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salt and free base). In the spectral range of 1500 to 1800 cm -1, there are two distinct and
strong API peaks located at 1609.4 cm-1 (Peak I) and 1638.3 cm-1 (Peak II) with minimal
spectral interference from the excipients. These two API peaks enable us not only to
readily discriminate the API from the excipients, but also to differentiate the neutral form
of PIO from its salt form. To be specific, the spectrum of PIO-HCl salt contains both
Peak I and II, while PIO free base spectrum only contains Peak I. Therefore, a calibration
curve can be generated on the basis of this spectral difference to quantitatively study PIOHCl disproportionation in mixtures.
A series of calibration sets were prepared by mixing PIO-HCl salt and free base in a
known weight percentage ranging from 100% PIO-HCl (0% PIO free base) to 10% PIOHCl (90% PIO free base). Each calibration sample was prepared in triplicate and
evaluated by bulk Raman measurement. Spectra of the 33 calibration standards in the
specific spectral region are shown in Figure 5.5A. It can be clearly observed from Figure
5.5A that the intensity of peak II increases with an increasing weight percentage of PIOHCl (red arrow indicates the increasing amount of PIO free base). A calibration curve
with good linearity was established (Figure 5.5B) by plotting the intensity ratio of Peak I
and II as a function of the weight percentage of PIO-HCl salt in the mixtures. The
calibration curve was further validated by using another set of samples (each level of the
validation standards was prepared in triplicate). Good consistency between the calibration
points (blue) and the validation points (red) are shown in Figure 5.5B demonstrating the
accuracy and robustness of the calibration curve. Moreover, this calibration model shows
a low value of root mean squares error of prediction (RMSEP) calculated using the
equation listed in Figure 5.5B. Therefore, this validated calibration curve was applied to
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enable the quantitative investigation of PIO-HCl salt disproportionation in solid
formulations during storage and manufacturing (Vide infra).
5.5.2

Salt disproportionation at high RH storage

The level of disproportionation (% conversion of salt) following storage at high RH
condition was quantified by Raman spectroscopy. Croscarmellose sodium (CCNa) was
used in all solid formulations as a representative problematic excipient that can induce
the disproportionation of PIO-HCl salt, based on the presence of a proton accepting group
and a relative high alkalinity. 41, 62, 154 Blends prepared by mixing CCNa with PM or CSD
of PIO-HCl and PVPVA were stressed at high relative humidity (40°C and 75%RH)
condition for a period up to 3 days. Samples stored for longer time periods could not be
analyzed due to the formation of sticky agglomerates caused by the hygroscopic nature of
PVPVA. A considerable amount of salt disproportionation (>10% conversion) was
observed for both PM and CSD of PIO-HCl and PVPVA (Figure 5.6A). To be specific,
more than 20% disproportionation was observed in the PM of PIO-HCl and PVPVA after
storage at 40°C/75%RH for 1 day. Approximately 15% of PIO-HCl disproportionation
was detected in the salt-PVPVA dispersion stored at the same high RH condition for 2
days. Clearly, the CSD of PIO-HCl and PVPVA has a lower level of salt
disproportionation than in the corresponding PM samples, presumably because the
polymer coated the PIO-HCl crystals, acting as a physical barrier to protect the salt from
interacting with the problematic excipient (i.e. CCNa). Similarly, using HPMCAS to
form a CSD can also potentially reduce the e xposure of PIO-HCl to CCNa, and in turn
slow down salt disproportionation in solid formulation. As shown by Figure 5.6B, less
than 5% conversion of PIO-HCl salt to PIO free base was observed for the dispersion,
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while the PM samples were shown to have around 10% salt disproportionation over a
period of 7 days. This result suggests that dispersing a crystalline salt into a polymeric
carrier can be utilized as a means of API protection to reduce the extent of salt
disproportionation.
It is noteworthy that different extents and kinetics of salt disproportionation were
observed between samples prepared with different polymers. To be specific, a significant
amount (~23%) of disproportionation with a rapid rate was observed in the PIO-HCl and
PVPVA physical mixture, while the mixture of PIO-HCl salt and HPMCAS shows a
lower level (< 10%) and a slower rate of salt-to-base conversion. Similarly, the dispersion
with PVPVA has a higher extent and faster kinetics of disproportionation than the saltHPMCAS dispersion. Three aspects relating to difference in polymer properties most
likely contribute to these observations. First and foremost, HPMCAS and PVPVA have
different hygroscopicities. Based on the previously reported isotherm of pure PVPVA
and HPMCAS, the amount of water sorbed by PVPVA at 75% RH is almost five times
higher than that sorbed by HPMCAS. 212, 215, 216 The greater hygroscopicity of PVPVA
most likely provides more water to the crystal surface. As salt disproportionation is a
solution mediated reaction, the role of water present in the formulation is of significance
to mediate the transfer of protons from the ionized drug molecule to the proton accepting
group. Therefore, samples prepared with PVPVA which contain a greater amount of
water can presumably increase the proton diffusivity between PIO-HCl and CCNa, and in
turn to accelerate the salt disproportionation process. Second, the high weight percentage
of succinyl group, an acidic substituent present in HPMCAS, can reduce the
microenvrionmental pH. For a salt of a weak base formed with acidic counterion,
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lowering the microenvironmental pH is favorable to avoid the occurrence of salt-to-base
conversion.14 Hence, the extent of PIO-HCl salt disproportionation is reduced when
formulating PIO-HCl salt with HPMCAS as a PM or CSD. Third, it is speculated that
PVPVA and HPMCAS can have a different inhibitory effects on the crystallization of
PIO free base during the salt-to-base conversion, which may impact the observed kinetic
differences. In order to evaluate the inhibitory effects of each polymer on the
crystallization of free base, amorphous solid dispersions (ASDs) of PIO free base were
prepared as thin films using HPMCAS (Figure 5.7A) or PVPVA (Figure 5.7B) as the
polymeric carrier. Polarized light microscopy was then conducted on both the freshly
prepared ASD thin films and the same samples stressed at 40°C/75%RH for 24 hours. In
Figure 5.7A-B, no evidence of birefringence was observed under polarized light for
freshly prepared samples confirming their amorphous nature. After stressing these
amorphous thin films for 24 hours, birefringence were observed both in dispersions of
PIO-HPMCAS (Figure 5.7C) and PIO-PVPVA (Figure 5.7D). Clearly, smaller crystals
are present in the dispersion of PIO and HPMCAS (Figure 5.7C) indicating that
HPMCAS has a better inhibitory effect on the crystallization of PIO free base. However,
in considering the impact on crystallization kinetics, it should be noted that there are
different amounts of water present in various solid dispersions, because of the different
hygroscopicities of the polymers. It has been reported previously that the amount of water
plays

an important

role

in affecting

nucleation, crystal

growth,

and salt

disproportionation.61, 217 Typically, a higher amount of sorbed water around solid surfaces
would be expected to enhance mobility leading to crystallization as well as increased
interaction with other solvated species in the vicinity.

182-186

Therefore, the impact of the
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polymeric inhibitor on of PIO-HCl salt disproportionation under a condition where the
water content was similar was investigated.
5.5.3

Salt disproportionation at conditions with normalized water content

In order to find storage conditions whereby the CSDs had an equivalent water content,
the water sorption isotherms for the two systems were compared. Based on the data
shown in Figure 5.8A, it is apparent that exposing the salt-PVPVA dispersion to storage
conditions of 25°C/52% RH will lead to the approximately the same water content (~4%)
as storage of the salt-HPMCAS dispersion at 25°C/86% RH. These results are consistent
with the previously reported moisture sorption isotherms of PVPVA and HPMCAS. 212, 215,
216

Hence, PVPVA CSD and HPMCAS CSD were stored at 25°C/52% RH and 25°C/86%

RH respectively for 20 days to quantitatively study the PIO-HCl salt disproportionation
in the dispersions at an equivalent water content, again utilizing Raman spectroscopy.
Based on the disproportionation profiles (Figure 5.8B), it is apparent that the dispersion
with HPMCAS has slower conversion kinetics and a lower level of PIO-HCl salt
disproportionation over the period of up to 20 days. To be specific, differences of
percentage conversion between the two CSDs can be clearly discerned after 7 days. For
example, the % conversion in the salt-PVPVA CSD is almost 5% higher than that in saltHPMCAS CSD after 10 days of storage. The extent of disproportionation in the PVPVA
CSD (>10%) is approximately twice that observed for the HPMCAS CSD (~4%) after 20
days. These results suggest that HPMCAS has a greater ability to reduce PIO-HCl salt
disproportionation than PVPVA, at an equivalent water content. Thus, the acidity of
HPMCAS

is

perhaps

of

greatest

significance

in impacting

PIO-HCl

salt

disproportionation. Specifically, the acidity of the succinyl substituents can reduce the
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microenvironmental pH, and consequently decrease the extent of PIO-HCl salt
disproportionation. Further evidence supporting the role of HPMCAS as a pH modifier
which hinders salt disproportionation is provided by wet granulation studies discussed
subsequently.
The inhibitory effects of polymeric carriers on the crystallization of PIO free base might
be considered as another factor influencing PIO-HCl disproportionation. In order to
investigate the impact of different polymers on the crystallization of PIO free base with a
normalized water content in the system, ASD thin films of PIO-HPMCAS and PIOPVPVA were stressed at 25°C/86% RH and 25°C/52% RH respectively for 48 hours. In
Figure 5.9A and B, the absence of birefringence under polarized light indicated that the
freshly prepared films contained amorphous drug. For the stressed film samples, the PIOHPMCAS dispersion showed the presence of small crystals on the surface of the film
(Figure 5.9C), while larger needle shape crystals were observed in the PIO-PVPVA
dispersion (Figure 5.9D). These results suggest that using HPMCAS as a polymeric
carrier can more effectively disrupt the crystalline self-assembly of PIO free base, and
impede the conversion from PIO-HCl salt to its free base as a result. Probing the
individual chemical features of PIO and polymeric carriers can provide a possible
explanation for this observed difference in inhibitory effect on PIO crystallization. To be
specific, the carboxylic acid from the succinyl group of HPMCAS can function as a
strong hydrogen bond donor, while the carbonyl group from the PVPVA can function as
a strong hydrogen bond acceptor. Based on the chemical features of PIO free base, there
are more hydrogen bond acceptors existed in its structure. For instance, the nitrogen on
the pyridine ring and the carbonyl groups of PIO are categorized as strong hydrogen bond
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acceptors in the pK BHX database.99, 100 Furthermore, the nitrogen located on the pyridine
ring of PIO can also be protonated by a strong acid (such as HCl) to form a PIO salt,
suggestive of its potential as a good hydrogen bond acceptor. Therefore, stronger
intermolecular interaction would be expected between PIO free base and HPMCAS.
Generally, stronger drug-polymer intermolecular interactions lead to more effective
inhibition of API crystal growth in an ASD. For instance, it has been demonstrated that
formation

of

more

extensive

hydrogen

bonds

between

felodipine

and

polyvinylpyrrolidone appear to be linked to a slower crystal growth rate. 218 A similar
phenomenon was observed for bifonazole, whereby stronger intermolecular drug and
polymer interaction led to reduced crystal growth.75
5.5.4

Salt disproportionation during the wet granulation

Introducing bulk water to solid formulations during wet granulation would be expected to
increase the susceptibility of systems undergoing solution mediated reactions such as salt
conversion or hydrolytic degradation. 219,

220

The disproportionation extent of each

formulation following wet granulation is shown in Figure 5.10 as a function of the
amount of added water. In this case, we observed a higher extent and a faster kinetics of
PIO-HCl disproportionation with exposure to larger quantities of water during processing
relative to storing at high RH, further highlighting the significance of water to the
disproportionation process. Applying pH modifiers in a formulation has been reported to
lower the risk of unwanted acid-base reactions and improved stability of the salt. 210, 220 In
the present study, low molecular weight pH modifiers were incorporated into the
granulation fluid as a means to lower the extent of PIO-HCl salt disproportionation. For
comparison, acidic polymers were also included to the solid formulations.
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In the absence of low molecular weight pH modifiers or acidic polymers, the largest
extent of disproportionation was observed (formulation 1, Figure 5.10A, black line).
However, when using 10mg/mL maleic acid (red line) or succinic acid (blue line)
solution as the granulation fluid, the percentage of conversion was significantly reduced
by 10% indicating that adding pH modifier in granulation fluid is an effective strategy to
lower the risk of disproportionation for a weakly basic salt. No significant differences of %
conversion were observed in Figure 5.10A between the using maleic acid and succinic
acid suggesting that both compounds can effectively adjust the microenvrionmental pH to
slow down disproportionation of PIO-HCl salt. At 35% (w/w) granulation fluid addition,
it is noteworthy that the % weight of succinic acid or maleic acid used is only 0.36%
(w/w) of the entire solid formulation. The extent of disproportionation is expected to be
further reduced with an increasing amount of pH modifier, which will be investigated in
the future studies.
In Figure 5.10B, formulation 2 (PIO-HCl and HPMCAS mixtures) granulated with pure
water (blue line) was shown to have a lower level of salt disproportionation than
formulation 1 (black line). Hence, even without using an acidic granulation fluid, the
extent of conversion in formulation 2 was observed to be similar to that of formulation 1
with a pH modifier in granulation fluid (red line). Based on the certificate of analysis of
HPMCAS-LF, the weight percentage of succinyl group is 14.6%, and the moles of
carboxylic acid group from the succinyl substituent of HPMCAS can be calculated
accordingly; this turns out to be very similar to the number of moles of carboxylic acid
from succinic acid when 35% (w/w) granulation fluid is added. These results further
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suggest that HPMCAS can be applied as pH modifier in solid formulations to slow down
salt disproportionation.
Furthermore, using the CSD of PIO-HCl and HPMCAS (formulation 3) can further
reduce the extent of disproportionation during wet granulation. From Figure 5.10C, it can
be seen that the percentage conversion in formulation 3 (blue line) was 10% less than that
in formulation 1 (black line) after 25% (w/w) water addition. Moreover, differences in
PIO-HCl disproportionation between formulation 3 (salt-HPMCAS CSD) and
formulation 2 (salt-HPMCAS PM) in wet granulations are also apparent. Clearly, the
CSD of with HPMCAS (blue line) have a lower extent of salt-to-base conversion than
PMs of salt and HPMCAS (red line). For instance, at 25% and 35% (w/w) water
additions, larger than 5% differences of salt disproportionation extent were observed
between dispersion and physical mixture. Interestingly, combining the CSD approach
with HPMCAS in the solid blend and maleic acid in the granulation fluid (purple line),
led to minimal disproportionation (<3%) during granulation, further highlighting that
rationale formulation strategies can be used to improve PIO-HCl stability in solid
formulations.
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5.6

Conclusion

Dispersing crystalline PIO-HCl salt in a polymeric carrier (HPMCAS or PVPVA) can
serve as an innovative formulation strategy to protect the PIO-HCl salt from interacting
with problematic excipients (i.e. CCNa), which in turn slows down and reduces the extent
of salt-to-base conversion during high RH storage or wet granulation. Compared to
PVPVA, HPMCAS was found to be more effective at reducing the extent of the PIO-HCl
disproportionation reaction. This was attributed to a lower hygroscopicity, the presence
of acidic functional groups, as well as a better inhibitory effect on PIO free base
crystallization. This study thus provides mechanistic insight into the impact of polymer
physicochemical properties on the disproportionation reaction.
Using low molecular weight pH modifiers dissolved in the granulation fluid can serve as
an alternative approach to reduce the extent of disproportionation of PIO-HCl following
wet granulation. HPMCAS was also successfully used as a pH modifier to improve salt
stability in solid formulation following wet granulation, showing as effective as succinic
acid/maleic acid solutions. Furthermore, by combining the crystalline salt-HPMCAS
dispersion with an acidic granulation fluid, the extent of PIO-HCl disproportionation was
minimized, allowing wet granulation to be successfully performed. The formulation
approaches developed herein thus can be applied to reduce salt disproportionation during
storage and manufacturing for formulations containing a salt form of the API.
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Figure 5.1 Chemical structure of pioglitazone HCl salt (A); croscarmellose sodium (B);
HPMCAS whereby the weight percentage of substituents are listed (C); PVPVA (D);
succinic acid (E); maleic acid (F)
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Figure 5.2 Polarized light microscope images of pioglitazone HCl salt (A), CSD of PIOHCl and PVPVA (B); CSD of PIO-HCl and HPMCAS (C)
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Figure 5.3 X-ray diffactogram of CSD and PM of PIO-HCl and PVPVA (50%: 50% w/w)
(A); CSD and PM of PIO-HCl and HPMCAS (50%: 50% w/w) (B)
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Figure 5.4 Raman spectra of API and excipients over the spectral range 200cm-1 to
2000cm-1, the expanded spectral region (1500-1800cm-1) is shown in the window
whereby peaks used for analysis (Peak I and Peak II) are highlighted
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Figure 5.5 Raman spectra of the calibration samples (10% PIO-HCl to 100% PIO-HCl)
over the spectral range 1500-1800 cm-1, Peaks I and II are labeled (A) Calibration curve
generated by plotting peak intensity ration (Peak II/Peak I) against the % PIO-HCl salt in
the drug mixture (C), R2 and RMSEP are shown
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Figure 5.6 Disproportionation rate and extent of PMs and CSDs of PIO-HCl and PVPVA
stored at 40°C/75%RH for 3 days (A); Disproportionation rate and extent of PMs and
CSDs of PIO-HCl and HPMCAS stored at 40°C/75%RH for 7 days (B)
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Figure 5.7 Polarized light microscope images of amorphous solid dispersion (ASD) of
PIO-free base and HPMCAS (A); ASD of PIO free base and PVPVA (B); ASD of PIOfree base and HPMCAS stressed at 40°C/75%RH for 24 hours (C); ASD of PIO-free base
and PVPVA stressed at 40°C/75%RH for 24 hours (D)
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Figure 5.8 Moisture sorption isotherms of CSD of PIO-HCl and PVPVA (Blue) and CSD
of PIO-HCl and HPMCAS (Red) at 25°C (A); Disproportionation studies of CSD of PIOHCl and PVPVA (Blue) storing at 25°C/52% RH and CSD of CSD of PIO-HCl and
HPMCAS (Red) storing at 25°C/86% RH (B)
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Figure 5.9 Polarized light microscope images of amorphous solid dispersion (ASD) of
PIO-free base and HPMCAS (A); ASD of PIO free base and PVPVA (B); ASD of PIOfree base and HPMCAS stressed at 25°C/85%RH for 48 hours (C); ASD of PIO-free base
and PVPVA stressed at 25°C/50%RH for 48 hours (D)
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Figure 5.10 Disproportionation studies in wet granulation including using maleic acid
and succinic acid solution as granulation fluid (A); disproportionation of the salt and
HPMCAS physical mixtures (B); disproportionation of salt-HPMCAS CSD in
presence/absence of pH modifier in granulation fluid (C)
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CHAPTER 6. ANALYTICAL APPROACHES TO INVESTIGATE SALT
DISPROPORTIONATION IN TABLET MATRICES BY RAMAN
SPECTROSCOPY AND RAMAN MAPPING3

6.1

Abstract

It has always been challenging to use spectroscopic methods to analyze salt
disproportionation in a multi-component tablet matrix due to the spectral interference
generated by the various excipients. Although combining Raman spectroscopy and
chemometrics can be a powerful approach to study the extent of salt disproportionation, it
was found in the present study that bulk measurements and chemometric modeling have
obvious limitations when the targeted component is present at low levels in the tablet.
Hence, a two-step Raman mapping approach was developed herein to investigate salt
disproportionation in tablets with a low drug loading (5% w/w). The first step is to locate
the area of interest where the drug particles reside throughout the tablet surface by using
a statistically optimized sampling method termed deliberate sub-sampling. The second
step, referred to herein as close-step mapping, utilize a step by step mapping of the
targeted area to find more details of salt disproportionation in the tablet regions where the
drug is concentrated. By using this two-step Raman mapping approach, we successfully
detected the existence of minor species embedded in multi-component low drug loading

3

The content of this chapter is adapted from Journal of Pharmaceutical and Biomedical Analysis, Vol. 118,
Haichen Nie et al., Analytical approaches to investigate salt disproportionation in tablet matrices by Raman
spectroscopy and Raman mapping, Pages 328-337, Copyright (2016), with permission from Elsevier.
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tablet matrices, where bulk measurements from routine techniques usually lack of
sensitivity. This approach will help formulation scientists detect and understand salt
disproportionation and in situ drug-excipients compatibility issues in low dose solid
dosage formulations.
6.2

Keywords

Salt stability; Pioglitazone; low drug loading; drug excipient compatibility; statistically
optimized sampling; chemometrics;
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6.3

Introduction

Most drug substances are reported to be either weak acids or weak bases. 1 Formulating
poorly water-soluble weak acids or weak bases into salts can not only increase
bioavailability, but also improve many other physicochemical properties. 35, 45, 156 Hence,
salt formation of active pharmaceutical ingredients (APIs) is recognized as one of the
most widely used formulation approaches. 15 However, a potential risk of employing salt
formation is that salt forms of APIs have a propensity to revert back to the unionized
form/free base, a process termed salt disproportionation. 52, 53 Disproportionation, a proton
exchange involving an acid base reaction, can be significantly influenced by several
factors including the physicochemical properties of excipients, drug loading, and storage
conditions.61 Theoretically, the tendency for disproportionation can be anticipated based
on assessment of the microenvironment and knowledge of the salt pH max, based on the
assumption that disproportionation is a solution mediated process. 15,
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It has been

reported that salt disproportionation has detrimental effects on pharmaceutical product
performance including loss of potency, increased tablet hardness, and reduced dissolution
rate and bioavailability.12,

42, 54-56

Therefore, it is essential to develop a mechanistic

understanding of how excipients lead to disproportionation and, perhaps more
importantly, develop more sensitive approaches to detect disproportionation.
A variety of analytical methods have been employed to reveal influential factors in
disproportionation. Raman spectroscopy was shown to be a useful tool to quantify the
free base and to study effects of excipients on the integrity of salts of weak bases in a
binary mixture.52 For example, coupling multivariate analysis with vibrational
spectroscopy, Christensen et al. demonstrated that acidic excipients can induce the
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calcium salt of atorvastatin to disproportionate at elevated temperature and humidity. 16
John et al. illustrated that the proton accepting and hygroscopic capacity of excipients
have significant impact on salt disproportion in powder blends.41 However, there are
limited studies of salt disproportionation in tablet matrices containing commonly used
components due to the analytical interference from excipients as well as challenges with
limits of detection (LOD) when the drug is present at a low weight percent, as is common
in tablet formulations. Therefore, development of an applicable analytical method with an
improved LOD is highly desirable to detect the existence of low-level unwanted species
in multi-component systems.
Taking advantage of higher Raman scattering coefficients of active pharmaceutical
ingredients (APIs) compared to those of typical excipients, Raman mapping is capable of
detecting low levels of APIs and related substances by generating a chemical map with
high lateral resolution. 221-225 For instance, Widjaja et al. successfully targeted magnesium
stearate, a minor component in a model pharmaceutical tablet, by applying Raman
microscopy and multivariate analysis. 226 Šašić et al. demonstrated the spatial distribution
of alprazolam in commercial tablets with API contents lower than 1%

(w/w) by

combining Raman mapping with chemometrics. 227 It has been reported that a minor
amount of a polymorph, as low as 0.025% w/w, in a low-content API formulation was
detectable by an innovative method which combined Raman mapping with statistically
optimized sampling.228, 229 Applying a similar method to salt disproportionation studies
might enable quantitation of low levels of free base embedded in a multi-component
formulation
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The primary objective of this study is to develop applicable methodologies for
conventional

Raman

mapping

to

detect

minor

components

resulting

from

disproportionation and to understand the “in-situ compatibility issues” between drug and
excipients in a pharmaceutical tablet with low drug loading. In addition, by using
chemometrics and Raman spectroscopy, we are expecting to further explore the impact of
commonly used excipients

and storage

conditions

on the

kinetics

of salt

disproportionation in tablets. Pioglitazone (PIO) hydrochloride (HCl) salt, a compound
with high efficacy and tolerability to treat type II diabetes, was selected as a model
compound for disproportionation studies, based on previous reports of the existence of
free base in the bulk powder of the salt and the low calculated pH max value.

41, 159, 160, 162

In this study, we used chemometric modeling and bulk Raman measurement of 30% drug
loading (DL) tablets to reveal the kinetics of disproportionation for PIO-HCl at different
storage conditions. We also applied a statistical sampling method (deliberate subsampling) to identify the suspected disproportionation area on the surface of 5% DL
tablet. After identification of regions of interest (drug particles dispersed in the tablet
matrix), a close-step mapping approach was conducted on the area of interest to further
investigate the disproportionation of PIO-HCl in a low content API tablet. By using the
proposed methods, we could successfully discern the minor component in a
multicomponent matrix, which was difficult to achieve by using bulk Raman
measurements and chemometrics.
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6.4

Experimental Section
6.4.1

Chemicals

Pioglitazone hydrochloride salt was purchased from TCI Co, ltd. (Portland, OR).
Pioglitazone neutral forms/free base were obtained from Dr. Reddy's Laboratory (India).
Magnesium Stearate (Mgst) was obtained from Mallinckrodt (St. Louis, MO). Sodium
Croscarmellose (CCNa) and Avicel PH-101 were purchased from FMC Biopolymers
(Philadelphia, PA). Crospovidone was supplied by ISP Tec. (International Specialty
Products, Wayne, NJ). Mannitol was ordered from SPI Pharm. (Wilmington, DE).
Anhydrous Dibasic Calcium Phosphate (A-TAB) was purchased from JRS Inc. (Patterson,
NY). Chemical structures of API and excipients used in this study are shown in the
supporting information (Figure A.21 A-D).
6.4.2

Tablets Preparation

Formulations of calibration tablets and the tablets for stability tests are listed in the
supporting documents (Table A.14 to A.16). Powders of API and excipients were
gravimetrically dispensed (+/- 2% weight standard deviation) into a 20ml glass vial by a
Symyx Powdernium powder dispensing robot. The weighed powders were mixed by a
LABRAM mixer (Butte, MT) with 30% intensity for 3 minutes. 100 mg of the mixture
was carefully poured into a 7.14 mm diameter tablet die held in place with a flat-faced
lower punch. Afterwards, the flat-faced upper punch was gently placed on the powder
bed. Axial pressure (200 MPa) was applied to the powder bed by a single station MTS
Alliance RT equipped with a 50 kN (variation +/- 1N) loading cell (MTS Systems
Corporation, Eden Prairie, MN). Tablets (n=6) formulated with Mgst, CCNa, or A-TAB
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were subjected to stability studies at 40°C/75% R.H. (relative humidity) or 40°C/35%
R.H. chambers in an open dish condition.
6.4.3

Raman Spectroscopy Bulk Measurement

Raman spectroscopy bulk measurements were conducted by employing a 785nm Kaiser
Raman RXN1 Workstation (Kaiser Optical Systems, Inc., Ann Arbor, MI) equipped with
a PhAT™ large volumetric bulk sampling probe utilizing HoloGrams™ v4.1 software for
data acquiation. The PhAT probe was connected to the base unit via a fiber bundle (1
fiber excitation, 50 fiber collections) to deliver the excitation energy from the Invictus™
diode laser located within the base unit. Laser power was set electronically to 400 mW
for the bulk measurement. A 250 mm focal length was employed to generate a 6mm laser
spot. Utilizing both the Kaiser Hololab™ calibration accessory and a Raman calibration
standard, calibrations of the spectrograph wavelength (neon atomic lines; ASTM
standard), laser excitation wavelength (cyclohexane; ASTM standard) and instrument
spectral response (white-light source; NIST standard) were performed to ensure spectral
quality. Taking into account the penetration of the PhAT Raman measurement, powder
samples (each component of tablets) were placed into a beaker with controlled thickness
(20mm) for reproducibility. The tablets were placed on specially designed tablet holder
which could be affixed to the stage of the workstation. To mitigate the baseline offset due
to dark noise from the camera, the CCD was cooled to -40°C and a dark subtraction was
automatically applied to each spectrum. Data acquisition time for Raman spectroscopic
bulk measurements was set as 10 seconds and 6 accumulations were averaged for all the
samples. All Raman spectral data was processed by Grams AI (Thermo, Inc. Waltham,
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MA) for visual inspection. Multivariate analysis software SIMCA v13 (Umetrics AB,
Umeå, Sweden) was used for chemometric analyses.
6.4.4

Raman Microscopy

Kaiser Raman RXN1 workstation, along with both Kaiser HoloMap and HoloGrams
software packages, were used for Raman mapping experiments. To avoid sample damage,
the Invictus laser power was set to 50% of the maximum (200 mW). A single mode
excitation fiber, a multimode collection fiber (100 µm), and a 50× microscope objective
were used to increase spatial resolution of Raman imaging. The size of the laser spot on
the surface of sample was measured before the experiments by direct visualization and
measurement under the optical microscope with the laser powered up. The visual laser
spot size was found to range from 10-15 μm on the tablet surface. Samples were placed
on a tablet holder affixed to a motorized stage (Prior Scientific, Fulbourn, United
Kingdom). The steps of the stage translation were set in the HoloMap software before
scanning the tablets, and the XY coordinate of each point was recorded in the system.
Raman spectral acquisition parameters for each spot were set as a 10 seconds acquisition
time with 6 accumulations. Analyses of the mapping results were carried out by HoloMap
module running inside MatLab (The Mathworks Inc., Natick, MA).
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6.5
6.5.1

Results and Discussions

Characterization of initial tablet components

In order to verify the purity of pioglitazone neutral form and its hydrochloride salt,
transmission powder X-ray diffraction (Panalytical X'pert Pro diffractometer) and Fourier
transform infrared spectroscopy (Smiths Detection Inc., MD) were employed. The X-ray
diffraction patterns (Figure A.22A) demonstrate that peak positions of pioglitazone HCl
salt and its free base are consistent with literature reports. The IR spectra (Figure A.22 B)
of PIO-HCl and PIO free base also show good agreement with the previous study. 162
Based on these analyses, we can confirm that both chemical composition and solid state
form of the API were pure prior to the tableting process.
Raman spectra of all tablet ingredients are shown in Figure 6.1, including pioglitazone
(HCl salt and free base), mannitol, Mgst, crospovidone, A-TAB, Avicel, and CCNa. In
this study, we are focusing on 1500-1800 cm-1 spectral range for two reasons. First and
foremost, in this specific spectral region, both pioglitazone salt and free base are Raman
active, while all the excipients used in our formulation are largely Raman inactive. The
strong and distinct API peaks in this spectral range enable us to directly discriminate the
API from the excipients used in this study. Secondly, although the spectra of pioglitazone
salt and free base are overlapped in the emphasized region, the spectral differences are
significant enough to be readily discerned without applying any multivariate analysis. To
be specific, pioglitazone HCl salt demonstrates a doublet located at 1600-1650 cm-1,
while pioglitazone free base shows a singlet in the same region. A possible explanation
for this spectral difference is that the protonation of pioglitazone changes the vibrational
modes of the pyridine ring and the carbonyl group. 169 Additionally, in order to rule out
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the impacts of laser on the disproportionation of PIO-HCl salt, both PIO-HCl salt and its
mixture with excipients found to expedite disproportionation, CCNa and Mgst, were
exposed at the laser with same power set for 10 minutes. No drift in the data was
observed in the spectral region of interest for both bulk meas urement (Figure A.23 A-C)
and microscopic measurements (Figure A.23 D-F).
6.5.2

Raman spectroscopy

6.5.2.1 Theoretical section
In this section, based on the result of Raman bulk measurements, the chemometric
models for calibration tablets with high API content (30% DL) and low API content (5%
DL) were established. According to the statistical parameters of these chemometric
models, we will discuss whether the proposed approaches are appropriate for the tablets
with different drug loadings.
As summarized in Table A.15, standard tablets with 30% (w/w) drug loading were
prepared for generating a calibration curve ranging from 100% PIO-HCl (0% PIO free
base) to 80% PIO-HCl (20% PIO free base). The excipients used in the calibration tablets
were reported as inert ingredients which would not cause disproportionation of PIO-HCl
salt.41 Each calibration standard was scanned five times with the macroscopic Raman
system. In Figure 6.2A, 18 randomly selected Raman spectra (out of 30 total) showing
the spectral region of interest are presented. From Figure 6.2A, it is clear that the
intensity of peak I and peak II decrease with an increasing amount of PIO free base
(whereby the red arrow indicates increasing free base). Therefore, even without a
derivative treatment of the spectra, these differences between each calibration standard
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are significant enough for us to build chemometric models and directly discern the
existence of PIO free base in the Raman spectrum.
In order to eliminate the multiplicative interferences from light scattering and particle
size variations for solid state samples, standard normal variate (SNV) transformation was
employed to pre-process the spectra of calibration tablets.174,
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Principal Component

Analysis (PCA) was conducted for the pre-treated 30 spectra, and the results
demonstrated that over 96.5% of the spectral variation was captured in the first two
principal components. No outliers are observed in the Hotelling’s T2 ellipse at 95%
probability level (Figure 6.2B). All calibration standards form unique and discriminating
clusters along the first two principle components. PC1 is the dominant factor describing
the interclass differences, while PC2 captures the variation within each class. Although
most of the classes could be separated by PC1 with satisfaction, 99% PIO-HCl and 100%
PIO-HCl samples show overlap suggesting some level of sub-sampling/ inhomogeneity.
This drawback indicates that the Raman bulk measurement and/or the chemometric
model have limitations in detecting the existence of low levels of distinct species. From
the loading plot of the PCA (Figure A.24), we observed that the loadings from PC1 and
PC2 are very similar and represent contributions from variations of peaks I, II, and II.
Moreover, PC1 captures 82% of the total variance, which is much larger than that of PC2
(14.2%). Therefore, it is reasonable to choose PC1 as the only principal component for
the partial least square (PLS) models in order to avoid over fitting. 230, 231 This decision is
also supported by “leave-one-out” cross validation to get a tradeoff between the goodness
of fit (R2Y) and goodness of prediction (Q2), which will be discussed subsequently.
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On the basis of above analysis, PLS calibration with PC1 as the principle component was
carried out for 30% DL tablets and the results are plotted in Figure 6.3A. A low value of
root mean squares error of cross validation (RMSECV) indicates the balance between
predictive power and fitting. The reasonable values of R 2Y and Q2 suggest that the PLS
model is applicable and appropriate to evaluate the amount of PIO free base for 30% DL
tablets. In this study, one side of each calibration tablet was scanned to generate the PLS
calibration curve. The other side of the each calibration tablet was then scanned to
validate the PLS model. It is clear that the validation outcomes match well with the
calibration results (Figure 6.3A). The low value of the root mean squares error of
prediction (RMSEP) not only suggests that this PLS model is robust, but also indicates
the good uniformity and homogeneity across samples.
Similarly, PCA and PLS models were developed for 5% DL calibration tablets using the
same pre-processing methods over the identical spectral region. For PCA, all levels are
not well separated in the PC1-PC2 score plot (Figure 6.2D) due to the weak signal of the
specific peaks in the focused spectral region (Figure 6.2C), and there are clear outliers.
As for the PLS model, PC1 and PC2 were selected as the principal components, based on
the cross-validation. The RMSEE (root mean squares error of estimation) of 5% DL
calibration curve is significantly lower than that of the 30% DL calibration curve
indicating a poor fit (Figure 6.3B and Table A.17). In addition, the value of RMSEP is
over 75 for the PLS calibration curve of 5% DL standards (Figure 6.3B and Table A.17),
confirming the poor predictive power of this model. Thus, the approach of combining the
bulk Raman measurements and chemometric models is insufficient to characterize low
drug loading PIO tablets. Insufficient detection of free base embedded in a tablet matrix
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with low API content might lead to poor prediction of the degree of salt disproportion,
which could in turn lead to failure of such tablets. Hence, a statistically based sampling
method termed “deliberate sub-sampling” (vide infra) was used to investigate the
existence of the neutral form of pioglitazone in a tablet matrix with 5% DL.
6.5.2.2 Disproportionation kinetic studies for 30% DL tablets
Understanding the disproportion kinetics of the 30% DL tablet would be useful for
estimating the amount of the free base present in the low drug loading tablets with the
same ratio of drug and disproportionating agents and the storage condition. According to
the previous discussion, it is appropriate to investigate the disproportional kinetics of 30%
DL PIO-HCl tablets by bulk Raman measurements with the models outlined above.
Tablets containing PIO-HCl salt and disproportionating agents were stressed at 40°C/75%
R.H. and 40°C/35% R.H. for 14 days. Based on the above validated PLS model for 30%
DL tablets, the kinetics of disproportionation for stressed tablets are shown in Figure 6.4.
Both the rate and the extent of disproportionation for tablets stressed at 40°C/75% R.H.
(solid line) are higher than for tablets exposed at 40°C/35% R.H. (dashed line). This
observation is consistent with the consensus that salt disproportionation is a solution
mediated reaction and indicates that the relative humidity is a dominate factor for PIOHCl disproportionation.6 A-Tab, Mgst, and CCNa all led to the disproportionation of
PIO-HCl in tablets stressed at both 40°C/75% R.H. and at 40°C/35% R.H., which can be
attributed to the following factors: First, A-tab, Mgst and CCNa have the potential to
produce a high pH microenvironment based on results of slurry pH tests. The slurry pH
values of these three excipients (10% slurry, pH=5-7) are significantly higher than that
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the pH max of PIO-HCl salt (pHmax=3), which indicates that A-Tab, Mgst and CCNa can
cause disproportionation of the PIO-HCl salt.8, 232, 233 Second, the HPO 42- group of A-Tab
and the COO- group of Mgst and CCNa are proton acceptors. These proton acceptors
could acquire a certain amount of protons and convert the pioglitazone from its
hydrochloride salt form to its free base from. 42, 154 Third, Mgst, CCNa, and A-Tab are
hygroscopic ingredients. Hence, these three excipients can lead to the presence of water
in the tablet which will promote the salt disproportion reaction, when exposed to high
relative humidity conditions.234,

235

For Mgst and A-Tab, MgCl2 and CaCl2 are formed as products of the disproportionation
reaction, based on the need to maintain charge neutrality (Figure A.21 F and G). It should
be pointed out that both magnesium chloride and calcium chloride are deliquescent at low
R.H. conditions.236 Hence, the deliquescence of MgCl 2 or CaCl2 could reduce the critical
R.H. for the system and accelerate the rates of disproportionation. 237 In addition, tablets
formulated with Mgst demonstrated a faster and greater extent of disproportionation than
other samples due to the existence of alkaline impurities in Mgst. It has been reported that
magnesium oxide exists as the major basic impurity in the Mgst, which could further
enhance the alkalinity of the microenvironment and provide additional proton
acceptors.63 It is important to note that, the disproportionation of PIO-HCl in tablet
matrices has not been observed without exposure to stressed conditions due to the limit of
detection provided by Raman spectroscopy. Disproportionation under ambient conditions
might occur and perhaps can be detected with a more sensitive analytical technique.
Hence, Raman mapping methods were carried out to test this hypothesis.
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6.5.3

Raman Microscopy

6.5.3.1 Mapping method and proof-of-concept study
Given the aforementioned issues with the Raman bulk measurements for detecting
disproportionation in low content API multi-component tablet matrices, we decided to
use Raman mapping as an analytical method to study the disproportionation of the 5%
DL Pioglitazone tablets. Tuning the laser spot to a few microns can significantly improve
the spatial resolution of the imaging, effectively concentrating the sample which in turn
enables Raman microscopy to discern the presence of the unwanted species at low
content level. However, one drawback of applying conventional Raman mapping method
is the long acquisition time.238 If we want to scan the entire tablet surface, step by step, to
determine the existence of any neutral form of pioglitazone, the size of laser spot and
exposure time described in the experimental section, we need to collect about 250,000
spectra to cover a 5mm×5mm tablet surface, resulting in a total data acquisition time of
155 days for one tablet. Therefore, a statistical sampling approach must be applied to
efficiently locate the area of interest within a reasonable analytical period. Šašić’s
research on low-level polymorph detection provided a solution for our time-consuming
problem; in this study, the authors used statistically optimized sampling methods. 228
Specifically, the method stipulated that the minimal number of spectra that need to be
acquired to statistically guarantee detection of a minor component is set as five multiples
of the intuitive minimal number of spectra which is related to the approximated
concentration of the targeted substance. 229
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A calibration tablet, 5% DL with 20% PIO free base, was used as an example to illustrate
this sampling method. In this case, PIO free base is the targeted species and is present at a
concentration of 1% of the total weight of the tablet. Therefore, 100 spectra acquired
from the entire tablet surface would be the intuitive minimal number of spectra to yield at
least one spectrum of the PIO free base. Based on the calculation of a binomial
distribution probability, acquiring 100 spectra for this calibration tablet can only provide
limited probability (63.39%) of detecting PIO free base. However, when we acquire five
times the intuitive minimal number of spectra (in this case 500 spectra), the probability of
detecting the targeted substance would dramatically increase from 63.39% to 99.34%.
Hereby, we define this approach as “deliberate sub-sampling”. On the other hand, the
close step-by-step mapping is termed as close-step mapping and is differentiated from the
deliberate sub-sampling method. After locating a spot of interest via deliberate subsampling (in this case, particles of pioglitazone), the close-step mapping method is
applied in the vicinity of the area of interest to gain a more detailed picture of salt
disproportionation.
As a proof-of-concept study, we first applied the deliberate sub-sampling and close-step
mapping methods to the above mentioned calibration tablet (Figure 6.5). A total 529
spectra (23×23 spots) were collected across the entire tablets surface (5mm×5mm) with a
step size of 227μm, to generate the maps of the deliberate sub-sampling (Figure 6.5A).
The API concentrated area could be unambiguously identified as the “hot pixel” regions
(Figure 6.5A1), by analyzing the spectral range with characteristic drug peaks (shaded
area, 1500-1800cm-1). In contrast, regions with a higher concentration of excipients are
shown as “cold pixels” (Figure 6.5A2). Select areas containing high API concentration
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were then analyzed via a close-step mapping approach (shown as an orange square for
clarity), and a detailed map is generated (Figure 6.5B). The spectrum of spot B1 shows a
doublet in the spectra region 1600-1650cm-1(Figure 6.5B1). This doublet coincides with
the spectrum of PIO-HCl salt (Figure 6.1). On the other hand, the spectrum of spot B2
shows a singlet in the same spectra region (Figure 6.5B2), which matches with the
spectrum of PIO free base. These observations further supported the fact that the
proposed approach is sound and capable of detecting both the PIO-HCl salt and the PIO
free base in a low-content API tablet matrix. In summary, this method for 5% DL PIO
tablets can be described as a two-stage approach. First, we use a deliberate sub-sampling
method to look for the areas where the pioglitazone resides. Secondly, once piogl itazone
rich regions are identified, a closed step mapping of this area is conducted to discern the
form of pioglitazone present. Noteworthy, for calibration tablets, the PIO-HCl salt and
PIO free base are most often spatially separated in the tablet matrix, because we
intentionally spike the free base of PIO into the powder mixture. The results of close-step
mapping for the stressed tablets naturally present a different scenario. Specifically, it is
reasonable to assume that the PIO free base will reside spatially adjacent to the PIO-HCl
salt from which is came. Hence, intensity of the peak II and peak III are used to further
identify the disproportionation of PIO-HCl salt, which will be illustrated in the following
section.
6.5.3.2 Disproportionation studies for 5% DL tablets
In this study, we used 5% DL tablets formulated with inert excipients and Mgst (model
tablet 1) or CCNa (model tablet 2) as examples to investigate the drug-excipients
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compatibility and salt disproportionation within a multi-component tablet matrix
(detailed formulations are listed in Table 2S). Deliberate sub-sampling and close-step
mapping were conducted on both the freshly prepared model tablets and the same model
tablets stressed at 40°C/75% R.H. for 12 hours. Before scanning the model tablets, it is
necessary to estimate the minimal number of acquired spectra for deliberate sub-sampling.
The kinetics study for the 30% DL tablets (Figure 6.4) provides the information that
about 10% PIO-HCl converted to the PIO Free base for the tablets in presence of Mgst or
CCNa. The 5% DL tablets were exposed to the same stressed conditions and have a
similar ratio of drug to disproportionating agents. Hence, it is reasonable to assume that
10% PIO-HCl would convert to its neutral form after 12 hours for the 5% DL tablets.
Based on the previous discussion about the deliberate sub-sampling, 1024 spectra (32×32
spots, step size =161.2 μm) were collected throughout the surface of the model tablet to
ensure a high probability of finding one interesting spot for close-step mapping. The
deliberate sub-sampling results for both the model tablets and stressed model tablets are
shown in the supporting information (Figure A.25 to Figure A.28), and the areas targeted
for close-step scanning are marked for clarity.
The close-step mapping for initial model tablet 1 is shown in Figure 6A. The spectrum of
A2, a hot pixel located at the edge of the API concentrated area, shows that peak II has a
lower intensity than peak III. As the spectrum of pure PIO-HCl is expected to
demonstrate similar intensity for peak II and peak III (Figure 6.1), the spectral
discrepancy between A2 and pure PIO-HCl indicates the existence of PIO free base in the
API concentrated area. This observation indicates that disproportionation of PIO-HCl salt
tablets formulated with Mgst could occur even at ambient conditions. However, at
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ambient conditions, we did not observe any disproportionation of the 30%DL tablet
formulated with Mgst by the combined chemometrics and Raman bulk measurements due
to poor detection limits for low content substances.
For the stressed model tablet 1 (Figure 6.6B), the spectrum (Figure 6.6B1 and 6.6B2)
from the API concentrated area displays lower intensity for peak II suggesting that the
larger amount of PIO-HCl salt has converted to its free base. It has also been observed
that the peak II of B2 has slightly lower intensity than that of B1. A possible explanation
is that surface of the API particle is coated with Mgst, which contributes to a faster
disproportionation rate at the surface than for the material in the core. The results of
close-step mapping (Figure 6.7) for model tablet 2 could be interpreted in a same way.
Based on the mapping results of the initial model tablet 2 (Figure 6.7A), we did not
observe PIO free base at ambient conditions probably due to higher critical R.H. for
disproportionation of this system. For the stressed model tablet 2 (Figure 6.7B), the
spectrum of B2, at the edge of API concentrated area, shows a lower intensity of peak II,
indicating the occurrence of disproportionation.
Although the approaches we have proposed in this study could be applied to detect the
existence of a minor component with satisfaction, we came to realize that this Raman
mapping method is best suited to qualitatively detect the targeted substances, rather than
for quantification for the following two reasons. First, the deliberate sub-sampling
method was derived from a binomial distribution, which means that it is only able to
conceptually tell a “yes” or “no” for the targe t species. Second, in this study, the closestep mapping only analyzed a 200 μm×200 μm area out of a 5mm×5mm tablet surface. It
is not representative enough to quantify a small portion of the sample, since the target
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components generally have a wide distribution over the tablet surface and the core. In
addition, although the analytical time to generate the imaging is significantly reduced by
the employment of deliberate sub-sampling, it is important to point out that it is still a
very time consuming process. With the development of non-linear optical imaging
approaches, broadband coherent anti-stokes Raman scattering (BCARS) microscopy can
provide a possible remedy to further resolve our time-consuming problem by taking
advantage of its fast acquisition time and high spatial resolution.239 Using BCARS to
study salt disproportionation will be carried out in a future study.
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6.6

Conclusion

This study demonstrated that Raman bulk measurements combined with chemometrics
are appropriate to analyze the kinetics of disproportionation for 30% DL PIO-HCl tablets.
A-Tab, Mgst, CCNa all has the potential to facilitate disproportionation of PIO-HCl due
to their high alkalinity and capacity to accept protons. At 40°C/75 R.H., approximate 10%
of PIO-HCl formulated with Mgst or CCNa converts to PIO free base in 12 hours. In
addition, this is the first time it has been reported that A-tab can lead to
disproportionation of pioglitazone hydrochloride. Hence, formulation scientists should
exert caution when formulating salts of weak bases with A-Tab, Mgst, and CCNa due to
the potential risk of disproportionation.
Deliberate sub-sampling and close-step mapping methods were applied for low drug
loading (5% DL) PIO-HCl tablets. Applying the deliberate sub-sampling method, we
successfully detected the suspected area of disproportionation for both calibration and
stressed tablets. This statistically optimized sampling method is very effective and was
able to significantly reduce the data analysis time. Utilizing the proposed two-step
mapping approach, the presence of PIO free base was observed in a model tablet exposed
at ambient conditions, which could not be detected by Raman bulk measurements. This
important finding suggests that the proposed method has the potential to detect minor
species in a multi-component tablet matrix. Moreover, this finding also indicates that
Mgst could lead to the disproportionation of PIO-HCl even at ambient conditions (below
the reported critical R.H.). To the best of our knowledge, this is the first time that Raman
mapping has been employed to study salt disproportionation in a multi-component tablet
matrix. The success of applying Raman microcopy to detect the product of
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disproportionation, which is a minor component embedded in a tablet, will help
formulation scientists better understand in situ drug-excipients compatibility. Hence the
findings of this study could profoundly impact the formulation design of dosage forms
containing pharmaceutical salts.
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Figure 6.1 Raman spectra of API and excipients over the spectral range 200cm-1 to
2000cm-1
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Figure 6.2 Raman spectra of 30% DL calibration tablets over the spectral range 1500cm-1
to 1800cm-1 (A); PCA model for 30%DL calibration tablets (B);
Raman spectra of 5% DL calibration tablets over the spectral range 1500cm-1 to 1800cm-1
(C); PCA model for 5%DL calibration tablets (D);

191

Figure 6.3 PLS model for 30%DL calibration tablets (A); PLS model for 5%DL
calibration tablets (B)
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Figure 6.4 Kinetics of disproportionation for 30% DL Pio-HCl tablets stressed at
40°C/75% R.H. (solid line) or 40°C/35% R.H. (dash line)
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Figure 6.5 Raman imaging of calibrated tablets (5% DL, 80% Pio-HCl salt) deliberate
sub-sampling (A) and close-step mapping (B)
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Figure 6.6 Raman close-step mapping for Pio-HCl tablet formulated with Mgst (model
tablet 1) at initial condition (A) and the model tablet 1stored at 40°C/75% R.H. for 12
hours (B)
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Figure 6.7 Raman close-step mapping of Pio-HCl tablet formulated with CCNa (model
tablet 2) at initial condition (A) and the model tablet 2 stored at 40°C/75% R.H. for 12
hours (B)
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Figure A. 1 PXRD stability data for dispersion system of CLF with different polymers
stressed at 40°C 75%RH conditions (A: HPMCP; B: HPMC and C: PVPVA). Percentage
in the legend indicates CLF loading

230

Figure A. 2 Proton NMR assignment for CLF

231

Figure A. 3 1D 1H NMR for CLF in DMSO, 298K

Figure A. 4 2D COSY for CLF in DMSO, 298K

232

Figure A. 5 2D HSQC of CLF in DMSO, 298K

Figure A. 6 2D NOESY of CLF in DMSO, 298K
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Figure A. 7 1D 1H NMR of CLF with acetic acid and HPMCP in CDCl 3, 298K

Figure A. 8 1D 1H NMR of CLF with Phthalic acid and HPMCP in CDCl 3, 298K

234

Figure A. 9 2D DOSY of CLF with different polymers
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Figure A. 10 Simulated NMR spectrum for CLF and complex I and Complex II

236

Figure A. 11 Simulated UV/Vis spectra for CLF and complex I and Complex II

237

Figure A. 12 Pictures of Pure CLF and amorphous solid dispersion of CLF and HPMCP
in 1:1 weight ratio
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Figure A. 13 Infrared spectra of PIO-HCl salt and PIO-FB

Figure A. 14 X-Ray Diffraction Pattern of PIO-HCl salt and PIO-FB

239

Figure A. 15 API and metallic stearates mixtures exposed at same laser power source
(described at experimental section) for 10mins (A: pure PIO-HCl sample; B: PIO-HCl
and NaSt mixtures; C: PIO-HCl and MgSt mixtures; D: PIO-HCl and CaSt mixtures)

240

Figure A. 16 Loading plot of PC1 and PC2

241

Figure A. 17 Moisture absorption profile of PIO-HCl at the % RH range of 30% to 95%

Figure A. 18 Water sorption curves of pure PIO-HCl (Red) and pure PIO-FB (Blue) at
40°C 65% RH over the period of 48 hours

242

Figure A. 19 Water sorption curves of pure CaSt (Red), pure MgSt (Blue), and pure NaSt
(grey) at 40°C 65% RH over the period of 48 hours

243

Figure A. 20 Tensile strength of high speed compacted tablets (A) and low speed
compacted tablets (B) studies for mannitol placebo formulation with 0.5% and 1%
stearates addition

244

Figure A. 21 Chemical structure of Pioglitazone and excipients and the
disproportionation reaction of PIO with different excipients

245

Figure A. 22 (A) PXRD of Pio-HCl salt and Pio free base, (B) FT-IR of Pio –HCl salt
and Pio Free base

246

Figure A. 23 PIO-HCl salt and its mixtures with disproportionation agents exposed at
same laser power source (described at experimental section) for 10mins (A-C is bulk
measurement, D-F is microscopic measurement, A and D are pure PIO-HCl sample, B
and E are PIO-HCl and CCNa mixtures, C and F are PIO-HCl and Mgst mixtures)

247

Figure A. 24 Loading plot of 30%DL calibration tablets

248

Figure A. 25 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with
Mgst at initial condition

249

Figure A. 26 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with
Mgst stored at 40°C/75% R.H. for 12 hours

250

Figure A. 27 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with
CCNa at initial condition

251

Figure A. 28 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with
CCNa stored at 40°C/75% R.H. for 12 hours
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Table A. 1 Optimized Cartesian coordinates, natural population analysis, and isotropic
magnetic shielding tensors of pure CLF, calculated at the level of B3PW91 with 6311++G (2d, 2p) basis sets

Atomic
Type
Cl
Cl
N
N
C
C
N
C
C
C
N
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

Coordinates(Angstroms)
X
Y
Z
8.57929 0.70438 0.20117
-6.96678 -2.33405 0.30340
0.08787 2.77828 -0.16436
-2.17413 1.14860 -0.02273
-0.92483 0.56464 -0.04051
1.52816 0.91705 -0.11050
2.93334 -1.07215 -0.07029
0.21950 1.47720 -0.10523
-2.33307 2.52604 -0.08258
5.25061 -1.37969 -0.56999
0.88340 -2.62405 -0.02109
0.57893 -1.36804 -0.02587
1.73853 -0.42938 -0.05779
4.23871 -0.59566 -0.00222
-3.83940 -0.05297 1.29676
-1.16773 3.32165 -0.15777
-3.33343 0.30745 0.05487
-0.73263 -0.78672 -0.01272
-4.96075 -0.86602 1.37776
5.92598 0.98447 0.70899
4.59800 0.58765 0.64988
-1.30440 4.71687 -0.22263
-2.54884 5.31069 -0.21148
6.90764 0.19823 0.12901
-3.59224 3.13477 -0.06974
-5.55877 -1.31023 0.20735
-0.13835 -3.65427 -0.00754
6.57683 -0.99110 -0.50432
-3.69331 4.51268 -0.13382

Natural
Charge(e)
-0.00125
0.01827
-0.45669
-0.38952
0.31490
-0.27753
-0.53210
0.15735
0.28526
-0.14170
-0.54172
0.23097
0.18777
0.12600
-0.14130
0.06111
0.09306
-0.40698
-0.23558
-0.22138
-0.22382
-0.18716
-0.22846
-0.07236
-0.29401
-0.04361
-0.07321
-0.24630
-0.18715

Isotropic magnetic
shielding tensor(ppm)
708.9403
690.4833
-60.7806
103.7129
47.4209
84.1422
136.1622
31.1400
51.4044
60.0886
-52.8164
30.7503
40.4934
43.0956
49.6256
44.9712
45.0816
94.4555
49.9542
52.6299
63.8541
53.0886
59.6242
49.7895
68.8093
38.7639
133.2955
52.2951
55.1051
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Table A. 1 continued

Atomic
Type
C
C
C
C
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H

Coordinates(Angstroms)
X
Y
Z
-3.93856 -0.14334 -1.11078
-5.06015 -0.95700 -1.03814
-0.52460 -4.02093 -1.44221
0.39540 -4.86815 0.74601
1.28777 -5.26013 0.25364
-0.35451 -5.66062 0.78141
0.66214 -4.60308 1.77003
-1.58611 -1.44538 0.01012
2.34094 1.62215 -0.18724
-0.39768 5.30516 -0.28056
-4.48607 2.53033 -0.01053
7.34686 -1.60505 -0.95025
-1.04025 -3.30939 0.51360
6.19296 1.89939 1.21954
-3.53510 0.14234 -2.07321
-5.36488 -1.15025 2.33901
3.85293 1.18866 1.14832
-2.63930 6.38780 -0.26157
-3.35890 0.30274 2.19856
-4.67402 4.97063 -0.12331
4.98938 -2.30260 -1.07268
-5.54039 -1.31191 -1.93897
2.78999 -2.07853 -0.14492
-0.92438 -3.15754 -1.97566
-1.28074 -4.80821 -1.44536
0.34957 -4.38237 -1.98743

Natural
Charge(e)
-0.19026
-0.21844
-0.57691
-0.54806
0.19533
0.19683
0.20628
0.22822
0.22782
0.22595
0.22748
0.22989
0.17123
0.23000
0.23669
0.23575
0.22732
0.21693
0.22912
0.21620
0.21225
0.23652
0.42531
0.20332
0.20497
0.20567

Isotropic magnetic
shielding tensor(ppm)
49.5801
50.0098
164.3251
161.0774
30.3906
30.5956
30.5534
26.2069
24.2707
23.5507
24.9227
24.0039
28.1268
23.8707
23.9729
23.5576
23.5758
24.0465
23.9343
24.1657
24.3498
23.5464
22.2766
30.8624
30.6935
30.8371
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Table A. 2 Calculated energies of the pure CLF under temperature of 298.15 Kelvin and
pressure of 1.00 atm

Zero-point correction
Thermal correction to Energy
Thermal correction to Enthalpy
Thermal correction to Gibbs Free Energy
E(RB3PW91)
Sum of electronic and zero-point Energies
Sum of electronic and thermal Energies
Sum of electronic and thermal Enthalpies
Sum of electronic and thermal Free Energies

0.429324 (Hartree/Particle)
0.457493
0.458437
0.366616
-2181.35315634
-2180.923832
-2180.895663
-2180.894719
-2180.986540
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Table A. 3 Optimized Cartesian coordinates, natural population analysis, and isotropic
magnetic shielding tensors of the complex I, calculated at the level of B3PW91 with 6311++G (2d, 2p) basis sets

Atomic
Type
Cl
Cl
N
N
C
C
N
C
C
C
N
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

Coordinates(Angstroms)
X
Y
Z
-7.68268 2.64768 -0.45174
7.17515 -2.48455 -0.40050
0.51282 3.09341 0.30079
2.63927 1.30794 0.07801
1.36211 0.83669 0.00573
-1.04231 1.33572 0.05530
-2.63278 -0.44875 -0.21798
0.28504 1.80723 0.12344
2.90156 2.65391 0.26316
-4.88142 -0.04005 0.52789
-0.53641 -2.25168 -0.38380
-0.25735 -0.96541 -0.21961
-1.36257 0.01151 -0.12317
-3.79630 0.34009 -0.26384
4.26926 0.10794 -1.28879
1.79247 3.53023 0.37386
3.73947 0.38496 -0.03665
1.06770 -0.50154 -0.15360
5.33132 -0.77703 -1.40377
-5.11964 2.13798 -1.18354
-3.93024 1.42845 -1.12795
2.03534 4.90627 0.56499
3.31770 5.38915 0.64194
-6.18354 1.75042 -0.38271
4.20657 3.15780 0.34257
5.84363 -1.37176 -0.25938
0.45578 -3.32092 -0.51204
-6.07604 0.66094 0.46761
4.40499 4.50843 0.52971

Natural
Charge(e)
-0.00075
0.02692
-0.39130
-0.34344
0.35090
-0.29844
-0.60517
0.13202
0.28644
-0.20570
-0.50466
0.27256
0.21630
0.14992
-0.19059
0.06702
0.09557
-0.39590
-0.21410
-0.22338
-0.21341
-0.18075
-0.21137
-0.05897
-0.28432
-0.04011
-0.05234
-0.21900
-0.17345

Isotropic magnetic
shielding tensor(ppm)
705.2324
684.9506
-81.9411
77.7577
48.3249
81.8958
120.4140
35.6761
53.1113
54.4976
92.1246
30.0124
39.3163
41.9198
51.0405
42.5922
45.7090
92.8903
49.9191
53.6051
58.8601
51.1835
55.8608
46.5212
66.0951
37.4957
135.8688
51.3938
52.3668

256
Table A. 3 continued

C
C
C
C
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
O
C
C
H
H
H

4.25530
5.31660
0.90767
-0.13119
-1.01868
0.60687
-0.41083
1.87454
-1.82017
1.17551
5.05260
-6.91316
1.31343
-5.22168
3.83194
5.75562
-3.11358
-1.51532
3.49355
3.85665
5.41579
-4.77370
5.72905
-2.82566
1.31447
1.67948
0.06889
-3.12998
-3.67180
-3.69265
-4.44041
-3.75885
-4.88711
-5.22071

-0.21192
-1.09852
-3.81564
-4.44234
-4.86459
-5.23563
-4.08107
-1.21230
2.07560
5.55772
2.49144
0.36559
-2.91120
2.97850
0.01344
-1.00064
1.71269
-2.58537
6.44646
0.58121
4.88992
-0.88898
-1.57063
-1.46574
-3.00405
-4.57799
-4.25416
-3.13781
-2.93390
-3.54152
-4.86116
-5.64702
-5.14224
-4.77634

1.10505
0.99496
0.86104
-1.35932
-0.88703
-1.47809
-2.34916
-0.21129
0.16438
0.64793
0.25865
1.08478
-1.04810
-1.85578
2.07483
-2.37218
-1.77727
-0.31011
0.78904
-2.16976
0.59048
1.19281
1.87516
-0.10169
1.46488
0.74726
1.40305
-0.17097
1.99006
0.90946
0.79853
0.46829
1.74960
0.04027

-0.19075
-0.21349
-0.58829
-0.58488
0.21843
0.21370
0.21350
0.23982
0.24890
0.23204
0.23294
0.23081
0.19810
0.22979
0.24060
0.23923
0.22825
0.44172
0.22192
0.23951
0.22106
0.24937
0.23968
0.44616
0.21122
0.21224
0.21621
-0.84572
-0.75581
0.79687
-0.69004
0.21453
0.20817
0.21820

51.7584
49.3221
166.1825
165.5475
29.9838
30.6200
30.3694
25.6546
23.8469
23.2013
24.4683
23.8628
28.1313
23.9119
24.0498
23.4544
23.7395
19.7410
23.6783
23.8431
23.7955
23.3384
23.4162
17.9317
30.4587
30.7786
30.6544
12.6727
-53.5009
2.6289
160.8492
29.6330
30.0257
29.5726
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Table A. 4 Calculated energies of complex I under temperature of 298.15 Kelvin and
pressure of 1.00 atm

Zero-point correction
Thermal correction to Energy
Thermal correction to Enthalpy
Thermal correction to Gibbs Free Energy
E(RB3PW91)
Sum of electronic and zero-point Energies
Sum of electronic and thermal Energies
Sum of electronic and thermal Enthalpies
Sum of electronic and thermal Free Energies

0.493224 (Hartree/Particle)
0.527141
0.528085
0.423258
-2410.44999132
-2409.956767
-2409.922850
-2409.921906
-2410.026733
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Table A. 5 Optimized Cartesian coordinates, natural population analysis, and isotropic
magnetic shielding tensors of the complex II, calculated at the level of B3PW91 with 6311++G (2d, 2p) basis sets.

Atomic
Type
Cl
Cl
N
N
C
C
N
C
C
C
N
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

Coordinates(Angstroms)
X
Y
Z
-7.62533 -2.75090 0.73472
7.15649 2.40229 0.80066
0.48551 -3.05212 -0.56459
2.61988 -1.30663 -0.12907
1.33530 -0.81785 -0.09539
-1.07402 -1.31372 -0.24807
-2.65550 0.44474 0.17418
0.26094 -1.78336 -0.31906
2.87903 -2.64530 -0.38608
-4.96503 0.01516 -0.40207
-0.63826 2.25853 0.18023
-0.29773 1.00316 0.09816
-1.38680 -0.00482 -0.00070
-3.81324 -0.34951 0.29421
4.16476 -0.18059 1.38923
1.77398 -3.49993 -0.60624
3.71606 -0.40693 0.09505
1.04321 0.50332 0.10699
5.22649 0.68471 1.61068
-5.02333 -2.19763 1.27444
-3.85878 -1.45829 1.14143
2.01356 -4.85892 -0.87169
3.29663 -5.35756 -0.91679
-6.15559 -1.81960 0.56847
4.17942 -3.15989 -0.43076
5.82303 1.31357 0.52735
0.38586 3.27434 0.42886
-6.13773 -0.71180 -0.26351
4.38027 -4.50158 -0.69379

Natural
Charge(e)
0.00098
0.02011
-0.45022
-0.37890
0.32393
-0.31041
-0.64242
0.14526
0.28257
-0.19617
-0.55326
0.19885
0.34719
0.14634
-0.14319
0.06369
0.07859
-0.40931
-0.23392
-0.22371
-0.20866
-0.18315
-0.22470
-0.05788
-0.29135
-0.04408
-0.06536
-0.22142
-0.18571

Isotropic magnetic
shielding tensor(ppm)
706.8703
689.2134
-63.1730
97.3801
47.5082
83.7448
138.6902
32.5930
51.6839
54.6151
-21.8689
25.9122
35.7815
42.9609
50.1542
44.4889
44.7204
92.3096
50.0142
53.3444
56.2635
52.6240
58.9171
46.5206
67.8840
38.5555
131.4664
52.2908
54.7453
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Table A. 5 continued
C
C
C
C
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
O
O
C
C
H
H
H

4.31783
5.38032
1.00085
-0.22971
-1.01322
0.53484
-0.66586
1.85317
-1.84824
1.15316
5.02564
-7.02677
1.18545
-5.05277
3.95885
5.58601
-2.98521
-1.81525
3.46678
3.68694
5.39097
-4.94313
5.85804
-2.79620
1.44303
1.78168
0.24291
-2.37996
-3.98548
-3.59931
-4.44833
-4.46325
-5.45840
-4.01436

0.22812
1.09442
3.78026
4.41810
4.92035
5.15648
4.04998
1.20502
-2.05561
-5.49421
-2.51005
-0.42198
2.84713
-3.05340
0.04503
0.86667
-1.73741
3.02184
-6.40618
-0.68004
-4.88751
0.87896
1.59271
1.44815
2.96524
4.51325
4.26019
3.60819
3.13516
3.74262
4.70749
4.42834
4.72086
5.70635

-0.98302
-0.76914
-0.87860
1.22974
0.66063
1.47779
2.15882
0.21699
-0.37381
-1.03751
-0.26008
-0.80601
1.04285
1.93442
-1.98710
2.61353
1.71406
-0.72985
-1.12237
2.22161
-0.72561
-1.05121
-1.60069
0.25272
-1.45270
-0.66834
-1.49930
-1.34706
0.12970
-0.85437
-1.62740
-2.68122
-1.22948
-1.56344

-0.14709
-0.23324
-0.59412
-0.58205
0.20447
0.20614
0.21029
0.23028
0.23146
0.22426
0.22802
0.23035
0.18177
0.23060
0.23026
0.23639
0.23072
0.49902
0.21782
0.22991
0.21708
0.23016
0.23644
0.44157
0.20634
0.20898
0.21016
-0.73162
-0.67013
0.81942
-0.68713
0.23493
0.22666
0.23693

50.4861
49.8214
166.0610
162.8510
30.2959
30.6565
30.4883
26.0279
24.4635
23.5290
24.8067
23.8821
28.1862
23.9296
24.0234
23.5191
23.6848
17.0173
23.9939
23.8960
24.1064
24.3045
23.5051
22.3667
30.7271
30.7645
30.6897
81.7044
-73.1908
3.1301
164.1599
29.3933
29.9144
29.3837
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Table A. 6 Calculated energies of the complex II under temperature of 298.15 Kelvin and
pressure of 1.00 atm

Zero-point correction
Thermal correction to Energy
Thermal correction to Enthalpy
Thermal correction to Gibbs Free Energy
E(RB3PW91)
Sum of electronic and zero-point Energies
Sum of electronic and thermal Energies
Sum of electronic and thermal Enthalpies
Sum of electronic and thermal Free Energies

0.492050 (Hartree/Particle)
0.526187
0.527132
0.420792
-2410.44555476
-2409.953505
-2409.919367
-2409.918423
-2410.024763
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Table A. 7 Optimized Cartesian coordinates and isotropic magnetic shielding tensors of
TMS, calculated at the level of B3PW91 with 6-311++G (2d, 2p) basis sets

Atomic
Type
Si
C
H
H
H
C
H
H
H
C
H
H
H
C
H
H
H

Coordinates(Angstroms)
X
Y
Z
0.000000
0.000000
0.000000
0.000000
0.000000
1.881823
0.882586
-0.509561
2.275011
0.000000
1.019123
2.275011
-0.882586
-0.509561
2.275011
0.000000
-1.774199
-0.627274
-0.882586
-2.314755
-0.277918
0.000000
-1.805193
-1.719175
0.882586
-2.314755
-0.277918
-1.536502
0.887100
-0.627274
-1.563343
1.921719
-0.277918
-1.563343
0.902597
-1.719175
-2.445930
0.393035
-0.277918
1.536502
0.887100
-0.627274
2.445930
0.393035
-0.277918
1.563343
0.902597
-1.719175
1.563343
1.921719
-0.277918

Isotropic magnetic
shielding tensor(ppm)
339.1847
186.9601
31.6975
31.6975
31.6975
186.9601
31.6975
31.6975
31.6975
186.9601
31.6975
31.6975
31.6975
186.9601
31.6975
31.6975
31.6975

Table A. 8 Changes of calculated NMR chemical shifts (ppm) and experimental
chemical shifts (ppm) for H4 and H6

H4
H6

Experimental chemical Shifts
Pure CLF
CLF+HPMCP
5.27
5.76
6.44
6.94

Calculated chemical Shifts
Pure CLF Complex I
Complex II
5.49
6.04
5.67
7.43
7.85
7.23
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Table A. 9 Drug loading dependent chemical shift change of isopropyl-C (-CH(CH3)2) in
CLF-HPMCP complex.

ASDs (CLF:HPMCP ratio)

Pure CLF

Samples
1:9
13

C, ppm

1:2

1:1

47.0 47.2 47.5

1:0.75 1:0.25 Crystalline API Amorphous API
47.8

48.1

49.4

49.4
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Table A. 10 Optimized Cartesian coordinates, natural population analysis, and isotropic
magnetic shielding tensors of pure CLF, calculated at the level of B3PW91 with 6311++G (2d, 2p) basis sets

Optimized Structure

Coordinates(Angstroms)
X

Y

Z

Natural
Charge(e)

6.96497
-8.57554
-0.88997
-2.93251
-0.08004
2.17885
0.73308
-0.58112
-1.73767
-1.52396
1.31285
2.55709
3.70067

-2.34197
0.70736
-2.61850
-1.06522
2.77901
1.14646
-0.78703
-1.36475
-0.42301
0.92228
4.71451
5.30792
4.51094

-0.32879
-0.23235
0.04165
0.09037
0.17890
0.02566
0.02359
0.04245
0.07650
0.13004
0.23240
0.21552
0.13145

0.02925
0.01003
-0.53475
-0.53186
-0.43855
-0.39714
-0.40561
0.23413
0.18750
-0.27136
-0.17810
-0.22462
-0.18480

Atom
Cl1
Cl2
N3
N4
N5
N6
C7
C8
C9
C10
C11
C12
C13

Isotropic magnetic
shielding
tensor(ppm)

Relative
chemical
shift

684.8764
702.7735
-53.8368
136.5883
-67.3732
106.6676
94.9237
31.0403
40.8414
83.4594
52.2162
59.9295
56.0676

NA
NA
NA
NA
NA
NA
91.6519
155.5353
145.7342
103.1162
134.3594
126.6461
130.508
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Table A. 10 continued

C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
H34
H35
H36
H37
H38
H39
H40
H41
H42
H43
H44
H45
H46
H47

3.59927
2.34046
1.17527
-0.21429
0.92747
3.33476
3.95150
5.07165
5.56153
4.95145
3.83184
-4.23700
-4.59169
-5.91905
-6.90790
-6.57979
-5.25433
0.12219
0.49790
-0.42059
-2.78534
1.58396
-2.33220
0.40414
2.64791
4.68131
4.49269
3.55494
5.56080
5.34833
3.34194
-3.84019
-6.18398
-7.35528

3.13294
2.52537
3.31999
1.47936
0.56326
0.30494
-0.14401
-0.95874
-1.31863
-0.87663
-0.06229
-0.58926
0.59467
0.98986
0.20370
-0.98559
-1.37317
-3.65546
-4.03316
-4.85916
-2.07209
-1.44914
1.63154
5.29869
6.38500
4.96904
2.52816
0.14617
-1.31214
-1.16631
0.29098
1.19567
1.90522
-1.59896

0.06680
0.08590
0.16717
0.11987
0.04996
-0.05829
1.10216
1.02288
-0.22447
-1.38984
-1.30192
0.01154
-0.64137
-0.71254
-0.14449
0.49011
0.56853
0.02557
1.46009
-0.73792
0.15561
-0.00262
0.21359
0.29507
0.26600
0.11610
0.00209
2.06626
1.91960
-2.35262
-2.19976
-1.13028
-1.22343
0.92738

-0.29557
0.28238
0.06405
0.15622
0.31299
0.09855
-0.19063
-0.21842
-0.04390
-0.23556
-0.14158
0.12714
-0.22216
-0.21743
-0.06959
-0.24258
-0.14137
-0.07123
-0.57428
-0.54563
0.42390
0.22289
0.22775
0.22498
0.21104
0.20944
0.22101
0.23060
0.23044
0.22966
0.22317
0.22296
0.22404
0.22367

70.0641
52.0423
44.6101
31.4721
47.8462
44.6241
49.7003
50.4750
38.3801
50.3588
49.7901
43.4411
64.4502
52.7197
48.9103
52.5142
61.0764
133.3554
164.0618
160.8518
22.2777
26.3378
24.2757
23.5408
24.1627
24.3270
25.1028
24.0911
23.6688
23.6824
24.0678
23.6485
23.9850
24.1265

116.5115
134.5333
141.9655
155.1035
138.7294
141.9515
136.8753
136.1006
148.1955
136.2168
136.7855
143.1345
122.1254
133.8559
137.6653
134.0614
125.4992
53.2202
22.5138
25.7238
9.4342
5.3741
7.4362
8.1711
7.5492
7.3849
6.6091
7.6208
8.0431
8.0295
7.6441
8.0634
7.7269
7.5854
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Table A. 10 continued

H48
H49
H50
H51
H52
H53
H54
H55

-4.99614
1.03022
0.90414
1.24420
-0.38385
-0.68327
-1.31887
0.32035

-2.29540
-3.31620
-3.17632
-4.82998
-4.38428
-4.58298
-5.24361
-5.65999

1.07458
-0.48989
1.99924
1.46537
1.99934
-1.75976
-0.25102
-0.77755

0.20398
0.16656
0.20208
0.20156
0.20653
0.20715
0.19585
0.19346

24.5435
28.1798
30.8910
30.7521
30.8080
30.5338
30.3752
30.6590

7.1684
3.5321
0.8209
0.9598
0.9039
1.1781
1.3367
1.0529
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Table A. 11 Optimized Cartesian coordinates, natural population analysis, and isotropic
magnetic shielding tensors of the complex I, calculated at the level of B3PW91 with 6311++G (2d, 2p) basis sets

Optimized Structure

Coordinates(Angstroms)
Natural

Isotropic
magnetic

Atom

Cl1
Cl2
N3
N4
C5
C6
N7
C8
C9
C10
N11
C12

Relative
chemical
shift

X

Y

Z

Charge(e)

shielding
tensor(ppm)

-7.68973
7.19769
0.45827

2.59461
-2.42208
3.08564

-0.28619
-0.29395
0.21370

0.01038
0.03868
-0.38762

696.5541
679.1959
-79.9411

NA
NA
NA

2.60951
1.33703
-1.07280
-2.63466
0.24511
2.85408
-4.82386
-0.52633
-0.25968

1.32132
0.83257
1.30971
-0.49662
1.79563
2.67550
-0.06207
-2.27513
-0.99108

0.05758
-0.03633
-0.04538
-0.32422
0.04645
0.23352
0.58080
-0.42697
-0.27690

-0.36142
0.34576
-0.30475
-0.59176
0.13322
0.27675
-0.19641
-0.49515
0.27829

85.6160
48.6174
83.0503
114.9628
35.2700
54.1428
52.3357
75.7003
28.7222

NA
137.9582
103.5253
NA
151.3056
132.4328
134.2399
NA
157.8534
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Table A. 11 continued

C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
H34
H35
H36
H37
H38
H39
H40
H41
H42
H43
H44

-1.37805
-3.80763
4.27656
1.73177
3.71986
1.06279
5.35069
-5.19326
-4.00399
1.95527
3.23011
-6.19236
4.14996
5.85358
0.46870
-6.01807
4.32973
4.22692
5.30046
0.81994
-0.07118
-1.01055
0.65261
-0.25676
1.87710
-1.86043
1.08342
5.00554
-6.80627
1.36538
-5.34977
3.78372

-0.02224
0.28630
0.12192
3.53654
0.41242
-0.50786
-0.75157
2.05184
1.34032
4.91608
5.41708
1.69836
3.19550
-1.32601
-3.34430
0.64250
4.55141
-0.16479
-1.03976
-3.83867
-4.46162
-4.84897
-5.27565
-4.10219
-1.21212
2.04230
5.55400
2.53813
0.37688
-2.94211
2.86725
0.06969

-0.21450
-0.30826
-1.26391
0.31015
-0.02609
-0.18545
-1.34971
-1.19155
-1.19985
0.49196
0.59150
-0.29673
0.33459
-0.19037
-0.49617
0.58466
0.51173
1.12992
1.05015
0.90681
-1.38164
-0.98699
-1.43156
-2.39412
-0.21247
0.04038
0.54934
0.27569
1.27526
-0.97175
-1.88385
2.08888

0.22467
0.14521
-0.19211
0.06698
0.10349
-0.40264
-0.21531
-0.22324
-0.20883
-0.17579
-0.21274
-0.05262
-0.28880
-0.04153
-0.04974
-0.21517
-0.17967
-0.19250
-0.21446
-0.58666
-0.58532
0.22972
0.20613
0.21096
0.23119
0.25028
0.22992
0.22444
0.22619
0.18773
0.22367
0.23367

37.2488
42.8044
51.0684
42.6147
45.2341
94.4669
50.3404
54.2212
57.9018
50.8742
57.1417
44.2766
67.9637
37.2474
135.4767
51.1016
55.0444
51.8555
49.6521
165.7214
165.6767
29.5884
30.8115
30.4695
25.9399
24.0612
23.2958
24.7750
23.9324
28.2659
24.0160
24.1974

149.3268
143.7712
135.5072
143.9609
141.3415
92.1087
136.2352
132.3544
128.6738
135.7014
129.4339
142.299
118.6119
149.3282
51.0989
135.474
131.5312
134.7201
136.9235
20.8542
20.8989
2.1235
0.9004
1.2424
5.772
7.6507
8.4161
6.9369
7.7795
3.446
7.6959
7.5145
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Table A. 11 continued

H45
H46
H47
H48
H49
H50
H51
H52
H53
H54
H55
H56
O57
O58
C59
C60
H61
H62
H63

5.79505
-3.23400
-1.52337
3.38815
3.87168
5.33460
-4.65855
5.70563
-2.80780
1.20392
1.57907
-0.06341
-2.99334
-3.34450
-3.52743
-4.45110
-3.91436
-4.84727
-5.27237

-0.98497
1.59432
-2.63027
6.47833
0.57892
4.94554
-0.88448
-1.49588
-1.52136
-3.02926
-4.62043
-4.24818
-3.21001
-2.89198
-3.51391
-4.71988
-5.59330
-4.92731
-4.53176

-2.30695
-1.91614
-0.35941
0.73149
-2.15732
0.58995
1.26783
1.94232
-0.23279
1.52880
0.85131
1.39764
-0.27527
1.91053
0.86194
0.83368
0.45919
1.82485
0.13999

0.23313
0.22137
0.44542
0.21485
0.23235
0.21302
0.25462
0.23377
0.45104
0.20741
0.20572
0.22470
-0.84325
-0.71498
0.79028
-0.68484
0.21009
0.21013
0.21641

23.5792
23.9475
16.4745
23.8959
23.9890
24.0852
23.3364
23.5437
17.8959
30.6047
30.8970
30.3969
13.3272
-77.6898
3.8583
161.3616
29.7610
30.0182
29.6562

8.1327
7.7644
15.2374
7.816
7.7229
7.6267
8.3755
8.1682
13.816
1.1072
0.8149
1.315
NA
NA
182.7173
25.214
1.9509
1.6937
2.0557
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Table A. 12 Optimized Cartesian coordinates, natural population analysis, and isotropic
magnetic shielding tensors of the complex II, calculated at the level of B3PW91 with 6311++G (2d, 2p) basis sets

Optimized Structure

Coordinates(Angstroms)

Isotropic
magnetic
shielding
tensor(ppm)

Relative
chemical
shift

X

Y

Z

Natural
Charge(e)

Cl1
Cl2

7.63172
-7.12110

2.73651
-2.37487

0.94989
1.00961

0.00879
0.03139

702.6859
682.8733

NA
NA

N3
N4
C5
C6
N7
C8
C9
C10
N11
C12

-0.48982
-2.61503
-1.32754
1.07810
2.66909
-0.25889
-2.88054
5.03673
0.65563
0.31367

3.02874
1.30366
0.81620
1.31116
-0.42407
1.77365
2.63099
-0.09657
-2.24392
-0.99284

-0.70692
-0.15830
-0.12685
-0.33150
0.16729
-0.40775
-0.47166
-0.17296
0.20949
0.10321

-0.43263
-0.38928
0.32230
-0.26860
-0.59303
0.14513
0.27958
-0.13779
-0.57577
0.36933

-69.3083
101.4706
48.1676
81.7244
137.0895
32.7391
52.2527
55.5216
-26.5639
25.3547

NA
NA
138.408
104.8512
NA
153.8365
134.3229
131.054
NA
161.2209

Atom
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Table A. 12 (continued)
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
C29
C30
C31
C32
C33
H34
H35
H36
H37
H38
H39
H40
H41
H42
H43
H44
H45

1.39956
3.82183
-4.12384
-1.77868
-3.70364
-1.02996
-5.17766
4.97315
3.80876
-2.02297
-3.30640
6.16632
-4.18077
-5.80001
-0.35982
6.20481
-4.38582
-4.33106
-5.38618
-1.02843
0.28893
1.04788
-0.46229
0.76688
-1.83448
1.84434
-1.16261
-5.02394
7.14126
-1.13426
4.95503
-3.99444
-5.51446

0.01503
0.36364
0.23175
3.47238
0.41441
-0.49446
-0.62669
2.28405
1.55627
4.81702
5.31440
1.81744
3.14362
-1.29655
-3.25317
0.62318
4.47226
-0.26163
-1.12113
-3.78023
-4.38408
-4.89355
-5.11943
-3.99943
-1.19537
2.05154
5.43903
2.50310
0.25837
-2.81409
3.20480
-0.11334
-0.77501

-0.03302
0.33766
1.43309
-0.74947
0.12236
0.12092
1.71046
1.25041
1.06520
-1.07358
-1.11945
0.72119
-0.51636
0.66657
0.50994
0.01938
-0.83782
-0.91577
-0.64632
-0.76289
1.30300
0.70791
1.59719
2.20413
0.26991
-0.50327
-1.28270
-0.30003
-0.37902
1.14905
1.81680
-1.93345
2.72676

0.16608
0.12812
-0.14386
0.06598
0.08465
-0.44763
-0.23386
-0.21991
-0.21651
-0.17436
-0.22182
-0.06060
-0.29379
-0.04448
-0.07670
-0.23863
-0.18423
-0.14846
-0.23314
-0.58935
-0.58543
0.20576
0.20167
0.21645
0.22476
0.23355
0.22342
0.22128
0.22297
0.18073
0.22354
0.22411
0.23033

36.9535
43.5886
50.5064
44.2732
44.3640
92.4056
50.4494
54.1653
59.9425
51.6441
59.2879
47.0489
69.2656
38.0320
131.2554
52.6836
55.7792
50.4607
50.4793
166.0912
162.4106
30.2247
30.7499
30.4368
26.1754
24.2329
23.5042
24.9871
24.0814
28.2866
24.0719
24.0976
23.6437

149.6221
142.987
136.0692
142.3024
142.2116
94.17
136.1262
132.4103
126.6331
134.9315
127.2877
139.5267
117.31
148.5436
55.3202
133.892
130.7964
136.1149
136.0963
20.4844
24.165
1.4872
0.962
1.2751
5.5365
7.479
8.2077
6.7248
7.6305
3.4253
7.64
7.6143
8.0682
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Table A. 12 (continued)
H46
H47
H48
H49
H50
H51
H52
H53
H54
H55
H56
O57
O58
C59
C60
H61
H62
H63

2.88982
1.77135
-3.47959
-3.62584
-5.39677
5.06450
-5.88312
2.80912
-1.48965
-1.80302
-0.29808
2.25257
4.02807
3.52853
4.28836
4.20021
5.33267
3.85560

1.91116
-3.04730
6.35256
0.76150
4.85773
-1.03755
-1.65106
-1.42907
-2.97376
-4.50610
-4.27354
-3.64880
-3.12504
-3.75029
-4.71073
-4.41262
-4.73315
-5.70798

1.50925
-0.79974
-1.37068
2.23450
-0.86938
-0.70344
-1.44662
0.21988
-1.33409
-0.50837
-1.40507
-1.45896
-0.20844
-1.12389
-1.99297
-3.03827
-1.69672
-1.90461

0.22526
0.50070
0.21188
0.22372
0.21019
0.22688
0.23039
0.44248
0.20223
0.20372
0.21738
-0.72505
-0.65473
0.81521
-0.68404
0.23050
0.22473
0.23042

23.7496
18.0122
24.1169
24.0690
24.2989
23.8688
23.6628
22.3972
30.7555
30.8726
30.5834
84.6437
-83.8943
5.7669
164.4378
29.5077
29.9314
29.5138

7.9623
13.6997
7.595
7.6429
7.413
7.8431
8.0491
9.3147
0.9564
0.8393
1.1285
NA
NA
180.8087
22.1378
2.2042
1.7805
2.1981
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Table A. 13 Optimized Cartesian coordinates and isotropic magnetic shielding tensors of
TMS, calculated at the level of B3PW91 with 6-311++G (2d, 2p) basis sets

Atomic

Coordinates(Angstroms)

Isotropic magnetic

Type

X

Y

Z

shielding tensor(ppm)

Si
C
H
H
H
C
H
H
H
C

0.00000
1.08666
1.72988
1.72988
0.48240
-1.08666
-1.72988
-1.72988
-0.48240
-1.08666

0.00000
1.08666
0.48240
1.72988
1.72988
-1.08666
-0.48240
-1.72988
-1.72988
1.08666

0.00000
1.08666
1.72988
0.48240
1.72988
1.08666
1.72988
0.48240
1.72988
-1.08666

339.4622
186.5756
31.7119
31.7119
31.7119
186.5756
31.7119
31.7119
31.7119
186.5756

H
H
H
C

-0.48240
-1.72988
-1.72988
1.08666

1.72988
0.48240
1.72988
-1.08666

-1.72988
-1.72988
-0.48240
-1.08666

31.7119
31.7119
31.7119
186.5756

H
H
H

1.72988
0.48240
1.72988

-1.72988
-1.72988
-0.48240

-0.48240
-1.72988
-1.72988

31.7119
31.7119
31.7119
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Table A. 14 Formulation of calibration tablets

5% DL formulation

30%DL formulation

Drug mixture
%Pio%PioHCl
FB

Material

%wt./wt.

Material

%wt./wt.

Drug mixture

5

Drug mixture

30

100

0

Mannitol

45

Avicel

32

99

1

Avicel

45

Mannitol

32

97.5

2.5

crospovidone

5

crospovidone

6

95

5

90

10

80

20

Table A. 15 Formulation of 30% DL tablets for disproportionation studies

30%DL formulation for kinetics of disproportionation studies
%wt./
%wt./
%wt./
Material
wt.
Material
wt.
Material
wt.
Material
Pioglitaz
Pioglitaz
Pioglitaz
Pioglitaz
one HCl
30
one HCl
30
one HCl
30
one HCl

%wt./
wt.
30

Mannitol

30

Mannitol

33

A-TAB

32

Mannitol

32

Avicel
crospovid
one

30

Avicel

33

32

CCNa

4

Avicel
crospovid
one

32

6

Avicel
crospovid
one

Mgst

4

6

6
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Table A. 16 Formulation of 5% tablets for disproportionation studies
5% DL formulation for mapping studies
Material
%wt./wt.
Material
Pioglitazone HCl
5
Pioglitazone HCl
Mannitol
47
Mannitol
Avicel
47
Avicel
ccNa
1
crospovidone
Mgst

%wt./wt.
5
45
45
4.5
0.5

Table A. 17 Parameters of PLS model for 30%DL and 5%DL tablets

30%DL

5% DL

Number of Principle component

1

3

Range of Raman shift (cm-1)

1500-1800

1500-1800

R2X

0.823

0.682

R2Y

0.996

0.984

Q2

0.996

0.972

RMSEE

0.436

0.982

RMSECV

0.454

1.278

RMSEP

1.387

75.872

13

VITA
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